

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

EXELIXIS, INC.,)	
)	
Plaintiff,)	
)	
v.)	C.A. No. 19-2017 (RGA) (SRF)
)	CONSOLIDATED
MSN LABORATORIES PRIVATE LIMITED)	
and MSN PHARMACEUTICALS, INC.,)	
)	REDACTED -- PUBLIC VERSION
Defendants.)	

LETTER TO THE HONORABLE SHERRY R. FALLON
REGARDING THE PROTECTIVE ORDER DISPUTE

OF COUNSEL:

William F. Lee
Lisa J. Pirozzolo
Emily R. Whelan
Kevin S. Prussia
Timothy A. Cook
Katherine P. Kieckhafer
WILMER CUTLER PICKERING
HALE AND DORR LLP
60 State Street
Boston, MA 02109
(627) 526-6000

Kevin J. O'Brien
WILMER CUTLER PICKERING
HALE AND DORR LLP
2600 El Camino Real, Suite 400
Palo Alto, CA 94306
(650) 858-6000

Benjamin J. Dach
WILMER CUTLER PICKERING
HALE AND DORR LLP
7 World Trade Center
250 Greenwich Street
New York, NY 10007 USA
(212) 230-8800

Gerard A. Salvatore
WILMER CUTLER PICKERING
HALE AND DORR LLP
1875 Pennsylvania Avenue, NW
Washington, DC 20006
(202) 663-6000

Cristina Salcedo
WILMER CUTLER PICKERING
HALE AND DORR LLP
350 South Grand Street, Suite 2400
Los Angeles, CA 90071
(213) 443 5412

MORRIS, NICHOLS, ARSHT & TUNNELL LLP
Jack B. Blumenfeld (#1014)
Anthony D. Raucci (#5948)
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899
(302) 658-9200
jblumenfeld@morrisnichols.com
araucci@morrisnichols.com

Attorneys for Plaintiff Exelixis, Inc.

Original Filing Date: July 8, 2021
Redacted Filing Date: July 15, 2021

CONFIDENTIAL—FILED UNDER SEAL

Dear Judge Fallon:

In this Hatch-Waxman patent infringement case, Plaintiff Exelixis Inc. (“Exelixis”) seeks an order preventing Defendants MSN Laboratories Private Limited and MSN Pharmaceuticals (collectively, “MSN”) from disclosing information designated by Exelixis as confidential under the Protective Order to Dr. Kondal Reddy Bairy. As the [REDACTED], Dr. Bairy is not an “in-house attorney or legal department personnel”—the only category of party employees permitted to receive confidential information under the Protective Order. Further, as [REDACTED]

Accordingly, disclosure of Exelixis’s highly confidential scientific and business information to Dr. Bairy would create an unreasonable risk of misuse. For these reasons, and those further discussed below, Exelixis respectfully requests that the Court grants its requested relief.

I. The Protective Order Does Not Permit Disclosure of Confidential Information to Employees Who Are Not “In-House Attorneys or Legal Department Personnel.”

The jointly stipulated Protective Order places strict limits on who may have access to Confidential Information.¹ (D.I. 12.) In particular, the only party employees who are eligible to access Confidential Information are “two (2) in-house attorneys or legal department personnel each for Exelixis and MSN and their support staff assisting in the prosecution or defense of this action whose duties and responsibilities require access to material designated CONFIDENTIAL INFORMATION” (D.I. 12 at 9-10.)

II. Dr. Bairy is Not an In-House Attorney or Legal Department Personnel.

Dr. Bairy is not eligible to access Confidential Information under the Protective Order. First, Dr. Bairy is not in-house counsel for MSN. Indeed, he is not an attorney. (Exhibit A (“Bairy Dep.”) 59:1.) Second, Dr. Bairy is not legal department personnel. [REDACTED]

¹ The Protective Order defines “‘CONFIDENTIAL INFORMATION’ as any form of trade secret or other confidential research, development, or commercial information within the meaning of Fed. R. Civ. P. 26(c)(1)(G).” (D.I. 12 at 2.) Among the material that Exelixis has designated Confidential Information is highly proprietary information regarding Exelixis’s manufacturing process for cabozantinib-(s)-malate—the active ingredient of CABOMETYX[®]—and the controls that Exelixis employs to ensure that the polymorphic form of cabozantinib-(s)-malate used in CABOMETYX[®] (*i.e.*, Exelixis’s patented N-2 form) does not convert to another form such as Exelixis’s also patented N-1 form. One of the central issues in this case is whether the polymorphic form of the cabozantinib-(s)-malate used in MSN’s proposed generic product is purely in a form called Form-S (as MSN contends), or includes (either by conversion or otherwise) Exelixis’s patented N-1 or N-2 forms (as Exelixis contends).

CONFIDENTIAL—FILED UNDER SEAL

2.

[REDACTED]

During the parties' meet and confers, MSN suggested that Dr. Bairy is eligible because he supposedly supports outside counsel with litigation. Even assuming that is correct, it does not make Dr. Bairy qualified to receive Confidential Information under the Protective Order. For one, the "support staff" provision in section 11.B of the Protective Order, which MSN appears to be relying upon, explicitly only applies when such "support staff" assist "in-house attorneys or legal department personnel." (D.I. 12 at 9.) [REDACTED]

[REDACTED]) Further, the Protective Order makes clear that such "support staff" only qualify when their "duties and responsibilities *require* access to material designated Confidential Information." (D.I. 12 at 9 (emphasis added).) Nothing in [REDACTED] requires access to Exelixis's Confidential Information and MSN has not contested otherwise. And while the 11.A provision for outside counsel also identifies categories of people like secretaries who support outside counsel, in view of the separate in-house provision in 11.B, 11.A cannot be an end-run to allow access for any additional in-house employees who work with outside counsel.

In sum, because Dr. Bairy is not an attorney or legal department personnel, he is not permitted access to Confidential Information under the Protective Order.

III. MSN Does Not Have Good Cause to Amend the Protective Order to Permit Disclosure to a Non-Attorney Employee Like Dr. Bairy.

As the plain language of the Protective Order does not permit non-attorney employees to have access to Confidential Information, MSN must seek to amend the Protective Order if it wishes to disclose such information to Dr. Bairy. MSN has not done so. Even if it did, it would not have good cause for such an amendment. *PhishMe, Inc. v. Wombat Sec. Techs., Inc.*, 2017 WL 4138961, at *2 (D. Del. Sept. 18, 2017). As the U.S. Regulatory Agent involved in competitive decision-making and the development of the accused generic product, Dr. Bairy is the prototypical person who should not have access to confidential and proprietary information in a Hatch-Waxman case.

This District has a long history of prohibiting a competitive decision-maker from accessing confidential information. *See Safe Flight Instrument Corp. v. Sundstrand Data Control Inc.*, 682 F. Supp. 20 (D. Del. 1988); *R.R. Donnelley & Sons Co. v. Quark, Inc.*, 2007 WL 61885 (D. Del. Jan. 4, 2007). For example, in *Safe Flight*, the court denied plaintiff's president access to protected information due to his involvement in strategic product development. The case is instructive as the court distinguishes between non-attorney employees and in-house counsel. *Safe Flight*, 682 F. Supp. at 22. As the decision illustrates, disclosure to non-attorneys is disfavored because such employees present a greater risk of misuse (whether inadvertent or otherwise)—especially when those employees are involved in scientific and business decision-making. As the court explains, "attorneys simply do not face [the president's] prospect of having to distill one's own thoughts from a competitor's thoughts during the course of future [work]." *Id.* Likewise, in *R.R. Donnelley*, the court held that the president of corporate strategic initiative who served in a supervisory role

CONFIDENTIAL—FILED UNDER SEAL

3.

in research and development engaged in competitive decision-making, creating the sort of disclosure risk that weighed heavily against granting access. 2007 WL 61885, *2. This is precisely what the Court here must prevent and exactly why the Court must enforce the Protective Order put in place eighteen months ago.

Like the non-attorney employees in *SafeFlight* and *R.R. Donnelley*, Dr. Bairy is a competitive decision-maker, and with his Ph.D. in synthetic organic chemistry he has relevant technical knowledge. He was MSN's Rule 30(b)(6) corporate designee on several competitive topics, including the company's identification of the accused product for potential development, the company's decision to submit an ANDA seeking approval of the accused generic product with the FDA, and the drafting and preparation of the ANDA. (Bairy Dep. at 22:7-17 (noting Dr. Bairy's designation for Topic No. 1, i.e., "MSN's identification of cabozantinib as a candidate for a potential product for development . . ."; Topic No. 4, i.e., "The decision to file MSN's ANDA . . ."; and Topic 5, i.e., "MSN's ANDA and any amendments or supplements thereto, including the drafting, preparation, and filing of the foregoing . . ."). During his deposition, Dr. Bairy testified about

Dr. Bairy's ongoing role in connection with the accused product presents a particular risk of misuse. Dr. Bairy would have to "distill" his own thoughts from those gleaned from Exelixis's Confidential Information *now* not during the course of *future* work as was at issue in *Safe Flight*.

Even with the best intentions, it would be difficult for Dr. Bairy to compartmentalize his knowledge from this litigation to his regular employment obligations. Given the high risk of misuse, Dr. Bairy should not be granted access to Exelixis's information.

IV. The Transcript from the Obeticholic Acid Litigation Does Not Support Modifying the Protective Order to Permit Dr. Bairy to Have Access in This Case.

During the meet and confer process, MSN identified a transcript from the obeticholic acid litigation where Judge Noreika permitted protective order access to one non-attorney MSN employee. (See Exhibit C ("Obeticholic Acid Litigation").) That decision is inapplicable here for at least the following reasons:

First, unlike here—where MSN *has already agreed to a protective order that expressly limits the categories of qualified individuals to lawyers*—the Obeticholic Acid Litigation involved a situation where the parties were negotiating the protective order provisions in the first instance at the start of the case. Here, the Protective Order has been in place *for eighteen months*. MSN has not sought leave to amend the Protective Order to encompass non-attorney employees

CONFIDENTIAL—FILED UNDER SEAL

4.

and would not meet the good cause standard to do so even if it did. *Pansy v. Borough of Stroudsburg*, 23 F.3d 772, 786 (3d Cir. 1994) (listing factors including the interest in privacy of the party seeking protection and whether the information is being sought for a legitimate purpose that a court should consider when a party seeks to modify a protective order); see *Crum & Crum Enterprises, Inc. v. NDC of California, L.P.*, 2011 WL 886356, at *3 (D. Del. Mar. 10, 2011) (denying plaintiff's request to modify the Protective Order because plaintiff failed to provide an adequate reason for modifying). Indeed, if it is correct that Dr. Bairy regularly assists outside counsel in patent infringement litigation, then MSN could have (and should have) raised any issue about his access to Confidential Information at the start of the case—not eighteen months into it.²

Second, the Obeticholic Acid Litigation decision appears to have been aimed at addressing the apparent fact that MSN does not have an in-house legal department. (Obeticholic Acid Litigation at 11.) But MSN was obviously aware that it did not have an in-house legal team when it negotiated the Protective Order in this case eighteen months ago. Furthermore, MSN is now a frequent litigator—as it is a defendant in at least 70 Hatch-Waxman cases, 32 of those cases having been filed since the beginning of this case. (See Exhibit D.) Having chosen the business model of seeking early generic entry in the U.S. by challenging Orange Book-listed patents, if MSN is going to demand employee access to the confidential information of innovator pharmaceutical companies in litigation, MSN should expect to join the ranks of the many other non-U.S.-based generic companies like Teva, Lupin, and Mylan, *who all have in-house counsel*.

Third, the Obeticholic Acid Litigation decision did not purport to create a pass for MSN in all future cases—rather it was intended to govern a “limited situation” where there are “appropriate safeguards” and the “individuals don’t have additional responsibilities for, for example, research and development.” (Obeticholic Acid Litigation at 7, 12.) Here, [REDACTED]

[REDACTED] Accordingly, the situation presented in the Obeticholic Acid Litigation does not apply in this case.

* * *

Dr. Bairy is not an in-house attorney or legal department personnel and therefore, does not qualify to receive Confidential Information under the Protective Order. Indeed, [REDACTED] trained in organic chemistry, who on a regular and ongoing basis [REDACTED]

[REDACTED] Disclosure of Exelixis’s Confidential Information to Dr. Bairy entails a significant risk of misuse even if inadvertent. As MSN has not sought to amend the terms of the stipulated Protective Order to encompass non-attorney employees (and would not meet the requisite good cause standard to do so in any event), the Court should prohibit Dr. Bairy from accessing Exelixis’s Confidential Information. For these foregoing reasons, Exelixis respectfully requests that the Court grant its requested relief.

² Had this issue been raised at the time the Protective Order was being negotiated, Exelixis would have sought additional provisions to protect against potential misuse such as an FDA bar (akin to the prosecution bar) or a multi-tiered designation system such that certain types of information would be limited to counsel-eyes only. But it is too late for such provisions now that Exelixis’s documents have already been produced.

CONFIDENTIAL—FILED UNDER SEAL

5.

Respectfully,

/s/ Anthony D. Raucci

Anthony D. Raucci (#5948)

Enclosures

cc: All Counsel of Record (w/enc.)

EXHIBIT A



**HIGHLY CONFIDENTIAL
SUBJECT TO PROTECTIVE ORDER**

Transcript of Kondal Reddy Bairy, Ph.D., Corporate Designee & Individually

Date: June 23, 2021

Case: Exelixis, Inc. -v- MSN Laboratories Private Limited, et al

Planet Depos

Phone: 888.433.3767

Email: transcripts@planetdepos.com

www.planetdepos.com

1 IN THE UNITED STATES DISTRICT COURT

2 FOR THE DISTRICT OF DELAWARE

3 x

4 EXELIXIS, INC., :

5 Plaintiff, :

6 v. : Civil Action No.:

7 MSN LABORATORIES PRIVATE : 19 2017 (RGA) (SRF)

8 LIMITED and MSN :

9 PHARMACEUTICALS, INC., :

10 Defendants. :

11 x

12
13 HIGHLY CONFIDENTIAL SUBJECT TO PROTECTIVE ORDER

14
15 Video deposition of MSN Laboratories Private

16 Limited and MSM Pharmaceuticals, Inc

17 By and through its Corporate Designee

18 KONDAL REDDY BAIRY, PH.D.,

19 and in his Individual Capacity

20 Conducted Virtually

21 Wednesday, June 23, 2021

22 10:07 a.m. EDT

23 Job No.: 381116

24 Pages: 1 199

25 Reported by: Judith E. Bellinger, RPR, CRR

HIGHLY CONFIDENTIAL

Transcript of Kondal Reddy Bairy, Ph.D., Corporate Designee & Individually
Conducted on June 23, 2021

2

1 Video deposition of KONDAL REDDY BAIRY,
2 PH.D., conducted virtually.

3
4
5
6
7
8
9
10
11 Pursuant to notice, before Judith E.
12 Bellinger, Registered Professional Reporter,
13 Certified Realtime Reporter, and Notary Public in
14 and for the State of Maryland.

HIGHLY CONFIDENTIAL

Transcript of Kondal Reddy Bairy, Ph.D., Corporate Designee & Individually
Conducted on June 23, 2021

3

A P P E A R A N C E S

ON BEHALF OF THE PLAINTIFF:

KEVIN S. PRUSSIA, ESQUIRE

WILMER CUTLER PICKERING HALE AND DORR LLP

60 State Street

Boston, MA 02109

617.526.6000

JERRY SALVATORE, ESQUIRE

WILMER CUTLER PICKERING HALE AND DORR LLP

1875 Pennsylvania Avenue NW

Washington, D.C. 20006

202.663.6000

ON BEHALF OF THE DEFENDANTS:

KEVIN E. WARNER, ESQUIRE

WINSTON & STRAWN LLP

35 West Wacker Drive

Chicago, IL 60601 9703

312.558.5600

HIGHLY CONFIDENTIAL

Transcript of Kondal Reddy Bairy, Ph.D., Corporate Designee & Individually
Conducted on June 23, 2021

4

A P P E A R A N C E S C O N T I N U E D

ALSO PRESENT:

Drew Halton, Videographer

Jordan Collins, Planet Depos Technician

Jeffrey Hessekiel, General Counsel, Exelixis,
Inc.

Amanda Baird

Iris Carbonel

HIGHLY CONFIDENTIAL

Transcript of Kondal Reddy Bairy, Ph.D., Corporate Designee & Individually
Conducted on June 23, 2021

5

C O N T E N T S

EXAMINATION OF KONDAL REDDY BAIRY, Ph.D.	PAGE
By Mr. Prussia	11
By Mr. Salvatore	164

E X H I B I T S

(Attached to the transcript)

Bairy Exhibits:	PAGE
Exhibit 1 Exelixis's Notice of Deposition of Kondal Reddy Bairy	18
Exhibit 2 Defendants MSN Laboratories Private Limited and MSN Pharmaceuticals Inc.'s Responses and Objections to Plaintiff's Notice of Deposition Pursuant to Federal Rule of Civil Procedure 30(b)(6)	19
Exhibit 3 Application to Market a New or Abbreviated New Drug or Biologic For Human Use, Bates Nos. MSNCABO 000001 0006	61
Exhibit 4 Module 1.12.12 from MSN's ANDA product, Bates No. MSNCABO 000018	65
Exhibit 5 Module 1.14.3.1 Annotated Comparison with Listed Drug, Bates Nos. MSNCABO 023871 3926	69

HIGHLY CONFIDENTIAL

Transcript of Kondal Reddy Bairy, Ph.D., Corporate Designee & Individually
Conducted on June 23, 2021

6

E X H I B I T S C O N T I N U E D

Exhibit 6	Highlights of Prescribing Information for cabozantinib tablets, Bates Nos. MSNCABO 023819 3844	73
Exhibit 7	Module 2.3.P Drug Product, Bates Nos. MSNCABO 000348 0423	75
Exhibit 8	Response to Information Request Quality, Bates Nos. MSNCABO 017723 7733	80
Exhibit 9	Question based Review (QbR) Drug Substance, Bates Nos. MSNCABO 094149 4175	94
Exhibit 10	Module 3.2.S.3.1 Elucidation of Structure and Other Characteristics, Bates No. MSNCABO 005553	103
Exhibit 11	Module 3.2.S.4.1 Specification, Bates Nos. MSNCABO 005568 5579	105
Exhibit 12	Patent and Exclusivity Certification, Bates Nos. MSNCABO 000213 0214	108
Exhibit 13	Patent and Exclusivity Certification, Bates Nos. MSNCABO 018971 8974	116

HIGHLY CONFIDENTIAL

Transcript of Kondal Reddy Bairy, Ph.D., Corporate Designee & Individually
Conducted on June 23, 2021

7

E X H I B I T S C O N T I N U E D

Exhibit 14	Response to the GDUFA DMF Complete	122
	Response Letter Dated on 27 January	
	2020, Bates Nos. MSNCABO 094093	
	4148	
Exhibit 15	GDUFA DMF Complete Response, Bates	129
	Nos. MSNCABO 094997 5002	
Exhibit 16	Discipline Review Letter	131
	Bioequivalence, Bates Nos.	
	MSNCABO 094945 4949	
Exhibit 17	Complete Response, Bates Nos.	142
	MSNCABO 094950 4958	
Exhibit 18	Product Initiation Form, Bates Nos.	144
	MSNCABO 084235 4238	
Exhibit 19	Intellectual Property Rights,	149
	Product Dossier For	
	Cabozantinib S Malate (Anti Cancer	
	Agent) (Version 0.0), Bates Nos.	
	MSNCABO 088556 8596	
Exhibit 20	Intellectual Property Rights, MSNL	150
	Opinion of Cabozantinib, Bates Nos.	
	MSNCABO 056811 6819	

HIGHLY CONFIDENTIAL

Transcript of Kondal Reddy Bairy, Ph.D., Corporate Designee & Individually

Conducted on June 23, 2021

8

E X H I B I T S C O N T I N U E D

Exhibit 21	MSN's Detailed Statement of the Factual and Legal Bases for Its Opinion That the Manufacture, Use, Importation, Sale, and Offer for Sale of Its Cabozantinib S Malate Product Will Not Infringe U.S. Patent Nos. 8,877,776, 9,724,342, 10,034,873 And 10,039,757, Bates Nos. EXEL 04224547 4590	153
Exhibit 22	International Application Published Under the Patent Cooperation Treaty (PCT), International Publication Number WO 2018/104954 AI, Bates Nos. MSNCABO 020959 1018	156
Exhibit 23	Excel spreadsheet, Bates No. MSNCABO 055778	165
Exhibit 24	Excel spreadsheet, Bates No. MSNCABO 056755	175
Exhibit 25	Defendants MSN Laboratories Private Limited and MSN Pharmaceuticals Inc.'s First Supplemental Objections and Responses to Plaintiff's Interrogatories Nos. 8 and 12 13	181

HIGHLY CONFIDENTIAL

Transcript of Kondal Reddy Bairy, Ph.D., Corporate Designee & Individually

Conducted on June 23, 2021

9

E X H I B I T S C O N T I N U E D

Exhibit 26 Product License and Supply 186

Agreement, Bates Nos. MSNCABO 031090

1133

Exhibit 27 Email chain. Top email from 197

hareesh.n@msnlabs.com to

venkatanarasayya.saladi@msnlabs.com,

8/9/2019, Bates Nos. MSNCABO 040510

0517

HIGHLY CONFIDENTIAL

Transcript of Kondal Reddy Bairy, Ph.D., Corporate Designee & Individually

Conducted on June 23, 2021

10

P R O C E E D I N G S

THE VIDEOGRAPHER: Here begins Tape

10:07:15

No. 1 in the videotaped deposition of Kondal Reddy

10:07:16

Bairy, in the matter of Exelixis, Inc. v. MSN

10:07:21

Laboratories Private Limited, et al, in the U.S.

10:07:24

District Court, District of Delaware, Civil Action

10:07:34

No. 19 2017 Consolidated.

10:07:36

Today's date is June 23rd, 2021. Time

10:07:40

on the video monitor is 10:07 a.m. Eastern.

10:07:43

The videographer today is Drew Halton,

10:07:47

representing Planet Depos.

10:07:50

All participants are attending

10:07:51

remotely.

10:07:54

Would counsel please voice identify

10:07:56

themselves and state whom they represent?

10:07:57

MR. PRUSSIA: Kevin Prussia on behalf

10:08:00

of the plaintiff, Exelixis, also from WilmerHale.

10:08:01

Also with me for my firm is Gerald Salvatore.

10:08:04

MR. WARNER: This is Kevin Warner from

10:08:09

Winston & Strawn. And I'm representing the

10:08:11

witness and the defendants, MSN.

10:08:13

THE VIDEOGRAPHER: The court reporter

10:08:21

today is Judy Bellinger, representing Planet

10:08:22

Depos.

10:08:23

Will the reporter please swear in the

10:08:23

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

HIGHLY CONFIDENTIAL

Transcript of Kondal Reddy Bairy, Ph.D., Corporate Designee & Individually

Conducted on June 23, 2021

11

1	witness.	10:08:25
2	KONDAL REDDY BAIRY, Ph.D.	10:08:25
3	Being first duly sworn, was examined	10:08:25
4	and testified as follows:	10:08:25
5	EXAMINATION BY COUNSEL FOR THE PLAINTIFF	10:08:25
6	BY MR. PRUSSIA:	10:08:43
7	Q Good morning, sir.	10:08:43
8	MR. WARNER: Kevin, Kevin Prussia,	10:08:45
9	sorry. Just there were there are a couple	10:08:45
10	other folks attending the deposition that didn't	10:08:49
11	make announcements on the record. But just so	10:08:51
12	it's clear, I understand there are two WilmerHale	10:08:56
13	summer associates who are bound by the terms of	10:08:58
14	the protective order in this case. Also, I	10:09:01
15	understand an attorney from Exelixis, in house at	10:09:03
16	Exelixis, is on the deposition. That attorney, my	10:09:08
17	understanding, has signed all necessary papers	10:09:11
18	under the protective order to be able to	10:09:14
19	participate in the deposition.	10:09:15
20	And just in anticipation of the	10:09:17
21	questions that we'll get, I'm going to designate	10:09:21
22	the transcript under the highest level of	10:09:23
23	confidentiality permitted by the protective order.	10:09:25
24	MR. PRUSSIA: Okay. Thank you.	10:09:27
25		

HIGHLY CONFIDENTIAL

Transcript of Kondal Reddy Bairy, Ph.D., Corporate Designee & Individually

Conducted on June 23, 2021

12

1	Q	Good morning, sir.	10:09:29
2	A	Good morning, again.	10:09:32
3	Q	Could you please state your name for	10:09:34
4		the record.	10:09:36
5	A	Myself, Kondal Reddy Bairy is my full	10:09:38
6		name.	10:09:45
7	Q	Thank you.	10:09:47
8		Is it Dr. Bairy?	10:09:47
9	A	Yes. My qualification is Ph.D. We	10:09:49
10		call it "Dr. Bairy." Bairy is my last name.	10:09:51
11		Yeah, we used I used to be called Dr. Bairy.	10:09:54
12	Q	All right. Thank you.	10:09:58
13		What city do you live in, sir?	10:09:59
14	A	Can you repeat that?	10:10:03
15	Q	What city do you live in?	10:10:04
16	A	It is Edison, New Jersey.	10:10:07
17	Q	And what city where are you located	10:10:12
18		right now?	10:10:15
19	A	This is Piscataway, New Jersey.	10:10:21
20	Q	You've been deposed before, correct?	10:10:23
21	A	Yes.	10:10:27
22	Q	Several times?	10:10:28
23	A	Yes.	10:10:30
24	Q	You're familiar with the process,	10:10:31
25		correct?	10:10:32

HIGHLY CONFIDENTIAL

Transcript of Kondal Reddy Bairy, Ph.D., Corporate Designee & Individually

Conducted on June 23, 2021

13

1	A	I do. But I know it's always the first	10:10:35
2		time for case to case. But, yeah, I do have the	10:10:38
3		basic knowledge, yes.	10:10:42
4	Q	Have you been deposed remotely during	10:10:44
5		the past year?	10:10:45
6	A	Yes, I did.	10:10:49
7	Q	Okay. And your testimony has been in	10:10:51
8		patent infringement cases, correct?	10:10:54
9	A	Yeah. This is one of the Hatch Waxman	10:10:59
10		case, yes.	10:11:04
11	Q	And your prior testimony has been on	10:11:06
12		behalf of MSN, correct?	10:11:08
13	A	Yes.	10:11:10
14	Q	Have you testified at trial on behalf	10:11:12
15		of MSN?	10:11:13
16	A	No.	10:11:17
17	Q	So you understand that you've just	10:11:20
18		taken an oath to tell the truth, correct?	10:11:21
19	A	Yes, I do.	10:11:25
20	Q	And you will tell the truth today,	10:11:26
21		correct?	10:11:28
22	A	Correct.	10:11:29
23	Q	Is there any reason why you cannot give	10:11:30
24		me your best testimony today?	10:11:32
25	A	There is no reason, I don't believe.	10:11:36

HIGHLY CONFIDENTIAL

Transcript of Kondal Reddy Bairy, Ph.D., Corporate Designee & Individually

Conducted on June 23, 2021

14

1	Q	And you will give me your best	10:11:38
2		testimony today, correct?	10:11:40
3	A	Correct.	10:11:42
4	Q	All right. And I'm going to ask you	10:11:43
5		questions today. And if there's anything about my	10:11:44
6		questions that you don't understand, I will ask	10:11:47
7		you to let me know so that I can clarify, okay?	10:11:49
8	A	That will be great help, yes.	10:11:54
9	Q	Okay. And if you do not tell me	10:11:56
10		otherwise, I will assume that you have heard and	10:11:59
11		understood my questions today.	10:12:01
12		Do you understand that?	10:12:03
13	A	Agree.	10:12:06
14	Q	All right. We're on this Zoom platform	10:12:07
15		right now, correct?	10:12:16
16	A	That's what I believe. Yes, it is	10:12:22
17		saying a Zoom meeting, yes.	10:12:24
18	Q	And is there any have you	10:12:26
19		experienced any technical difficulties with your	10:12:27
20		connection today, as of yet?	10:12:30
21	A	As of now, I do not. And it's clear	10:12:32
22		and the voice is so clear. Everything is clear	10:12:36
23		for me. But I know technical glitches in my area	10:12:41
24		and deletions. Yes, sir, there were some hiccups.	10:12:46
25	Q	So as of right now, you don't have any	10:12:50

HIGHLY CONFIDENTIAL

Transcript of Kondal Reddy Bairy, Ph.D., Corporate Designee & Individually

Conducted on June 23, 2021

21

1	A	Yes.	10:22:58
2		MR. PRUSSIA: Okay. If we could pull	10:23:02
3		that down and pull up and mark tab 4.	10:23:03
4		PLANET DEPOS TECHNICIAN: Please stand	10:23:08
5		by.	10:23:09
6		Counsel, please bear with me for a	10:23:29
7		moment. I'm getting a weird format when I open	10:23:32
8		this. Hold on, please.	10:23:35
9		MR. PRUSSIA: You know, I'm getting a	10:23:44
10		weird format, too, when I open it on mine. I	10:23:45
11		wouldn't worry about it.	10:23:48
12		PLANET DEPOS TECHNICIAN: It's not	10:23:56
13		letting me mark this one.	10:23:57
14		MR. PRUSSIA: Okay. That's fine. We	10:23:59
15		don't need to mark it. But if you can share it,	10:24:01
16		that would be nice.	10:24:05
17		PLANET DEPOS TECHNICIAN: Okay. One	10:24:07
18		moment.	10:24:08
19	Q	So, Dr. Bairy, what's on the screen is	10:24:13
20		an email from Kevin Warner to several individuals,	10:24:16
21		dated June 3rd of 2021.	10:24:19
22		Is that the document that you have in	10:24:24
23		front of you, sir?	10:24:25
24	A	I do have the tab 4 document, which is,	10:24:27
25		yeah, same hard copy.	10:24:31

HIGHLY CONFIDENTIAL

Transcript of Kondal Reddy Bairy, Ph.D., Corporate Designee & Individually

Conducted on June 23, 2021

22



1	Q	Okay. And I'm just showing you this so	10:24:32
2		that you can see the topics for which you've been	10:24:35
3		designated to provide testimony by MSN.	10:24:39
4		Do you see that?	10:24:45
5	A	In the second paragraph in the email,	10:24:48
6		yes, topics. I do see the topics there.	10:24:50
7	Q	Okay. So it's topics 1 to 3, to the	10:24:54
8		extent related to regulatory subject matter;	10:24:56
9		topics 4, 5, 7 through 11, 18, 44, 53 to 65, 67,	10:25:02
10		and 71, to the extent related to regulatory	10:25:12
11		subject matter; and all of those designations are	10:25:16
12		made subject to MSN's stated objections to the	10:25:19
13		topics.	10:25:22
14		Is that your understanding?	10:25:23
15	A	Yeah. I do not remember the topic	10:25:30
16		numbers, but I do I do have that understanding	10:25:33
17		for sure, yeah.	10:25:38
18	Q	Okay. So with that in mind and you	10:25:39
19		can keep that hard copy document out with you, but	10:25:41
20		let's go back to Exhibit 2.	10:25:46
21	MR. WARNER:	And, Kevin, just one	10:25:55
22		clarification, to the extent there's any sort of	10:25:58
23		ambiguity in the language. For topics 1, 2, 3,	10:26:00
24		all of those are to the extent related to	10:26:04
25		regulatory subject matter, not just topic 3.	10:26:07

HIGHLY CONFIDENTIAL

Transcript of Kondal Reddy Bairy, Ph.D., Corporate Designee & Individually

Conducted on June 23, 2021

23

1	I was just reading the email and wanted	10:26:10
2	to make that clear.	10:26:11
3	MR. PRUSSIA: Thank you for that	10:26:12
4	clarification.	10:26:13
5	A And when you say the "Exhibit 2," this	10:26:15
6	is going to be at tab 3, right?	10:26:17
7	Q That is correct, sir.	10:26:19
8	A Thank you.	10:26:21
9	Q All right. So we have Exhibit 2 on the	10:26:22
10	screen. And if we could go to page 6, please.	10:26:25
11	So you've been designated as to topic	10:26:39
12	1. And topic 1 is "MSN's identification of	10:26:41
13	cabozantinib as a candidate for potential product	10:26:46
14	for development, including individuals and	10:26:51
15	entities involved, the documents and other	10:26:52
16	information considered, and the date that MSN	10:26:54
17	first decided to develop a cabozantinib product."	10:26:56
18	Did I read that correctly?	10:27:01
19	A Yes, you did.	10:27:04
20	Q Now, why did MSN select cabozantinib as	10:27:04
21	a candidate for regulatory product development?	10:27:07
22	A So when you say that cabozantinib was a	10:27:37
23	candidate for potential product for development,	10:27:40
24	is it something like topic API, because MSN you	10:27:44
25	 	10:27:51

HIGHLY CONFIDENTIAL

Transcript of Kondal Reddy Bairy, Ph.D., Corporate Designee & Individually

Conducted on June 23, 2021

24

1	for this product, and we considered most of the,	10:27:55
2	[REDACTED]	10:27:59
3	[REDACTED] [REDACTED]	10:28:02
4	[REDACTED]	10:28:06
5	[REDACTED]	10:28:10
6	You know, we always considered most of the	10:28:16
7	products, including this.	10:28:18
8	Q So why did MSN decide to develop	10:28:22
9	cabozantinib as an API product?	10:28:29
10	A To start with, API development is	10:28:43
11	[REDACTED]	10:28:45
12	[REDACTED] [REDACTED]	10:28:49
13	[REDACTED] [REDACTED] [REDACTED]	10:28:54
14	point will be sometimes it could be from the	10:29:00
15	[REDACTED]	10:29:03
16	[REDACTED]	10:29:09
17	[REDACTED]	10:29:14
18	[REDACTED]	10:29:16
19	[REDACTED]	10:29:20
20	[REDACTED]	10:29:26
21	[REDACTED]	10:29:32
22	[REDACTED]	10:29:35
23	[REDACTED]	10:29:38
24	[REDACTED]	10:29:41
25	Q Thank you for that background.	10:29:43

HIGHLY CONFIDENTIAL

Transcript of Kondal Reddy Bairy, Ph.D., Corporate Designee & Individually

Conducted on June 23, 2021

25

1 Specifically with respect to the 10:29:45
2 decision regarding cabozantinib, what was the 10:29:46
3 reason? Was it because a customer approached MSN 10:29:50
4 or was it something else? 10:29:54

5 A For API, I do believe we might have 10:29:58
6 [REDACTED] I 10:30:04
7 development. Once that is there, you know, we 10:30:07
8 always consider several other factors, as we have 10:30:09
9 a practice at MSN. We always consider several 10:30:12
10 other things once the product is assigned for the 10:30:17
11 API product development. 10:30:22

12 Q When was the decision made to initiate 10:30:24
13 the API product? 10:30:29

14 A I do not want to guess here, but I know 10:30:33
15 we have one of the documents called, like, 10:30:35
16 [REDACTED] 10:30:37

17 the product. That is something, like, that is the 10:30:41

18 [REDACTED] 10:30:45

19 [REDACTED] 10:30:48

20 [REDACTED] 10:30:52

21 [REDACTED] 10:30:55

22 [REDACTED] 10:31:01

23 [REDACTED] 10:31:03

24 [REDACTED] 10:31:08

25 [REDACTED] 10:31:10

26

1 [REDACTED] 10:31:13
2 [REDACTED] 10:31:16
3 [REDACTED] 10:31:19
4 [REDACTED] 10:31:24
5 [REDACTED] 10:31:26
6 [REDACTED] 10:31:27
7 [REDACTED] 10:31:28
8 sir? 10:31:30
9 [REDACTED] 10:31:30
10 [REDACTED] 10:31:32
11 [REDACTED] 10:31:34
12 [REDACTED] 10:31:38
13 [REDACTED] t? 10:31:38
14 [REDACTED] 10:31:40
15 with that. 10:31:43
16 Q Is that product is that document 10:31:43
17 generated before or after the initiation form? 10:31:46
18 A Generally speaking, we always hear 10:31:52
19 whenever we hear from the BD team, I think that is 10:31:54
20 [REDACTED] 10:31:59
21 [REDACTED] 10:32:02
22 [REDACTED] 10:32:04
23 [REDACTED] 10:32:08
24 [REDACTED] 10:32:12
25 [REDACTED] 10:32:13

HIGHLY CONFIDENTIAL

Transcript of Kondal Reddy Bairy, Ph.D., Corporate Designee & Individually

Conducted on June 23, 2021

27

1 [REDACTED] 10:32:14
2 [REDACTED] 10:32:17
3 Q So if I were to so the best 10:32:19
4 strike that. 10:32:22
5 So the best document to identify when 10:32:22
6 the decision was made by MSN to initiate the 10:32:25
7 cabozantinib API project, the best document is the 10:32:31
8 [REDACTED] 10:32:36
9 A The best sorry. Did you say 10:32:41
10 something? 10:32:44
11 Q I just was asking you if that's 10:32:45
12 correct. 10:32:48
13 A Yes, that is the that is the 10:32:48
14 [REDACTED] 10:32:51
15 [REDACTED] 10:32:53
16 Q And who made the decision at MSN? 10:32:55
17 [REDACTED] 10:33:01
18 [REDACTED] 10:33:08
19 Q Would you kindly spell the first name 10:33:09
20 for the court reporter? 10:33:13
21 A First name of the person is 10:33:17
22 [REDACTED] 10:33:19
23 Q And the last name was "Reddy," correct? 10:33:26
24 [REDACTED] 10:33:29
25 Q Sorry. 10:33:33

HIGHLY CONFIDENTIAL

Transcript of Kondal Reddy Bairy, Ph.D., Corporate Designee & Individually

Conducted on June 23, 2021

28

1 Would you mind spelling that for the 10:33:36
2 court reporter, please. 10:33:37

3 [REDACTED] 10:33:39
4 [REDACTED] 10:33:49

5 Q Now, we've been talking about the 10:33:53
6 decision to initiate the API product. 10:33:54

7 At some point, MSN decided to submit an 10:33:58
8 A N D A, an ANDA, for cabozantinib. When was that 10:34:01
9 decision made? 10:34:05

10 A Again, I need to really look into, 10:34:09

11 [REDACTED] 10:34:11
12 [REDACTED] 10:34:14
13 [REDACTED] 10:34:17
14 [REDACTED] 10:34:21
15 [REDACTED] 10:34:26
16 [REDACTED] 10:34:31
17 [REDACTED] 10:34:35
18 [REDACTED] 10:34:40
19 [REDACTED] 10:34:43
20 [REDACTED] 10:34:46
21 [REDACTED] 10:34:48

22 [REDACTED] 10:34:55
23 [REDACTED] 10:34:57

24 Q Thank you. 10:35:01

25 [REDACTED] 10:35:01

HIGHLY CONFIDENTIAL

Transcript of Kondal Reddy Bairy, Ph.D., Corporate Designee & Individually

Conducted on June 23, 2021

55


1	A	That is correct. We do not want to	11:32:58
2			11:32:59
3			11:33:04
4			11:33:06
5			11:33:10
6			11:33:14
7			11:33:18
8			11:33:23
9			11:33:28
10			11:33:28
11			11:33:30
12			11:33:33
13			11:33:39
14			11:33:41
15	Q	Let's, briefly, discuss your	11:34:05
16		educational background.	11:34:06
17		You have a Ph.D. in organic chemistry,	11:34:07
18		correct?	11:34:11
19	A	Yeah. Ph.D. in synthetic organic	11:34:13
20		chemistry, correct.	11:34:14
21	Q	When did you receive that degree?	11:34:18
22	A	The year of 2011.	11:34:20
23	Q	From which institution?	11:34:22
24	A	From Osmania University.	11:34:26
25	Q	Where is that located?	11:34:29

HIGHLY CONFIDENTIAL

Transcript of Kondal Reddy Bairy, Ph.D., Corporate Designee & Individually

Conducted on June 23, 2021

56

1	A	Located in Hyderabad, India.	11:34:30
2	Q	What other degrees do you have?	11:34:33
3	A	I do have my master's degree in organic	11:34:37
4		chemistry.	11:34:42
5	Q	When did you receive that degree?	11:34:43
6	A	In the year of '94 '96 was the year.	11:34:46
7		'96 is the year.	11:34:53
8	Q	From which institution?	11:34:55
9	A	Same. Located in Hyderabad and the	11:34:57
10		John's College, but that was small university	11:35:01
11		again. University is small.	11:35:04
12	Q	When did you start working at MSN?	11:35:08
13	A	I started working at MSN in the year of	11:35:10
14		2004.	11:35:12
15	Q	What is your current title?	11:35:15
16	A	My title is senior director.	11:35:19
17	Q	Senior director of a particular	11:35:24
18		division? What's your role?	11:35:26
19	A	I do have my responsibility here at MSN	11:35:30
20		Pharmaceuticals. I'm currently employed for MSN	11:35:37
21		Pharmaceuticals here, located here in Piscataway,	11:35:41
22		New Jersey. And I have the responsibility of	11:35:46
23			11:35:49
24			11:35:51
25			11:36:00

HIGHLY CONFIDENTIAL

Transcript of Kondal Reddy Bairy, Ph.D., Corporate Designee & Individually

Conducted on June 23, 2021

57

1	[REDACTED]	11:36:04
2	[REDACTED]	11:36:09
3	Q When did you sorry. I apologize.	11:36:11
4	Please go.	11:36:13
5	A Go ahead. No problem. I'm done.	11:36:14
6	Q I was just going to ask when did you	11:36:14
7	[REDACTED]	11:36:16
8	A I do believe I started in the month of	11:36:20
9	[REDACTED]	11:36:22
10	Q And prior to that, what was your role	11:36:27
11	at the company?	11:36:31
12	A I was looking into all I think,	11:36:35
13	continuous into that. And one additional	11:36:38
14	responsibility I have is supervise looking into	11:36:42
15	[REDACTED]	11:36:47
16	[REDACTED]	11:36:50
17	[REDACTED]	11:36:54
18	And, also, I was acting as a technical	11:36:56
19	support technical support team for the U.S.	11:37:01
20	sales before that, U.S. sales and marketing team,	11:37:07
21	who are located here.	11:37:10
22	Did I say U.S. sales and marketing?	11:37:14
23	Sorry. Sorry to interrupt. I think when I say	11:37:16
24	U.S. sales and marketing, that is API, MSN API	11:37:18
25	sales.	11:37:23

HIGHLY CONFIDENTIAL

Transcript of Kondal Reddy Bairy, Ph.D., Corporate Designee & Individually

Conducted on June 23, 2021

58

1 Q When did you start working on the 11:37:24
2 cabozantinib project? 11:37:30

3 A I do not know the exact date and the 11:37:31
4 year. I do not remember. 11:37:34

5 Q Do you recall what your role was at the 11:37:37
6 time? 11:37:39

7 A I do not remember. 11:37:42

8 Q What is your current involvement in 11:37:46
9 connection with the cabozantinib project? 11:37:50

10 [REDACTED] 11:37:57

11 [REDACTED] 11:38:01

12 [REDACTED] 11:38:04

13 [REDACTED] 11:38:10

14 [REDACTED] 11:38:13

15 Q Whom do you report? 11:38:16

16 [REDACTED] 11:38:18

17 [REDACTED] 11:38:18

18 Q Would you kindly spell his name. 11:38:28

19 A Spelling? 11:38:33

20 Q Yes, please. Thank you. 11:38:35

21 A So it is going to be 11:38:36

22 [REDACTED] 11:38:39

23 [REDACTED] 11:38:39

24 [REDACTED] 11:38:40

25 Q Now, you're not a lawyer, correct? 11:39:01

HIGHLY CONFIDENTIAL

Transcript of Kondal Reddy Bairy, Ph.D., Corporate Designee & Individually

Conducted on June 23, 2021

59

1 A Yes, I'm not a lawyer. 11:39:06

2 Q But have you in connection with your 11:39:07

3 [REDACTED] 11:39:10

4 [REDACTED] 11:39:13

5 [REDACTED] 11:39:17

6 And I'm just asking for a yes or no to 11:39:19

7 that question. 11:39:21

8 A Can you can you repeat the question? 11:39:22

9 MR. WARNER: We're going to object to 11:39:30

10 it as vague. 11:39:30

11 You can answer. 11:39:32

12 Q Do you want me to repeat it? 11:39:32

13 A Can you repeat the question, please? 11:39:33

14 Q Yeah. And it's just a yes or no. I 11:39:35

15 don't want you to give me any details, just a yes 11:39:36

16 or no. 11:39:39

17 [REDACTED] 11:39:40

18 [REDACTED] 11:39:41

19 [REDACTED] 11:39:43

20 MR. WARNER: Object as vague. 11:39:53

21 But you can answer. 11:39:54

22 A No. 11:39:55

23 [REDACTED] 11:40:06

24 [REDACTED] 11:40:09


25 cabozantinib project? 11:40:14

HIGHLY CONFIDENTIAL

Transcript of Kondal Reddy Bairy, Ph.D., Corporate Designee & Individually

Conducted on June 23, 2021

60

1	A	Can you repeat that question one more	11:40:20
2		time, please?	11:40:21
3	Q	Yeah, sure. Outside of this	11:40:22
4		deposition, because obviously you've gotten	11:40:24
5		received legal counsel in connection with this	11:40:26
6		deposition, but putting this deposition to the	11:40:29
7			11:40:30
8			11:40:34
9		project.	11:40:38
10	MR. WARNER:	Object as vague. You can	11:40:40
11		answer yes, no, or I don't know.	11:40:41
12	A	Yes.	11:40:45
13	Q	When was that?	11:40:47
14	A	I do not remember the date of it.	11:40:51
15	MR. PRUSSIA:	If we could pull up tab 5	11:41:01
16		and mark that as an exhibit, please.	11:41:02
17	Q	Tab 5 in your box, sir. If you want to	11:41:11
18		look at it. I think it's	11:41:13
19	PLANET DEPOS TECHNICIAN:	Please stand	11:41:16
20		by. Tab 5?	11:41:16
21	Q	Tab 5, Exhibit 3, I think.	11:41:18
22	PLANET DEPOS TECHNICIAN:	Exhibit 3 is	11:41:47
23		now on the screen.	11:41:47
24		(Bairy Exhibit 3 marked for	11:41:48
25		identification and attached to the transcript.)	11:41:48

HIGHLY CONFIDENTIAL

Transcript of Kondal Reddy Bairy, Ph.D., Corporate Designee & Individually

Conducted on June 23, 2021

61

1	MR. PRUSSIA: Thank you very much.	11:41:50
2	[REDACTED]	11:41:50
3	[REDACTED]	11:41:56
4	A Yes, it is.	11:42:00
5	[REDACTED]	11:42:02
6	[REDACTED]	11:42:07
7	[REDACTED]	11:42:13
8	that?	11:42:29
9	MR. WARNER: I just want to the	11:42:31
10	witness can go ahead and answer. I just want to	11:42:32
11	point out, you know, earlier, Kevin P., you had	11:42:35
12	kind of talked about it's okay to interchangeably	11:42:37
13	use the two MSN defendants. I mean, it's a little	11:42:39
14	bit vague now that we've looked at some of these	11:42:42
15	documents that's only referring to one of them or	11:42:46
16	maybe another different context.	11:42:47
17	I just point that out that it may not	11:42:49
18	be technically correct to refer to them both in	11:42:51
19	the same spot or question.	11:42:54
20	MR. PRUSSIA: Okay.	11:42:56
21	[REDACTED]	11:43:02
22	[REDACTED]	11:43:07
23	Q And just to counsel's question, the	11:43:08
24	[REDACTED]	11:43:12
25	correct?	11:43:15

HIGHLY CONFIDENTIAL

Transcript of Kondal Reddy Bairy, Ph.D., Corporate Designee & Individually

Conducted on June 23, 2021

62

1	[REDACTED]	11:43:21
2	[REDACTED]	11:43:23
3	Q And the product, if you look at box 9,	11:43:24
4	[REDACTED]	11:43:27
5	A Yes, it is correct.	11:43:33
6	Q And so the product that's the subject	11:43:35
7	of the ANDA that was submitted by MSN is	11:43:38
8	[REDACTED]	11:43:45
9	A That is correct.	11:43:50
10	Q And the dosage form is a tablet,	11:43:51
11	correct?	11:43:57
12	A Dosage form is tablet, yes.	11:44:01
13	Q And the strengths of the cabozantinib	11:44:03
14	of tablets that are sought for approval are	11:44:05
15	20 milligrams, 40 milligrams, and 60 milligrams,	11:44:08
16	correct?	11:44:12
17	A Correct.	11:44:12
18	Q And the route of administration is	11:44:13
19	oral, correct?	11:44:15
20	A Yes. It says here.	11:44:20
21	Q And the proposed indication that's	11:44:22
22	sought for approval is for the treatment of	11:44:25
23	patients with advanced renal cell carcinoma,	11:44:27
24	correct?	11:44:32
25	A Yes, it is.	11:44:39

EXHIBIT B

EXHIBIT C

1

13:12:40

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

INTERCEPT PHARMACEUTICALS, INC.,)
et al.,)
Plaintiffs,)
v.) C.A. No. 20-1105(MN)
APOTEX, INC., et al.,)
Defendants.)

Tuesday, April 13, 2021
12:00 p.m.
Teleconference

844 King Street
Wilmington, Delaware

BEFORE: THE HONORABLE MARYELLEN NOREIKA
United States District Court Judge

APPEARANCES:

MORRIS NICHOLS ARSHT & TUNNEL LLP
BY: JEREMY A. TIGAN, ESQ.

-and-

COVINGTON & BURLING LLP
BY: MEGAN KEANE, ESQ.
BY: DOUGLAS BARON, ESQ.

Counsel for the Plaintiffs

3

1

11:51:08

2

12:07:06

3

12:07:08

4

12:07:36

5

12:07:38

6

12:07:43

7

12:07:46

8

12:07:48

9

12:07:58

10

12:08:00

11

12:08:06

12

12:08:07

13

12:08:12

14

12:08:15

15

12:08:19

16

12:08:23

17

12:08:23

18

12:08:26

19

12:08:27

20

12:08:31

21

12:08:35

22

12:08:40

23

12:08:42

24

12:08:50

25

THE COURT: Good afternoon, counsel. Who is there, please?

MR. TIGAN: Your Honor, this is Jeremy Tigan with Morris Nichols for Intercept. I'm joined by Megan Keane and Doug Barons from Covington. And Ms. Keane will address your questions today if that's okay.
THE COURT: Okay. Thank you.
MS. GAZA: Good afternoon, Your Honor. This is Anne Gaza on behalf of Amneal, MSN and Dr. Reddy's Laboratories, three of the defendants in the actions before you. With me on the line today is Alison Heydorn from Winston & Strawn. And I'm pleased to report that today Ms. Heydorn will be handling portions of the defendants' arguments and this will be her first argument before the District Court.

THE COURT: Great. Welcome.

MS. ORMEROD: Good afternoon, Your Honor. This is Eve Ormerod from Smith Katzenstein on behalf of the Apotex defendants. I have with me on the line, Arun Mohan from Schiff Hardin. And Mr. Mohan will be also participating in some of the arguments today.

THE COURT: All right. Great. Anyone else?

MR. MYER: Good afternoon, this is Touhey Myer

2

1 **APPEARANCES CONTINUED:**

2

3 **YOUNG CONAWAY STARGATT & TAYLOR LLP**
4 **BY: ANNE SHEA GAZA, ESQ.**

5 -and-

6 **WINSTON & STRAWN LLP**
7 **BY: ALISON M. HEYDORN, ESQ.**

8 **Counsel for the Defendants**
9 **Amneal, MSN Laboratories, and**
10 **Dr. Reddy's Laboratories, Inc.**

11 **SMITH KATZENSTEIN & JENKINS, LLP**
12 **BY: EVE H. ORMEROD, ESQ.**

13 -and-

14 **SCHIFF HARDIN LLP**
15 **BY: ARUN JOHN MOHAN, ESQ.**

16 **Counsel for the Defendant Apotex, Inc.**

17 **OFFIT KURMAN, P.A.**
18 **BY: R. TOUHEY MYER, ESQ.**

19 **Counsel for the Defendant**
20 **Optimus Pharma Pvt. Ltd.**

21 **PHILLIPS McLAUGHLIN & HALL, P.A.**
22 **BY: JOHN C. PHILLIPS, JR., ESQ.**

23 -and-

24 **KATTEN MUCHIN ROSENMAN LLP**
25 **BY: GUYLAINE HACHE, Ph.D., ESQ.**
BY: LANCE A. SODERSTROM, ESQ.

Counsel for the Defendant
Lupin Limited

4

12:08:53 **1 from Offit Kurman of Delaware for the Optimus defendants.**

12:08:55 **2 THE COURT:** Okay. Good afternoon.

12:09:00 **3 MR. PHILLIPS:** Good afternoon, Your Honor. This
12:09:01 **4 is Jack Phillips on behalf of Lupin, and with me on the**
12:09:05 **5 phone are Lance Soderstrom and Guylaine Hache from the**
12:09:08 **6 Katten Muchin firm.**

12:09:09 **7 THE COURT:** Good afternoon to all of you as
12:09:11 **8 well. Anyone else?**

12:09:15 **9 All right. So we've received the letters on the**
12:09:21 **10 protective order issues and I'm not sure it matters. Does**
12:09:31 **11 anyone have a preference, is there a particular order? I**
12:09:35 **12 was thinking I would just start with the plaintiffs' opening**
12:09:38 **13 letter. Any objection to that?**

12:09:42 **14 MS. KEANE:** Good afternoon, Your Honor. This is
12:09:44 **15 Megan Keane on behalf of the plaintiffs. That approach**
12:09:48 **16 sounds fine with us.**

12:09:49 **17 THE COURT:** All right. So the first issue is
12:09:54 **18 non-attorney employees having access to plaintiffs'**
12:10:00 **19 protective information. And that is just the confidential**
12:10:05 **20 information, not the highly confidential information. Is**
12:10:09 **21 that right, Ms. Keane?**

12:10:11 **22 MS. KEANE:** Yes, that's correct.

12:10:15 **23 THE COURT:** Okay. And before I hear from you on
12:10:17 **24 this, let me just make sure I understand a few things from**
12:10:24 **25 the defendants' response. I understand that MSN has no**

5

12:10:30 1 in-house legal counsel who works on overseeing litigation
 12:10:39 2 such that if I were to adopt plaintiffs' proposal, MSN would
 12:10:46 3 have no one able to see the information. Is that correct or
 12:10:51 4 incorrect, someone from MSN?
 12:10:56 5 MS. HEYDORN: Good afternoon, Your Honor, this
 12:10:59 6 is Alison Heydorn on behalf of MSN. That is correct, MSN
 12:11:04 7 does not have any in-house attorneys or counsel and the
 12:11:08 8 employee that oversees litigation is a non-attorney.
 12:11:11 9 THE COURT: Okay. Now for DRL and Optimus, it
 12:11:17 10 just says they have IP personnel who are not attorneys.
 12:11:21 11 Does that mean that they do not have in-house counsel who
 12:11:25 12 work on these matters, or not? First for Dr. Reddy's.
 12:11:32 13 MS. KEANE: Yes, this is Alison Keane. DRL does
 12:11:37 14 have in-house attorneys that work on these matters. They
 12:11:40 15 have a team and some of the members of that team are
 12:11:45 16 non-attorneys. The protective order allows for three people
 12:11:49 17 to have access to confidential information. And those three
 12:11:54 18 people, not all of them are attorneys. So if they were
 12:11:58 19 barred from having non-attorneys view the information, they
 12:12:02 20 would not be able to have all three of the team members.
 12:12:06 21 THE COURT: How many of them are attorneys?
 12:12:09 22 MS. KEANE: Two.
 12:12:14 23 THE COURT: And what about for Optimus?
 12:12:19 24 MR. MYER: Good afternoon, this is Touhey Myer,
 12:12:21 25 for the Optimus defendant. Optimus does not have any

6

12:12:24 1 in-house counsel.
 12:12:29 2 THE COURT: All right. So Ms. Keane, I guess my
 12:12:38 3 inclination is to allow at least someone from a party to
 12:12:50 4 have certain confidential information so that decisions can
 12:12:56 5 be made about a case. So with you understanding kind of
 12:13:03 6 where I'm coming from, tell me why I should adopt
 12:13:07 7 plaintiffs' proposed proposal?
 12:13:13 8 MS. KEANE: Sure, Your Honor. So just some
 12:13:17 9 additional clarifications based on some of the information
 12:13:23 10 that was just provided by counsel. What our objection to
 12:13:29 11 and what we have against Stern West is allowing in the
 12:13:33 12 protective order that non-attorney employees for the various
 12:13:38 13 defendants could have access to Intercept confidential
 12:13:42 14 information under the protective order, we think the misuse
 12:13:47 15 with respect to non-attorney employees, the potential for
 12:13:52 16 misuse there is higher. Non-attorneys are not bound by the
 12:13:56 17 same ethical requirements, they're not subject to the same
 12:14:00 18 sanctions. It's not clear here that individuals oversee
 12:14:06 19 with these subjects to the same requirements or same
 12:14:09 20 jurisdiction of the court.
 12:14:10 21 All of that said, we do recognize that -- that
 12:14:20 22 it is important for -- that it's important for the parties
 12:14:27 23 in the litigation to have access to in-house counsel who can
 12:14:33 24 manage and oversee the litigation or in this case in-house
 12:14:38 25 employees. So to the extent that defendants are

7

12:14:41 1 representing that they absolutely have no access to in-house
 12:14:45 2 counsel, which is what I understand MSN and Optimus to be
 12:14:51 3 saying, that there is nobody in-house that could take over
 12:14:54 4 the responsibility for managing the litigation or have
 12:14:58 5 responsibility for managing the litigation, if there are
 12:15:01 6 appropriate safeguards in place such that they can represent
 12:15:05 7 that that's the case, as well as have those individuals
 12:15:11 8 confirm throughout the course of the litigation that they
 12:15:15 9 are complying with those requirements, and in addition that
 12:15:19 10 those individuals don't have additional responsibilities
 12:15:25 11 for, for example, research and development, I think in those
 12:15:29 12 very limited situations we would agree that one person from
 12:15:35 13 each of those defendants should have access. What we are
 12:15:42 14 not comfortable with is in situations such as DRL's
 12:15:46 15 situation where there are in-house attorneys that are
 12:15:48 16 capable of managing the litigation. Additional employees
 12:15:54 17 who are non-attorneys, we do not agree that they should be
 12:15:58 18 permitted access to Intercept's confidential information in
 12:16:01 19 those circumstances.
 12:16:02 20 Particularly given here the issues that we
 12:16:07 21 expect to be at issue in this litigation, such as
 12:16:10 22 infringement, much of that relates to defendants'
 12:16:12 23 confidential information and validity which will in large
 12:16:18 24 part be based on what we expect to be based on publicly
 12:16:21 25 available information.

8

12:16:23 1 THE COURT: So when you mention safeguards, what
 12:16:27 2 are you talking about? I was thinking that we have these
 12:16:33 3 people sign an undertaking that they are abiding by the
 12:16:40 4 protective order and that they will submit to the
 12:16:42 5 jurisdiction of this Court for any breach of the protective
 12:16:46 6 order. And then before they are allowed to see information,
 12:16:51 7 it seems to me you don't know who these people are, so you
 12:16:55 8 would need them to be disclosed and to have an understanding
 12:16:59 9 that they do not have any other responsibilities in terms of
 12:17:04 10 R & D and things like that. Are those the safeguards or is
 12:17:08 11 there something else you were thinking of?
 12:17:11 12 MS. KEANE: Yes, Your Honor, I think all of
 12:17:13 13 those safeguards in addition to the confirmation that they
 12:17:16 14 don't have responsibility for R & D, and I think in these
 12:17:21 15 circumstances we would also like to see ongoing confirmation
 12:17:26 16 that those responsibilities have not changed, or at least
 12:17:29 17 the representation that the responsibilities will not change
 12:17:34 18 and to the extent that they do in the future, we would be
 12:17:37 19 notified and be able to assess the continuing access in
 12:17:43 20 those circumstances.
 12:17:44 21 In addition, when I say safeguards, that's
 12:17:47 22 another way of phrasing that it should be limited to the
 12:17:51 23 very particular situations where there is not in-house
 12:17:54 24 counsel that can handle the litigation from an in-house
 12:18:00 25 perspective. So I think that this should be limited to only

9

12:18:04 **1** those, the very particular circumstances where that is not
 12:18:07 **2** an option that is available to defendant.
 12:18:09 **3** THE COURT: Okay. Let me hear from the
 12:18:12 **4** defendants on this one. And I guess the first question I
 12:18:15 **5** have is, is this an issue for any of the defendants other
 12:18:21 **6** than MSN, DRL and Optimus?
 12:18:31 **7** MR. SODERSTROM: Your Honor, this is Lance
 12:18:33 **8** Soderstrom from Katten Muchin on behalf of Lupin. I think
 12:18:37 **9** unfortunately we're stuck in a spot where it's not exactly
 12:18:41 **10** the same situation but the individuals that would be
 12:18:44 **11** responsible for day-to-day oversight of the litigation would
 12:18:48 **12** be non-attorneys, this is not a situation where there is no
 12:18:52 **13** in-house attorneys, there is one, but that person is not
 12:18:57 **14** typically involved in day-to-day litigation. So I don't
 12:19:01 **15** think we would ask for too much, but I do think if the Court
 12:19:05 **16** is so inclined to permit one individual, we would ask the
 12:19:09 **17** same for us. And of course taking on those same obligations
 12:19:15 **18** to avoid any sort of -- these concerns that plaintiffs have
 12:19:20 **19** raised noting that they don't have involvement with R & D,
 12:19:24 **20** no oversight on R & D, and that they're strictly part of the
 12:19:30 **21** legal team.
 12:19:31 **22** MR. MOHAN: Your Honor, this is Arun Mohan on
 12:19:34 **23** behalf of the Apotex defendant. We don't have a situation
 12:19:36 **24** like DRL and Optimus, we actually have all attorneys
 12:19:40 **25** in-house, so it does not apply to us.

10

12:19:42 **1** THE COURT: All right. So is there -- thank you
 12:19:45 **2** for that confirmation.
 12:19:47 **3** As I understand it now, the only defendants who
 12:19:50 **4** this is an issue for are MSN and Optimus who have no
 12:19:55 **5** in-house counsel who can perform the role. DRL who has two
 12:20:01 **6** out of their three folks on their litigation team that they
 12:20:05 **7** want to use are attorneys and the third one is not. And
 12:20:08 **8** Lupin who has in-house counsel, but the person assigned to
 12:20:12 **9** work on this case is not an attorney. Is there any other
 12:20:17 **10** defendants -- go ahead.
 12:20:20 **11** MR. SODERSTROM: I'm sorry, Your Honor, just for
 12:20:22 **12** Lupin, I want to clarify, we're looking at three
 12:20:25 **13** individuals, it would be potentially one that is an
 12:20:28 **14** attorney, any others would not be attorneys.
 12:20:32 **15** THE COURT: All right. So let me hear from the
 12:20:36 **16** defendants. I don't think that I am at the point in reading
 12:20:45 **17** the case law that's been cited to me including the *Allergan*
 12:20:50 **18** case and the *Lumbeck* case that, you know, having multiple
 12:20:55 **19** non-attorneys on the case is something that I am
 12:21:05 **20** considering, but you can -- now that you know where I'm
 12:21:08 **21** coming from as I did with plaintiff, tell me why that
 12:21:11 **22** shouldn't be the case.
 12:21:20 **23** MS. HEYDORN: This is Alison Heydorn with the
 12:21:22 **24** DRL. With respect to DRL situation, like I mentioned before
 12:21:26 **25** the protective order specifically contemplates and allows

11

12:21:29 **1** for in-house individuals who work in teams and provide for
 12:21:34 **2** three individuals from each party to have access to the
 12:21:37 **3** confidential information. In our opinion defendant should
 12:21:42 **4** not be forbidden from using this kind of team system to
 12:21:46 **5** manage the litigation simply because one or two of the
 12:21:50 **6** individuals are attorneys on the team. For example, for
 12:21:56 **7** DRL, even though they do have attorneys on the team, one of
 12:22:00 **8** the crucial members of the team who is responsible for
 12:22:03 **9** managing the litigation would be barred from accessing
 12:22:08 **10** confidential information and that would hamper the entire
 12:22:11 **11** team from being able to cooperate with each other and work
 12:22:15 **12** with each other and outside counsel to make sure that
 12:22:18 **13** they're able to make the decisions that are necessary for
 12:22:21 **14** the litigation. In our opinion the protective order allows
 12:22:25 **15** for three in-house individuals. The protective order
 12:22:29 **16** provisions that provide protections to plaintiff to make
 12:22:33 **17** sure that the information are not misused would be
 12:22:37 **18** applicable to everybody. So that's where we're coming from
 12:22:43 **19** is that the protective order contemplates for multiple
 12:22:47 **20** individuals so that they are able to work in a team.
 12:22:55 **21** THE COURT: Anyone else want to chime in on this
 12:22:57 **22** one? Okay. So what I am going to do is I am going to adopt
 12:23:09 **23** plaintiffs' proposal for in-house counsel with the exception
 12:23:18 **24** that for MSN and for Optimus, because they have no in-house
 12:23:25 **25** counsel, and by definition would have no one who could see

12

12:23:32 **1** any confidential information, I will allow them to have one
 12:23:39 **2** person who is not an attorney have access under the
 12:23:42 **3** protective order. That person needs to be disclosed in
 12:23:44 **4** advance with some understanding of what that person's
 12:23:48 **5** responsibilities are and their role in the company, and
 12:23:54 **6** whether they have any role in R & D, et cetera. I don't
 12:24:02 **7** think that we need to have regular check-ins on that person,
 12:24:06 **8** but I do think if that person's responsibilities change such
 12:24:10 **9** that they would have responsibility for R & D or something,
 12:24:13 **10** that that should be -- that update should be given. The
 12:24:17 **11** person would need to sign on to say they're abiding under
 12:24:23 **12** the protective order and submit to the jurisdiction of the
 12:24:26 **13** court for any breach of the protective order.
 12:24:29 **14** Any questions on that issue? Okay. Then the
 12:24:37 **15** next issue.
 12:24:41 **16** MS. KEANE: No questions from plaintiffs, Your
 12:24:43 **17** Honor.
 12:24:43 **18** THE COURT: Thank you. The next issue in the
 12:24:45 **19** plaintiffs' opening letter is the FDA bar. And I guess here
 12:24:53 **20** what I need to understand from you, Ms. Keane, is what is
 12:24:58 **21** the real -- what is the real issue here with -- you gave me
 12:25:06 **22** some generalities saying if defendants' attorneys could be
 12:25:10 **23** called on to assist in crafting a regulatory strategy that
 12:25:14 **24** expedites the timing for approval. I need you to be a
 12:25:17 **25** little more concrete on that. What is it that you really

13

12:25:20 **1** think that they could do with confidential information in
 12:25:25 **2** allowing these folks to have any role in pursuing the ANDA?
 12:25:32 **3** MS. KEANE: Sure, Your Honor. I would be happy
 12:25:35 **4** to address that. So first with respect to the proposed bar,
 12:25:42 **5** Intercept's proposed bar, we've purposely tried to keep it
 12:25:47 **6** narrow with respect to what exactly the attorneys would be
 12:25:53 **7** barred from participating in, specifically with respect to
 12:25:57 **8** the proposed generic products, the proposed versions of
 12:26:04 **9** Ocaliva. Our concern is that --
 12:26:07 **10** THE COURT: Is it really narrow what you want to
 12:26:10 **11** -- it seems like they can't do anything on the ANDA. Is
 12:26:14 **12** that sufficiently narrow?
 12:26:20 **13** MS. KEANE: They would be barred from
 12:26:22 **14** communications with the FDA with respect to the ANDA, that
 12:26:26 **15** particular ANDA. That bar wouldn't extend to other products
 12:26:30 **16** or other broader communications with the FDA.
 12:26:33 **17** And our concern and the reason that we have
 12:26:39 **18** requested that the bar be entered is that through access to
 12:26:43 **19** Intercept's confidential information, whether it's the NDA
 12:26:47 **20** or early research and development materials, the regulatory
 12:26:54 **21** correspondence with the FDA about the Ocaliva NDA, the
 12:26:58 **22** concern is that attorneys with access to that information,
 12:27:01 **23** the communications back and forth that may have been related
 12:27:06 **24** to getting Ocaliva approved, particularly the strategies
 12:27:11 **25** that Intercept testing that Intercept did in order to

14

12:27:14 **1** support approval, that by reviewing that information,
 12:27:19 **2** attorneys then in communications with FDA with respect to
 12:27:23 **3** defendants' product could use that information to aid in
 12:27:28 **4** approval of their product, whether it is particular testing
 12:27:32 **5** to expedite approval in an event that changes to the ANDA
 12:27:37 **6** need to be made, changes or amendments to the ANDA or the
 12:27:40 **7** ANDA product based on information that was learned through
 12:27:43 **8** access to Intercept's confidential information.
 12:27:46 **9** And so that is our concern. And that is why we
 12:27:52 **10** proposed including again just the attorneys who have access
 12:27:57 **11** to Intercept's protected material from participating in
 12:28:01 **12** these communications with the FDA.
 12:28:04 **13** THE COURT: All right. Let me hear from the
 12:28:06 **14** defendants.
 12:28:09 **15** MR. MOHAN: Your Honor, this is Arun Mohan from
 12:28:11 **16** the Apotex defendant, speaking on behalf of all defendants.
 12:28:14 **17** We would agree that the proposal that plaintiffs have given
 12:28:17 **18** is quite broad. It's not allowing in-house representatives
 12:28:20 **19** to work on anything regarding the approval or review of the
 12:28:23 **20** ANDA products which I want to point out here is key. The
 12:28:28 **21** ANDA's have already been filed, they have already given the
 12:28:30 **22** information they need to the FDA. We struggle to see what
 12:28:34 **23** could be learned from plaintiffs' confidential information
 12:28:36 **24** that could be used to help with the ANDA approval process.
 12:28:39 **25** To the extent that plaintiffs would argue that

15

12:28:41 **1** it would expedite approval, that's moot here because there
 12:28:45 **2** is a thirty-month stay in this case. Even if the approval
 12:28:48 **3** was expedited before that day, they couldn't launch, so
 12:28:52 **4** there is no harm here to plaintiffs. On the other hand
 12:28:55 **5** there is a great burden of prejudice to defendants. As Your
 12:28:59 **6** Honor knows, in-house representatives often have multiple
 12:29:04 **7** hats in a company, and the person here, the in-house counsel
 12:29:06 **8** that works on the ANDA in the litigation versus
 12:29:09 **9** institutional knowledge to run the litigation after it's
 12:29:12 **10** filed, so it's hard to pass that knowledge on to somebody
 12:29:15 **11** new and the burden is not really necessary and often times
 12:29:17 **12** there is no other person to pass on the information that can
 12:29:21 **13** be used to split it in up into two people. So we don't
 12:29:24 **14** think plaintiffs have given a concrete harm that they're
 12:29:26 **15** going to undertake. Based on the letters, I think that's
 12:29:29 **16** true. And we don't think that outweighs the burden on us to
 12:29:32 **17** have to split up the information amongst two people.
 12:29:37 **18** THE COURT: All right. So Ms. Keane, I guess
 12:29:40 **19** what I'm trying to figure out is, is it really the
 12:29:45 **20** communications with the FDA that you're worried about, or is
 12:29:49 **21** it -- I mean, I'm missing how the communications with the
 12:29:55 **22** FDA that are the issue here rather than some more
 12:29:58 **23** generalized concern about misuse of the data in terms of
 12:30:03 **24** telling someone how to retool the product if that becomes
 12:30:07 **25** necessary.

16

12:30:09 **1** MS. KEANE: Well, Your Honor, I think in this
 12:30:12 **2** scenario where the accused product that's at issue is the
 12:30:19 **3** ANDA and at the same time defendants are seeking FDA
 12:30:23 **4** approval of that ANDA, those two things go hand in hand. So
 12:30:28 **5** the concern here is that, you know, for example, defendants,
 12:30:33 **6** or attorneys could have access to Intercept's confidential
 12:30:41 **7** information, go through the NDA, have access and understand
 12:30:44 **8** that a certain action was taken during approval of Ocaliva
 12:30:50 **9** to meet FDA standards and then to ultimately get approval,
 12:30:59 **10** whether it's a specific amendment, a specific amendment to a
 12:31:01 **11** product or something along those lines and then if presented
 12:31:05 **12** with a similar issue during approval of the ANDA leverage
 12:31:08 **13** that information they've learned from access to Intercept
 12:31:12 **14** confidential information and again use that to either devise
 12:31:15 **15** testing, make changes to the ANDA product, whatever that
 12:31:20 **16** might be and present that to FDA as -- to seek approval for
 12:31:27 **17** the ANDA product.
 12:31:28 **18** And so it's that, the cross use of information
 12:31:32 **19** from what's gleaned from Intercept product then in support
 12:31:36 **20** of the ANDA and I will say that typically that there is
 12:31:43 **21** regulatory, there are regulatory individuals who are
 12:31:46 **22** responsible for the communications with FDA and so the harm
 12:31:51 **23** here is limited where there are individuals and attorneys
 12:31:54 **24** focused on the patent litigation versus those who are
 12:31:58 **25** communicating with FDA and handling the process of the ANDA

17

12:32:02 **1** and regulatory approval of the ANDA and research and
 12:32:07 **2** development related to the ANDA.
 12:32:09 **3** THE COURT: Do the same -- does the same bar
 12:32:16 **4** prevent the plaintiff from doing anything if there are any
 12:32:20 **5** questions raised about the NDA or the product from the FDA?
 12:32:25 **6** MS. KEANE: So the -- well, the Ocaliva product
 12:32:31 **7** has already been approved and is out on the market. I think
 12:32:34 **8** the restriction on plaintiff, the weighted restriction on
 12:32:39 **9** plaintiff is there can be no communications with FDA
 12:32:42 **10** regarding approval for generic --
 12:32:45 **11** THE COURT: That wasn't my question. I know
 12:32:46 **12** that the product is already approved. But does that mean
 12:32:49 **13** that there are no communications with the FDA about that
 12:32:52 **14** product?
 12:32:54 **15** MS. KEANE: There may be ongoing communications.
 12:32:59 **16** THE COURT: And can the people from plaintiff
 12:33:03 **17** who have seen confidential information be participating in
 12:33:08 **18** those?
 12:33:10 **19** MS. KEANE: My understanding is as the bar is
 12:33:13 **20** currently drafted, that yes, that that would be permitted.
 12:33:25 **21** MR. MOHAN: Your Honor, this is Arun. If I
 12:33:27 **22** could point out under defendants' proposal, both plaintiffs
 12:33:31 **23** would be allowed to work on the NDA and also on the ANDA.
 12:33:36 **24** Ours is broader in that respect.
 12:33:38 **25** THE COURT: That's what made me ask the question

18

12:33:40 **1** because I was looking at the proposal and I saw that it
 12:33:43 **2** said -- it referred to both NDAs and ANDA.
 12:33:54 **3** I think I am going to adopt defendants' proposal
 12:33:57 **4** here. I think that the prejudice or the punitive risk of
 12:34:04 **5** harm that the plaintiffs have suggested is just a little bit
 12:34:10 **6** too tangential for me to agree that its proposal is correct.
 12:34:20 **7** So I think that takes care of the two issues in plaintiffs'
 12:34:23 **8** letter.
 12:34:24 **9** And now we have defendants' letter on the scope
 12:34:30 **10** of the prosecution bar and what the language of that
 12:34:36 **11** prosecution bar should be. Who is going to handle that for
 12:34:41 **12** the defendants?
 12:34:42 **13** MR. MOHAN: Your Honor, for defendants, this
 12:34:45 **14** Arun Mohan again.
 12:34:47 **15** THE COURT: Okay.
 12:34:48 **16** MR. MOHAN: As Your Honor said, the first issue
 12:34:55 **17** related to the prosecution bar. We had proposed the bar
 12:34:58 **18** should prevent working on amending and drafting patent
 12:35:02 **19** claims related to Obeticholic acid, whereas plaintiffs have
 12:35:03 **20** said it should be limited to patent applications that are
 12:35:09 **21** issued could be listed in the Orange Book, we think
 12:35:11 **22** plaintiffs' proposal is far too limited. The drug here is
 12:35:15 **23** Obeticholic acid, it's not Ocaliva. Defendants have not
 12:35:18 **24** sought an ANDA for Ocaliva. It's for the Obeticholic acid
 12:35:22 **25** product itself.

19

12:35:23 **1** So our proposal is tailored to any patents or
 12:35:27 **2** patent application related to that compound itself.
 12:35:31 **3** THE COURT: When we want to look at what is at
 12:35:37 **4** issue here, is it -- I mean, these patents for use of
 12:35:43 **5** Obeticholic acid for a particular use. Is that right? I
 12:35:47 **6** mean, it's not just claiming Obeticholic acid; right?
 12:35:53 **7** MR. MOHAN: That's right, Your Honor, it's
 12:35:54 **8** Obeticholic acid for a specific use, that's right.
 12:35:56 **9** THE COURT: Okay. So why should we limit it for
 12:36:04 **10** Obeticholic acid for other uses that have nothing to do with
 12:36:08 **11** this particular litigation?
 12:36:10 **12** MR. MOHAN: Well, Your Honor, I proposed to you
 12:36:15 **13** that the information that may be in an ANDA or an NDA
 12:36:19 **14** related to Obeticholic acid is not just specific to Ocaliva,
 12:36:21 **15** it can be such as things such as processes for developing
 12:36:25 **16** the compound itself, processes for making it, that can be
 12:36:29 **17** used for things beside Ocaliva, so it's not -- the
 12:36:33 **18** information in those ANDA's are not necessarily tailored to
 12:36:37 **19** Ocaliva, it can be given to other products.
 12:36:40 **20** I would also point out in plaintiffs' responsive
 12:36:42 **21** letter they state that they're also developing other
 12:36:45 **22** products with Obeticholic acid so the danger here of using
 12:36:48 **23** that information in the ANDA on those products is very real
 12:36:51 **24** and very harmful for defendants if that does happen.
 12:36:54 **25** So the information in the ANDA's is not

20

12:36:59 **1** necessarily related just to Ocaliva, it can be Obeticholic
 12:37:00 **2** acid in general, information can be there.
 12:37:06 **3** THE COURT: All right. Let me hear from the
 12:37:09 **4** plaintiffs.
 12:37:12 **5** MS. KEANE: Thank you, Your Honor.
 12:37:14 **6** First to address your question, I think the
 12:37:17 **7** proper issue to look at here and to consider here is the
 12:37:22 **8** scope of what the -- the confidential information that an
 12:37:28 **9** attorney who is permitted under the protective order to see
 12:37:32 **10** the confidential information, what that would be. And here
 12:37:35 **11** it's defendants' proposed generic versions of Ocaliva. And
 12:37:40 **12** so the prosecution bar that's in place should be tailored to
 12:37:45 **13** protect --
 12:37:46 **14** THE COURT: What about the issue that was just
 12:37:49 **15** raised, you know, process patents wouldn't have to be listed
 12:37:57 **16** in the Orange Book, and the footnote that was dropped on why
 12:38:01 **17** I shouldn't worry about those in plaintiffs' letter wasn't
 12:38:04 **18** terribly compelling. So why shouldn't we include anything
 12:38:11 **19** that deals with the use of Obeticholic acid for the
 12:38:17 **20** particular use that Ocaliva is used for as well as processes
 12:38:24 **21** for making it?
 12:38:26 **22** MS. KEANE: Well, Your Honor, I think that
 12:38:32 **23** protective order does already -- this is what was addressed
 12:38:36 **24** in our letter. The protective order does already limit use
 12:38:40 **25** of information that is disclosed under the protective order

21

12:38:44 1 to specifically -- specifically for this litigation. And so
 12:38:50 2 now to determine --
 12:38:51 3 THE COURT: Right. But that didn't stop you
 12:38:53 4 from wanting an FDA bar and that didn't stop you from
 12:38:56 5 wanting to control who saw it from the other side. That's
 12:39:00 6 the point of a prosecution bar; right, is to add a little
 12:39:04 7 belt and suspenders to the general provisions of the
 12:39:09 8 protective order. So, you know, for people where there
 12:39:14 9 might be a higher risk of disclosure whether intentional or
 12:39:21 10 not. So the method of manufacturing the process doesn't
 12:39:29 11 seem like -- the process of manufacturing Obeticholic acid
 12:39:34 12 doesn't seem to be out of bounds. And the thing -- under
 12:39:41 13 your proposal, and I'm not suggesting that plaintiffs would
 12:39:44 14 do this, but I just want to understand. Under your
 12:39:47 15 proposal, if one of the defendants used Obeticholic acid in
 12:39:52 16 a generic product and changed an excipient so that it was no
 12:39:57 17 longer covered by your patent, plaintiffs' counsel who are
 12:40:04 18 seeing confidential information of the defendants could go
 12:40:09 19 and patent that Obeticholic acid with that excipient and if
 12:40:15 20 it didn't cover Ocaliva or Ocaliva, if it didn't cover it,
 12:40:20 21 wouldn't be Orange Book listable, and that would be just
 12:40:24 22 fine under your proposal.
 12:40:27 23 So tell me aside from saying nobody would do
 12:40:30 24 that because you're not allowed to use it for improper
 12:40:33 25 purposes, why wouldn't that be allowed under your proposal?

22

12:40:38 1 MS. KEANE: So under -- just to be clear, under
 12:40:43 2 our proposal where the scope of the patents are those that
 12:40:48 3 could be listed for Ocaliva, our intent was that scope of
 12:40:56 4 the proposal was to cover essentially anything that -- any
 12:41:01 5 patent that could cover generic versions of Ocaliva, whether
 12:41:08 6 -- so our intent was not to limit it to exclude that
 12:41:12 7 particular situation by pointing to things that could be
 12:41:16 8 used to cover Ocaliva and put in the Orange Book, we were
 12:41:21 9 attempting to cover generic versions of Ocaliva --
 12:41:25 10 THE COURT: That's not what is proposed here.
 12:41:27 11 How would you amend what you have proposed here for me to
 12:41:30 12 consider and for the defendants to consider?
 12:41:34 13 MS. KEANE: So, I mean, it could be patent --
 12:41:38 14 prosecution for patent applications that could be listed for
 12:41:43 15 Ocaliva or could cover generic versions of Ocaliva,
 12:41:47 16 something along those lines. To be clear, we are not trying
 12:41:52 17 to exclude the particular situation where there is a new
 12:41:58 18 formulation, another formulation, for example, that
 12:42:00 19 defendants have and that somehow intersects through the bar
 12:42:05 20 would not cover going off and prosecuting a patent under
 12:42:08 21 that particular formulation. That was not the intent. We
 12:42:11 22 understood that both to be encompassed by the Orange Book
 12:42:14 23 listed language and also the standard bar in the protective
 12:42:19 24 order barring any sort of that behavior. So we could expand
 12:42:23 25 it to and/or generic versions of Ocaliva or something like

23

12:42:27 1 that that would potentially resolve the issue if that's
 12:42:31 2 helpful.
 12:42:32 3 MR. MOHAN: Your Honor, this is Arun. If I may?
 12:42:36 4 THE COURT: Could you just give your name again
 12:42:39 5 just so our record is clear every time you start to speak,
 12:42:43 6 it's helpful if you give your name.
 12:42:45 7 MR. MOHAN: I apologize. This is Arun Mohan on
 12:42:48 8 behalf of the Apotex defendants. I think what plaintiffs'
 12:42:51 9 counsel just asserted hits to the heart of it. Even under
 12:42:54 10 that what they proposed, it is very unclear what patent
 12:42:57 11 application could be lifted for Ocaliva or even generic
 12:43:00 12 versions of Ocaliva, I think even under that proposal Your
 12:43:04 13 Honor suggested changing one excipient may not be covered
 12:43:06 14 under that. I think plaintiffs' proposal is not helping
 12:43:09 15 them in that point either. I think our proposal is much
 12:43:12 16 more direct.
 12:43:13 17 THE COURT: Let's say I think your proposal is
 12:43:16 18 too broad and we need to work on something that -- I think
 12:43:19 19 their's is too narrow and your's is too broad. So what I
 12:43:23 20 was thinking of is something along the lines of for any
 12:43:26 21 patents or patent applications that if issued could be
 12:43:32 22 listed in the Orange Book for Ocaliva or that cover Ocaliva
 12:43:36 23 or generic, or could cover generic version of Ocaliva. What
 12:43:43 24 are we leaving out there, or Ocaliva, how do you say it,
 12:43:47 25 Ms. Keane, Ocaliva?

24

12:43:48 1 MS. KEANE: Ocaliva.
 12:43:50 2 THE COURT: Okay.
 12:43:52 3 MR. MOHAN: I believe -- this is Arun. I believe
 12:43:57 4 you're leaving out the process patent issue in that
 12:44:00 5 proposal. I don't believe I heard that in the proposal.
 12:44:05 6 THE COURT: Okay. So then if it were something
 12:44:09 7 along the lines of what I just said and including processes
 12:44:15 8 for manufacturing Obeticholic acid, am I leaving anything
 12:44:23 9 out then?
 12:44:27 10 MR. MOHAN: Hearing it for the first time, I
 12:44:31 11 can't think of anything. Again, this is the first time I
 12:44:35 12 have heard this.
 12:44:37 13 THE COURT: All right. Ms. Keane, give me your
 12:44:40 14 thoughts on that proposal.
 12:44:47 15 MS. KEANE: So my one -- I think if there is a
 12:45:04 16 way to tie process patents, process patents essentially
 12:45:11 17 related to any processes that defendants are using or
 12:45:16 18 something like that so that it is more narrowly tailored to
 12:45:20 19 the confidential information that's coming from defendants,
 12:45:23 20 I think would be our only proposal or change with respect to
 12:45:28 21 what Your Honor just proposed.
 12:45:32 22 THE COURT: All right. I think that's too
 12:45:34 23 confusing. So I think that what I am going to do is to send
 12:45:38 24 you back, to reject both proposals and to send you back to
 12:45:45 25 agree on a proposal along the lines of what I suggested

25

12:45:49 **1** which is that it would include patents or patent
 12:45:52 **2** applications that if issued could be listed in the Orange
 12:45:56 **3** Book for Ocaliva or that would cover Ocaliva or any generic
 12:46:03 **4** version of it. And this would include processes, patents or
 12:46:13 **5** patent applications for processes on the manufacture of
 12:46:17 **6** Obeticholic acid.
 12:46:23 **7** Then the last issue is the disclosure of one
 12:46:32 **8** defendant's protected material to outside counsel only of
 12:46:37 **9** the other defendants. So why is this not -- why doesn't
 12:46:47 **10** this make sense as an efficient way to litigate especially
 12:46:52 **11** when we're just talking about this being on an outside
 12:46:55 **12** counsel only basis?
 12:46:56 **13** Let me hear from the defendants first.
 12:47:00 **14** MS. HEYDORN: Yes, Your Honor. This is Alison
 12:47:03 **15** Heydorn. This litigation involves six different defendants
 12:47:05 **16** who are all generic pharmaceutical companies and are direct
 12:47:09 **17** competitors of one another and they have separate ANDA
 12:47:12 **18** products that may use unique ingredients and manufacturing
 12:47:16 **19** processes to create those products. Because each defendant
 12:47:19 **20** has a unique product and manufacturing process they can be
 12:47:22 **21** greatly harmed by their sensitive confidential information
 12:47:25 **22** being disclosed to other defendants.
 12:47:26 **23** THE COURT: But we're talking about outside
 12:47:28 **24** counsel only having it. And doesn't the fact that three
 12:47:32 **25** different defendants have the same outside counsel suggest

26

12:47:37 **1** that the concern about outside counsel having access to
 12:47:45 **2** different defendant's information isn't all that real?
 12:47:54 **3** MS. HEYDORN: Yes, Your Honor.
 12:47:55 **4** THE COURT: At least DRL, Amneal and MSN are
 12:47:59 **5** agreeable that the other two's information is fine and dandy
 12:48:03 **6** to be in the hands of outside counsel. Right?
 12:48:07 **7** MS. HEYDORN: Yes, it's correct that MSN, DRL
 12:48:11 **8** and Amneal are all represented by Winston, but we disagree
 12:48:14 **9** that this fact should result in plaintiffs having an
 12:48:17 **10** unrestricted ability to share confidential information among
 12:48:21 **11** all defendants. MSN, DRL and Amneal chose to have a joint
 12:48:23 **12** representation, but the other defendants didn't go that
 12:48:26 **13** route and are under no obligation to share their
 12:48:29 **14** confidential information with any other competitors.
 12:48:32 **15** THE COURT: So is there a joint defense
 12:48:35 **16** agreement here?
 12:48:37 **17** MS. HEYDORN: There is a joint defense agreement
 12:48:41 **18** between the parties to make sure that we are operating as
 12:48:44 **19** efficiently as possible during the case, but this agreement
 12:48:47 **20** does not say anything about the confidential information
 12:48:50 **21** being shared with one another or have any provisions
 12:48:55 **22** involving seeing each other's confidential information.
 12:48:58 **23** THE COURT: So under the defendants' proposal,
 12:49:00 **24** the defendants could readily share confidential information
 12:49:05 **25** with each other, it's just the plaintiff who isn't allowed

27

12:49:08 **1** to do so? Is that correct?
 12:49:13 **2** MS. HEYDORN: I do think that would be correct
 12:49:15 **3** except for the caveat that plaintiffs are able to share
 12:49:18 **4** confidential information if they have agreement from the
 12:49:21 **5** defendants. So if there is a situation where the
 12:49:24 **6** confidential information was being shared between the
 12:49:27 **7** defendants, that would mean that it was the type of
 12:49:30 **8** confidential information that we're not concerned about here
 12:49:33 **9** and we would be able to give plaintiffs permission to share
 12:49:38 **10** that, their own as well. What we're really trying to get at
 12:49:43 **11** here is the confidential information that is highly
 12:49:46 **12** sensitive and unique to each defendant's ANDA. The
 12:49:50 **13** patent-in-suit here involves highly technical processes and
 12:49:54 **14** formulations so each defendant has trade secrets involved
 12:49:57 **15** and has processes and formulations that are different
 12:50:00 **16** potentially from other defendants. So that's, you know, the
 12:50:04 **17** type of information that we're trying to get at.
 12:50:07 **18** And we made proposals to plaintiff to try to
 12:50:10 **19** narrow the type of information that we're trying to exclude
 12:50:14 **20** from being cross produced to make that burden as small as
 12:50:18 **21** possible and we're really trying to get at that very
 12:50:21 **22** confidential and sensitive information that defendants would
 12:50:24 **23** want to keep out of the hands of other competitors.
 12:50:41 **24** THE COURT: Is this issue for confidential
 12:50:46 **25** information for both confidential and highly confidential?

28

12:50:51 **1** MS. HEYDORN: Confidential.
 12:50:55 **2** THE COURT: Okay. Ms. Keane?
 12:51:00 **3** MS. KEANE: Sure, Your Honor. A couple of
 12:51:06 **4** points in response. Again, we are limiting this disclosure
 12:51:12 **5** to outside counsel only. And allowing disclosure of one
 12:51:17 **6** defendant's confidential information to outside counsel for
 12:51:20 **7** another defendant will only alleviate logistical burdens
 12:51:28 **8** both on the Court as well as on plaintiff in proceeding
 12:51:31 **9** through this litigation. There are six different
 12:51:35 **10** defendants. The cases are consolidated entirely up until
 12:51:38 **11** trial and everybody has the same trial date. And so it
 12:51:43 **12** would not really be workable and we don't think it would be
 12:51:46 **13** a workable scenario to require that certain information
 12:51:49 **14** could not be disclosed absent written consent that
 12:51:53 **15** Ms. Heydorn just referred to.
 12:51:56 **16** First, the topics and the type of information
 12:51:59 **17** that defendants are seeking to bucket into the ones that
 12:52:03 **18** require consent are ones that potentially would be relevant
 12:52:08 **19** if, for example, we're at claim construction hearing, Your
 12:52:12 **20** Honor has questions as to how claim construction position
 12:52:16 **21** affect infringement analysis, that's an area where it could
 12:52:21 **22** come up. These types of information could be relative to
 12:52:24 **23** interrogatory responses with respect to validity expert
 12:52:27 **24** reports with respect to validity, and it's not really
 12:52:31 **25** workable to require plaintiffs to go and seek consent to use

29

12:52:36 1 that information or to disclose that information. One,
 12:52:40 2 defendant could withhold that consent. Two, it requires
 12:52:44 3 multiday lead time and is not always workable. And three,
 12:52:48 4 it then puts the burden on plaintiffs and only plaintiffs to
 12:52:52 5 do these redactions. That in and of itself requires
 12:52:56 6 generally a lot of back and forth with defendants to confirm
 12:52:59 7 the redactions and could lead to disputes over what is
 12:53:02 8 properly redacted or not.
 12:53:04 9 On the flip side I don't see a harm here for
 12:53:07 10 defendants given as Your Honor noted, three of the
 12:53:09 11 defendants are represented by the same outside counsel.
 12:53:13 12 Defendants are obviously working together as far as strategy
 12:53:19 13 and development of the case goes. So really any sort of
 12:53:22 14 burden here is minimal. And it is limited to outside
 12:53:26 15 counsel. This isn't even a situation where we're seeking to
 12:53:29 16 be able to just disclose to in-house counsel of other
 12:53:33 17 defendants or anything like that. Given all the
 12:53:36 18 complications that could arise in litigation and the
 12:53:40 19 difficulties of the logistics, we don't see how there is any
 12:53:45 20 injury or harm to defendants that outweighs the orderly
 12:53:51 21 process of litigation.
 12:53:52 22 Finally, I'll note that the burden here,
 12:53:55 23 essentially the way that defendants are proposing setting
 12:53:57 24 this up, defendants could use it strategically to their
 12:54:01 25 advantage and decide at certain points they don't want to

30

12:54:04 1 disclose the information where it may be plaintiff seeking
 12:54:07 2 to disclose the information, but down the line where it's
 12:54:11 3 helpful to them, they may not be able to make a different
 12:54:16 4 decision and disclose the information.
 12:54:18 5 THE COURT: All right. For this one, I am going
 12:54:20 6 to adopt plaintiffs' proposal. I just think that
 12:54:23 7 defendants' proposal is going to add unnecessary logistical
 12:54:36 8 concerns to this and probably have disputes and delays in
 12:54:43 9 people getting information that is unnecessary given that
 12:54:48 10 we're talking about information being given to outside
 12:54:51 11 counsel only and not to in-house folks.
 12:54:56 12 Okay. I think that's the end of the issues that
 12:55:00 13 were in the letters. Is there anything else that we need to
 12:55:03 14 discuss?
 12:55:06 15 MS. KEANE: Not from plaintiffs, Your Honor.
 12:55:12 16 THE COURT: Okay. And hearing nothing from
 12:55:15 17 defendants, I understand that that is all we have. So
 12:55:21 18 everyone, thank you very much, and hope you enjoy the rest
 12:55:24 19 of the week.
 20 (Teleconference concluded at 12:55 p.m.)
 21
 22 I hereby certify the foregoing is a true and
 23 accurate transcript from my stenographic notes in the proceeding.
 24
 25 /s/ Dale C. Hawkins
 Official Court Reporter
 U.S. District Court

/	affect [1] - 28:21 afternoon [10] - 3:3, 3:10, 3:19, 3:25, 4:2, 4:3, 4:7, 4:14, 5:5, 5:24	18:20, 22:14, 23:21, 25:2, 25:5 apply [1] - 9:25 approach [1] - 4:15 appropriate [1] - 7:6 approval [15] - 12:24, 14:1, 14:4, 14:5, 14:19, 14:24, 15:1, 15:2, 16:4, 16:8, 16:9, 16:12, 16:16, 17:1, 17:10 approved [3] - 13:24, 17:7, 17:12 April [1] - 1:10 area [1] - 28:21 argue [1] - 14:25 argument [1] - 3:16 arguments [2] - 3:16, 3:23 arise [1] - 29:18 ARSHT [1] - 1:20 Arun [8] - 3:21, 9:22, 14:15, 17:21, 18:14, 23:3, 23:7, 24:3 ARUN [1] - 2:12 aside [1] - 21:23 asserted [1] - 23:9 assess [1] - 8:19 assigned [1] - 10:8 assist [1] - 12:23 attempting [1] - 22:9 attorney [8] - 4:18, 5:8, 6:12, 6:15, 10:9, 10:14, 12:2, 20:9 attorneys [25] - 5:7, 5:10, 5:14, 5:16, 5:18, 5:19, 5:21, 6:16, 7:15, 7:17, 9:12, 9:13, 9:24, 10:7, 10:14, 10:19, 11:6, 11:7, 12:22, 13:6, 13:22, 14:2, 14:10, 16:6, 16:23 available [2] - 7:25, 9:2 avoid [1] - 9:18	based [5] - 6:9, 7:24, 14:7, 15:15 basis [1] - 25:12 becomes [1] - 15:24 BEFORE [1] - 1:15 behalf [9] - 3:11, 3:20, 4:4, 4:15, 5:6, 9:8, 9:23, 14:16, 23:8 behavior [1] - 22:24 belive [1] - 24:3 belt [1] - 21:7 beside [1] - 19:17 between [2] - 26:18, 27:6 bit [1] - 18:5 Book [7] - 18:21, 20:16, 21:21, 22:8, 22:22, 23:22, 25:3 bound [1] - 6:16 bounds [1] - 21:12 breach [2] - 8:5, 12:13 broad [3] - 14:18, 23:18, 23:19 broader [2] - 13:16, 17:24 bucket [1] - 28:17 burden [7] - 15:5, 15:11, 15:16, 27:20, 29:4, 29:14, 29:22 burdens [1] - 28:7 BURLING [1] - 1:22 BY [11] - 1:20, 1:23, 1:23, 2:3, 2:6, 2:10, 2:12, 2:15, 2:19, 2:21, 2:22	chime [1] - 11:21 chose [1] - 26:11 circumstances [4] - 7:19, 8:15, 8:20, 9:1 cited [1] - 10:17 claim [2] - 28:19, 28:20 claiming [1] - 19:6 claims [1] - 18:19 clarifications [1] - 6:9 clarify [1] - 10:12 clear [4] - 6:18, 22:1, 22:16, 23:5 comfortable [1] - 7:14 coming [4] - 6:6, 10:21, 11:18, 24:19 communicating [1] - 16:25 communications [11] - 13:14, 13:16, 13:23, 14:2, 14:12, 15:20, 15:21, 16:22, 17:9, 17:13, 17:15 companies [1] - 25:16 company [2] - 12:5, 15:7 compelling [1] - 20:18 competitors [3] - 25:17, 26:14, 27:23 complications [1] - 29:18 complying [1] - 7:9 compound [2] - 19:2, 19:16 CONAWAY [1] - 2:3 concern [7] - 13:9, 13:17, 13:22, 14:9, 15:23, 16:5, 26:1 concerned [1] - 27:8 concerns [2] - 9:18, 30:8 concluded [1] - 30:20 concrete [2] - 12:25, 15:14 confidential [37] - 4:19, 4:20, 5:17, 6:4, 6:13, 7:18, 7:23, 11:3, 11:10, 12:1, 13:1, 13:19, 14:8, 14:23, 16:6, 16:14, 17:17, 20:8, 20:10, 21:18, 24:19, 25:21, 26:10, 26:14, 26:20, 26:22, 26:24, 27:4, 27:6, 27:8, 27:11, 27:22, 27:24, 27:25, 28:1, 28:6 confirm [2] - 7:8, 29:6 confirmation [3] - 8:13 8:15, 10:2
/s [1] - 30:24				
1				
12:00 [1] - 1:11 12:55 [1] - 30:20 13 [1] - 1:10	agree [5] - 7:12, 7:17, 14:17, 18:6, 24:25 agreeable [1] - 26:5 agreement [4] - 26:16, 26:17, 26:19, 27:4 ahead [1] - 10:10 aid [1] - 14:3 ai [2] - 1:4, 1:7 Alison [5] - 3:13, 5:6, 5:13, 10:23, 25:14 ALISON [1] - 2:6 Allergan [1] - 10:17 alleviate [1] - 28:7 allow [2] - 6:3, 12:1 allowed [5] - 8:6, 17:23, 21:24, 21:25, 26:25 allowing [4] - 6:11, 13:2, 14:18, 28:5 allows [3] - 5:16, 10:25, 11:14 amend [1] - 22:11 amending [1] - 18:18 amendment [2] - 16:10 amendments [1] - 14:6 Amneal [5] - 2:7, 3:11, 26:4, 26:8, 26:11 analysis [1] - 28:21 ANDA [26] - 13:2, 13:11, 13:14, 13:15, 14:5, 14:6, 14:7, 14:20, 14:24, 15:8, 16:3, 16:4, 16:12, 16:15, 16:17, 16:20, 16:25, 17:1, 17:2, 17:23, 18:2, 18:24, 19:13, 19:23, 25:17, 27:12 ANDA's [3] - 14:21, 19:18, 19:25 ANNE [1] - 2:3 Anne [1] - 3:11 apologize [1] - 23:7 Apotex [5] - 2:13, 3:21, 9:23, 14:16, 23:8 APOTEX [1] - 1:7 APPEARANCES [2] - 1:18, 2:1 applicable [1] - 11:18 application [2] - 19:2, 23:11 applications [5] -			
2				
20-1105(MN) [1] - 1:6 2021 [1] - 1:10				
8				
844 [1] - 1:13				
A				
abiding [2] - 8:3, 12:11 ability [1] - 26:10 able [10] - 5:3, 5:20, 8:19, 11:11, 11:13, 11:20, 27:3, 27:9, 29:16, 30:3 absent [1] - 28:14 absolutely [1] - 7:1 access [18] - 4:18, 5:17, 6:13, 6:23, 7:1, 7:13, 7:18, 8:19, 11:2, 12:2, 13:18, 13:22, 14:8, 14:10, 16:6, 16:7, 16:13, 26:1 accessing [1] - 11:9 accurate [1] - 30:22 accused [1] - 16:2 acid [16] - 18:19, 18:23, 18:24, 19:5, 19:6, 19:8, 19:10, 19:14, 19:22, 20:2, 20:19, 21:11, 21:15, 21:19, 24:8, 25:6 action [1] - 16:8 actions [1] - 3:12 add [2] - 21:6, 30:7 addition [3] - 7:9, 8:13, 8:21 additional [3] - 6:9, 7:10, 7:16 address [3] - 3:8, 13:4, 20:6 addressed [1] - 20:23 adopt [5] - 5:2, 6:6, 11:22, 18:3, 30:6 advance [1] - 12:4 advantage [1] - 29:25		B bar [16] - 12:19, 13:4, 13:5, 13:15, 13:18, 17:3, 17:19, 18:10, 18:11, 18:17, 20:12, 21:4, 21:6, 22:19, 22:23 BARON [1] - 1:23 Barons [1] - 3:7 barred [4] - 5:19, 11 9, 13 7, 13:13 barring [1] - 22:24	C C.A [1] - 1:6 capable [1] - 7:16 care [1] - 18:7 case [12] - 6:5, 6:24, 7:7, 10:9, 10:17, 10:18, 10:19, 10:22, 15:2, 26:19, 29:13 cases [1] - 28:10 caveat [1] - 27:3 certain [4] - 6:4, 16:8, 28:13, 29:25 certify [1] - 30:22 cetera [1] - 12:6 change [3] - 8:17, 12:8, 24:20 changed [2] - 8:16, 21:16 changes [3] - 14:5, 14:6, 16:15 changing [1] - 23:13 check [1] - 12:7 check-ins [1] - 12:7	

<p>confusing [1] - 24:23</p> <p>consent [4] - 28:14, 28:18, 28:25, 29:2</p> <p>consider [3] - 20:7, 22:12</p> <p>considering [1] - 10:20</p> <p>consolidated [1] - 28:10</p> <p>construction [2] - 28:19, 28:20</p> <p>contemplates [2] - 10:25, 11:19</p> <p>CONTINUED [1] - 2:1</p> <p>continuing [1] - 8:19</p> <p>control [1] - 21:5</p> <p>cooperate [1] - 11:11</p> <p>correct [7] - 4:22, 5:3, 5:6, 18:6, 26:7, 27:1, 27:2</p> <p>correspondence [1] - 13:21</p> <p>counsel [29] - 3:3, 5:1, 5:7, 5:11, 6:1, 6:10, 6:23, 7:2, 8:24, 10:5, 10:8, 11:12, 11:23, 11:25, 15:7, 21:17, 23:9, 25:8, 25:12, 25:24, 25:25, 26:1, 26:6, 28:5, 28:6, 29:11, 29:15, 29:16, 30:11</p> <p>Counsel [5] - 1:25, 2:7, 2:13, 2:16, 2:23</p> <p>couple [1] - 28:3</p> <p>course [2] - 7:8, 9:17</p> <p>COURT [47] - 1:1, 3:3, 3:9, 3:18, 3:24, 4:2, 4:7, 4:17, 4:23, 5:9, 5:21, 5:23, 6:2, 8:1, 9:3, 10:1, 10:15, 11:21, 12:18, 13:10, 14:13, 15:18, 17:3, 17:11, 17:16, 17:25, 18:15, 19:3, 19:9, 20:3, 20:14, 21:3, 22:10, 23:4, 23:17, 24:2, 24:6, 24:13, 24:22, 25:23, 26:4, 26:15, 26:23, 27:24, 28:2, 30:5, 30:16</p> <p>court [2] - 6:20, 12:13</p> <p>Court [7] - 1:16, 3:17, 8:5, 9:15, 28:8, 30:24, 30:25</p> <p>cover [11] - 21:20, 22:4, 22:5, 22:8, 22:9, 22:15, 22:20, 23:22, 23:23, 25:3</p> <p>covered [2] - 21:17,</p>	<p>23:13</p> <p>Covington [1] - 3:7</p> <p>COVINGTON [1] - 1:22</p> <p>crafting [1] - 12:23</p> <p>create [1] - 25:19</p> <p>cross [2] - 16:18, 27:20</p> <p>crucial [1] - 11:8</p> <p>D</p> <p>Dale [1] - 30:24</p> <p>dandy [1] - 26:5</p> <p>danger [1] - 19:22</p> <p>data [1] - 15:23</p> <p>date [1] - 28:11</p> <p>day-to-day [2] - 9:11, 9:14</p> <p>deals [1] - 20:19</p> <p>decide [1] - 29:25</p> <p>decision [1] - 30:4</p> <p>decisions [2] - 6:4, 11:13</p> <p>Defendant [3] - 2:13, 2:16, 2:23</p> <p>defendant [9] - 5:25, 9:2, 9:23, 11:3, 14:16, 25:19, 27:14, 28:7, 29:2</p> <p>defendant's [4] - 25:8, 26:2, 27:12, 28:6</p> <p>defendants [50] - 3:12, 3:21, 4:1, 6:13, 6:25, 7:13, 9:4, 9:5, 10:3, 10:10, 10:16, 14:14, 14:16, 15:5, 16:3, 16:5, 18:12, 18:13, 18:23, 19:24, 21:15, 21:18, 22:12, 22:19, 23:8, 24:17, 24:19, 25:9, 25:13, 25:15, 25:22, 25:25, 26:11, 26:12, 26:24, 27:5, 27:7, 27:16, 27:22, 28:10, 28:17, 29:6, 29:10, 29:11, 29:12, 29:17, 29:20, 29:23, 29:24, 30:17</p> <p>Defendants [2] - 1:8, 2:7</p> <p>defendants' [11] - 3:15, 4:25, 7:22, 12:22, 14:3, 17:22, 18:3, 18:9, 20:11, 26:23, 30:7</p> <p>defense [2] - 26:15, 26:17</p> <p>definition [1] - 11:25</p> <p>DELAWARE [1] - 1:2</p>	<p>Delaware [2] - 1:13, 4:1</p> <p>delays [1] - 30:8</p> <p>determine [1] - 21:2</p> <p>developing [2] - 19:15, 19:21</p> <p>development [4] - 7:11, 13:20, 17:2, 29:13</p> <p>devise [1] - 16:14</p> <p>different [6] - 25:15, 25:25, 26:2, 27:15, 28:9, 30:3</p> <p>difficulties [1] - 29:19</p> <p>direct [2] - 23:16, 25:16</p> <p>disagree [1] - 26:8</p> <p>disclose [5] - 29:1, 29:16, 30:1, 30:2, 30:4</p> <p>disclosed [5] - 8:8, 12:3, 20:25, 25:22, 28:14</p> <p>disclosure [4] - 21:9, 25:7, 28:4, 28:5</p> <p>discuss [1] - 30:14</p> <p>disputes [2] - 29:7, 30:8</p> <p>DISTRICT [2] - 1:1, 1:2</p> <p>District [3] - 1:16, 3:17, 30:25</p> <p>Doug [1] - 3:7</p> <p>DOUGLAS [1] - 1:23</p> <p>down [1] - 30:2</p> <p>Dr [3] - 2:8, 3:11, 5:12</p> <p>drafted [1] - 17:20</p> <p>drafting [1] - 18:18</p> <p>DRL [11] - 5:9, 5:13, 9:6, 9:24, 10:5, 10:24, 11:7, 26:4, 26:7, 26:11</p> <p>DRL's [1] - 7:14</p> <p>dropped [1] - 20:16</p> <p>drug [1] - 18:22</p> <p>during [3] - 16:8, 16:12, 26:19</p> <p>E</p> <p>early [1] - 13:20</p> <p>efficient [1] - 25:10</p> <p>efficiently [1] - 26:19</p> <p>either [2] - 16:14, 23:15</p> <p>employee [1] - 5:8</p> <p>employees [5] - 4:18, 6:12, 6:15, 6:25, 7:16</p> <p>encompassed [1] - 22:22</p>	<p>end [1] - 30:12</p> <p>enjoy [1] - 30:18</p> <p>entered [1] - 13:18</p> <p>entire [1] - 11:10</p> <p>entirely [1] - 28:10</p> <p>especially [1] - 25:10</p> <p>ESQ [11] - 1:20, 1:23, 1:23, 2:3, 2:6, 2:10, 2:12, 2:15, 2:19, 2:21, 2:22</p> <p>essentially [3] - 22:4, 24:16, 29:23</p> <p>et [3] - 1:4, 1:7, 12:6</p> <p>ethical [1] - 6:17</p> <p>Eve [1] - 3:20</p> <p>EVE [1] - 2:10</p> <p>event [1] - 14:5</p> <p>exactly [2] - 9:9, 13:6</p> <p>example [5] - 7:11, 11:6, 16:5, 22:18, 28:19</p> <p>except [1] - 27:3</p> <p>exception [1] - 11:23</p> <p>excipient [3] - 21:16, 21:19, 23:13</p> <p>exclude [3] - 22:6, 22:17, 27:19</p> <p>expand [1] - 22:24</p> <p>expect [2] - 7:21, 7:24</p> <p>expedite [2] - 14:5, 15:1</p> <p>expedited [1] - 15:3</p> <p>expedites [1] - 12:24</p> <p>expert [1] - 28:23</p> <p>extend [1] - 13:15</p> <p>extent [3] - 6:25, 8:18, 14:25</p> <p>F</p> <p>fact [2] - 25:24, 26:9</p> <p>far [2] - 18:22, 29:12</p> <p>FDA [18] - 12:19, 13:14, 13:16, 13:21, 14:2, 14:12, 14:22, 15:20, 15:22, 16:3, 16:9, 16:16, 16:22, 16:25, 17:5, 17:9, 17:13, 21:4</p> <p>few [1] - 4:24</p> <p>figure [1] - 15:19</p> <p>filed [2] - 14:21, 15:10</p> <p>finally [1] - 29:22</p> <p>fine [3] - 4:16, 21:22, 26:5</p> <p>firm [1] - 4:6</p> <p>first [11] - 3:16, 4:17, 5:12, 9:4, 13:4, 18:16, 20:6, 24:10, 24:11, 25:13, 28:16</p>	<p>flip [1] - 29:9</p> <p>focused [1] - 16:24</p> <p>folks [3] - 10:6, 13:2, 30:11</p> <p>footnote [1] - 20:16</p> <p>FOR [1] - 1:2</p> <p>forbidden [1] - 11:4</p> <p>foregoing [1] - 30:22</p> <p>formulation [3] - 22:18, 22:21</p> <p>formulations [2] - 27:14, 27:15</p> <p>forth [2] - 13:23, 29:6</p> <p>future [1] - 8:18</p> <p>G</p> <p>GAZA [2] - 2:3, 3:10</p> <p>Gaza [1] - 3:11</p> <p>general [2] - 20:2, 21:7</p> <p>generalities [1] - 12:22</p> <p>generalized [1] - 15:23</p> <p>generally [1] - 29:6</p> <p>generic [13] - 13:8, 17:10, 20:11, 21:16, 22:5, 22:9, 22:15, 22:25, 23:11, 23:23, 25:3, 25:16</p> <p>given [10] - 7:20, 12:10, 14:17, 14:21, 15:14, 19:19, 29:10, 29:17, 30:9, 30:10</p> <p>gleaned [1] - 16:19</p> <p>great [3] - 3:18, 3:24, 15:5</p> <p>greatly [1] - 25:21</p> <p>guess [4] - 6:2, 9:4, 12:19, 15:18</p> <p>Guyline [1] - 4:5</p> <p>GUYLAINE [1] - 2:21</p> <p>H</p> <p>Hache [1] - 4:5</p> <p>HACHE [1] - 2:21</p> <p>HALL [1] - 2:18</p> <p>hamper [1] - 11:10</p> <p>hand [3] - 15:4, 16:4</p> <p>handle [2] - 8:24, 18:11</p> <p>handling [2] - 3:15, 16:25</p> <p>hands [2] - 26:6, 27:23</p> <p>happy [1] - 13:3</p> <p>hard [1] - 15:10</p> <p>Hardin [1] - 3:22</p>
--	--	---	---	--

HARDIN [1] - 2:12 harm [6] - 15:4, 15:14, 16:22, 18:5, 29:9, 29:20 harmed [1] - 25:21 harmful [1] - 19:24 hats [1] - 15:7 Hawkins [1] - 30:24 hear [6] - 4:23, 9:3, 10:15, 14:13, 20:3, 25:13 heard [2] - 24:5, 24:12 hearing [3] - 24:10, 28:19, 30:16 heart [1] - 23:9 help [1] - 14:24 helpful [3] - 23:2, 23:6, 30:3 helping [1] - 23:14 hereby [1] - 30:22 HEYDORN [9] - 2:6, 5:5, 10:23, 25:14, 26:3, 26:7, 26:17, 27:2, 28:1 Heydorn [6] - 3:13, 3:15, 5:6, 10:23, 25:15, 28:15 higher [2] - 6:16, 21:9 highly [4] - 4:20, 27:11, 27:13, 27:25 hits [1] - 23:9 Honor [32] - 3:5, 3:10, 3:19, 4:3, 4:14, 5:5, 6:8, 8:12, 9:7, 9:22, 10:11, 12:17, 13:3, 14:15, 15:6, 16:1, 17:21, 18:13, 18:16, 19:7, 19:12, 20:5, 20:22, 23:3, 23:13, 24:21, 25:14, 26:3, 28:3, 28:20, 29:10, 30:15 HONORABLE [1] - 1:15 hope [1] - 30:18 house [25] - 5:1, 5:7, 5:11, 5:14, 6:1, 6:23, 6:24, 7:1, 7:3, 7:15, 8:23, 8:24, 9:13, 9:25, 10:5, 10:8, 11:1, 11:15, 11:23, 11:24, 14:18, 15:6, 15:7, 29:16, 30:11	5:7, 5:11, 5:14, 6:1, 6:23, 6:24, 7:1, 7:3, 7:15, 8:23, 8:24, 9:13, 9:25, 10:5, 10:8, 11:1, 11:15, 11:23, 11:24, 14:18, 15:6, 15:7, 29:16, 30:11 Inc [2] - 2:8, 2:13 INC [2] - 1:4, 1:7 inclination [1] - 6:3 inclined [1] - 9:16 include [3] - 20:18, 25:1, 25:4 including [3] - 10:17, 14:10, 24:7 incorrect [1] - 5:4 individual [1] - 9:16 individuals [12] - 6:18, 7:7, 7:10, 9:10, 10:13, 11:1, 11:2, 11:6, 11:15, 11:20, 16:21, 16:23 information [70] - 4:19, 4:20, 5:3, 5:17, 5:19, 6:4, 6:9, 6:14, 7:18, 7:23, 7:25, 8:6, 11:3, 11:10, 11:17, 12:1, 13:1, 13:19, 13:22, 14:1, 14:3, 14:7, 14:8, 14:22, 14:23, 15:12, 15:17, 16:7, 16:13, 16:14, 16:18, 17:17, 19:13, 19:18, 19:23, 19:25, 20:2, 20:8, 20:10, 20:25, 21:18, 24:19, 25:21, 26:2, 26:5, 26:10, 26:14, 26:20, 26:22, 26:24, 27:4, 27:6, 27:8, 27:11, 27:17, 27:19, 27:22, 27:25, 28:6, 28:13, 28:16, 28:22, 29:1, 30:1, 30:2, 30:4, 30:9, 30:10 infringement [2] - 7:22, 28:21 ingredients [1] - 25:18 injury [1] - 29:20 institutional [1] - 15:9 intent [3] - 22:3, 22:6, 22:21 intentional [1] - 21:9 INTERCEPT [1] - 1:4 Intercept [6] - 3:6, 6:13, 13:25, 16:13, 16:19 Intercept's [6] - 7:18, 13:5, 13:19, 14:8,	14:11, 16:6 interrogatory [1] - 28:23 intersects [1] - 22:19 involved [2] - 9:14, 27:14 involvement [1] - 9:19 involves [2] - 25:15, 27:13 involving [1] - 26:22 IP [1] - 5:10 issue [19] - 4:17, 7:21, 9:5, 10:4, 12:14, 12:15, 12:18, 12:21, 15:22, 16:2, 16:12, 18:16, 19:4, 20:7, 20:14, 23:1, 24:4, 25:7, 27:24 issued [3] - 18:21, 23:21, 25:2 issues [4] - 4:10, 7:20, 18:7, 30:12 itself [4] - 18:25, 19:2, 19:16, 29:5	key [1] - 14:20 kind [2] - 6:5, 11:4 King [1] - 1:13 knowledge [2] - 15:9, 15:10 knows [1] - 15:6 Kurman [1] - 4:1 KURMAN [1] - 2:15	25:15, 28:9, 29:18, 29:21 LLP [7] - 1:20, 1:22, 2:3, 2:5, 2:9, 2:12, 2:21 logistical [2] - 28:7, 30:7 logistics [1] - 29:19 look [2] - 19:3, 20:7 looking [2] - 10:12, 18:1 Ltd [1] - 2:17 Lumbeck [1] - 10:18 Lupin [5] - 2:23, 4:4, 9:8, 10:8, 10:12
I		J	L	M
important [2] - 6:22 improper [1] - 21:24 IN [1] - 1:1 in-house [25] - 5:1,		Jack [1] - 4:4 JENKINS [1] - 2:9 JEREMY [1] - 1:20 Jeremy [1] - 3:5 JOHN [2] - 2:12, 2:19 joined [1] - 3:6 joint [3] - 26:11, 26:15, 26:17 JR [1] - 2:19 Judge [1] - 1:16 jurisdiction [3] - 6:20, 8:5, 12:12	Laboratories [3] - 2:7, 2:8, 3:12 Lance [2] - 4:5, 9:7 LANCE [1] - 2:22 language [2] - 18:10, 22:23 large [1] - 7:23 last [1] - 25:7 launch [1] - 15:3 law [1] - 10:17 lead [2] - 29:3, 29:7 learned [3] - 14:7, 14:23, 16:13 least [3] - 6:3, 8:16, 26:4 leaving [3] - 23:24, 24:4, 24:8 legal [2] - 5:1, 9:21 letter [7] - 4:13, 12:19, 18:8, 18:9, 19:21, 20:17, 20:24 letters [3] - 4:9, 15:15, 30:13 leverage [1] - 16:12 lifted [1] - 23:11 limit [3] - 19:9, 20:24, 22:6 limited [7] - 7:12, 8:22, 8:25, 16:23, 18:20, 18:22, 29:14 Limited [1] - 2:23 limiting [1] - 28:4 line [3] - 3:13, 3:21, 30:2 lines [5] - 16:11, 22:16, 23:20, 24:7, 24:25 listable [1] - 21:21 listed [7] - 18:21, 20:15, 22:3, 22:14, 22:23, 23:22, 25:2 litigate [1] - 25:10 litigation [25] - 5:1, 5:8, 6:23, 6:24, 7:4, 7:5, 7:8, 7:16, 7:21, 8:24, 9:11, 9:14, 10:6, 11:5, 11:9, 11:14, 15:8, 15:9, 16:24, 19:11, 21:1,	manage [2] - 6:24, 11:5 managing [4] - 7:4, 7:5, 7:16, 11:9 manufacture [1] - 25:5 manufacturing [5] - 21:10, 21:11, 24:8, 25:18, 25:20 market [1] - 17:7 MARYELLEN [1] - 1:15 material [2] - 14:11, 25:8 materials [1] - 13:20 matters [3] - 4:10, 5:12, 5:14 McLAUGHLIN [1] - 2:18 mean [7] - 5:11, 15:21, 17:12, 19:4, 19:6, 22:13, 27:7 meet [1] - 16:9 Megan [2] - 3:6, 4:15 MEGAN [1] - 1:23 members [3] - 5:15, 5:20, 11:8 mention [1] - 8:1 mentioned [1] - 10:24 method [1] - 21:10 might [2] - 16:16, 21:9 minimal [1] - 29:14 missing [1] - 15:21 misuse [3] - 6:14, 6:16, 15:23 misused [1] - 11:17 Mohan [6] - 3:21, 3:22, 9:22, 14:15, 18:14, 23:7 MOHAN [12] - 2:12, 9:22, 14:15, 17:21, 18:13, 18:16, 19:7, 19:12, 23:3, 23:7

<p>24:3, 24:10 month [1] - 15:2 moot [1] - 15:1 MORRIS [1] - 1:20 Morris [1] - 3:6 MR [17] - 3:5, 3:25, 4:3, 5:24, 9:7, 9:22, 10:11, 14:15, 17:21, 18:13, 18:16, 19:7, 19:12, 23:3, 23:7, 24:3, 24:10 MS [31] - 3:10, 3:19, 4:14, 4:22, 5:5, 5:13, 5:22, 6:8, 8:12, 10:23, 12:16, 13:3, 13:13, 16:1, 17:6, 17:15, 17:19, 20:5, 20:22, 22:1, 22:13, 24:1, 24:15, 25:14, 26:3, 26:7, 26:17, 27:2, 28:1, 28:3, 30:15 MSN [14] - 2:7, 3:11, 4:25, 5:2, 5:4, 5:6, 7:2, 9:6, 10:4, 11:24, 26:4, 26:7, 26:11 Muchin [2] - 4:6, 9:8 MUCHIN [1] - 2:21 multiday [1] - 29:3 multiple [3] - 10:18, 11:19, 15:6 Myer [2] - 3:25, 5:24 MYER [3] - 2:15, 3:25, 5:24</p>	<p>21:23 non [10] - 4:18, 5:8, 5:16, 5:19, 6:12, 6:15, 6:16, 7:17, 9:12, 10:19 non-attorney [4] - 4:18, 5:8, 6:12, 6:15 non-attorneys [6] - 5:16, 5:19, 6:16, 7:17, 9:12, 10:19 NOREIKA [1] - 1:15 note [1] - 29:22 noted [1] - 29:10 notes [1] - 30:22 nothing [2] - 19:10, 30:16 notified [1] - 8:19 noting [1] - 9:19</p>	<p>operating [1] - 26:18 opinion [2] - 11:3, 11:14 Optimus [11] - 2:17, 4:1, 5:9, 5:23, 5:25, 7:2, 9:6, 9:24, 10:4, 11:24 option [1] - 9:2 Orange [7] - 18:21, 20:16, 21:21, 22:8, 22:22, 23:22, 25:2 order [21] - 4:10, 4:11, 5:16, 6:12, 6:14, 8:4, 8:6, 10:25, 11:14, 11:15, 11:19, 12:3, 12:12, 12:13, 13:25, 20:9, 20:23, 20:24, 20:25, 21:8, 22:24 orderly [1] - 29:20 ORMEROD [2] - 2:10, 3:19 Ormerod [1] - 3:20 outside [12] - 11:12, 25:8, 25:11, 25:23, 25:25, 26:1, 26:6, 28:5, 28:6, 29:11, 29:14, 30:10 outweighs [2] - 15:16, 29:20 oversee [2] - 6:18, 6:24 overseeing [1] - 5:1 oversees [1] - 5:8 oversight [2] - 9:11, 9:20 own [1] - 27:10</p>	<p>23:10, 23:21, 24:4, 25:1, 25:5, 27:13 patent-in-suit [1] - 27:13 patents [9] - 19:1, 19:4, 20:15, 22:2, 23:21, 24:16, 25:1, 25:4 people [9] - 5:16, 5:18, 8:3, 8:7, 15:13, 15:17, 17:16, 21:8, 30:9 perform [1] - 10:5 permission [1] - 27:9 permit [1] - 9:16 permitted [3] - 7:18, 17:20, 20:9 person [9] - 7:12, 9:13, 10:8, 12:2, 12:3, 12:7, 12:11, 15:7, 15:12 person's [2] - 12:4, 12:8 personnel [1] - 5:10 perspective [1] - 8:25 Ph.D [1] - 2:21 Pharma [1] - 2:17 pharmaceutical [1] - 25:16 PHARMACEUTICAL S [1] - 1:4 Phillips [1] - 4:4 PHILLIPS [3] - 2:18, 2:19, 4:3 phone [1] - 4:5 phrasing [1] - 8:22 place [2] - 7:6, 20:12 plaintiff [10] - 10:21, 11:16, 17:4, 17:8, 17:9, 17:16, 26:25, 27:18, 28:8, 30:1 Plaintiffs [2] - 1:5, 1:25 plaintiffs [19] - 4:15, 9:18, 12:16, 14:17, 14:25, 15:4, 15:14, 17:22, 18:5, 18:19, 20:4, 21:13, 26:9, 27:3, 27:9, 28:25, 29:4, 30:15 plaintiffs' [15] - 4:12, 4:18, 5:2, 6:7, 11:23, 12:19, 14:23, 18:7, 18:22, 19:20, 20:17, 21:17, 23:8, 23:14, 30:6 pleased [1] - 3:14 point [6] - 10:16, 14:20, 17:22, 19:20 21:6, 23:15</p>	<p>pointing [1] - 22:7 points [2] - 28:4, 29:25 portions [1] - 3:15 position [1] - 28:20 possible [2] - 26:19, 27:21 potential [1] - 6:15 potentially [4] - 10:13, 23:1, 27:16, 28:18 preference [1] - 4:11 prejudice [2] - 15:5, 18:4 present [1] - 16:16 presented [1] - 16:11 prevent [2] - 17:4, 18:18 proceeding [2] - 28:8, 30:22 process [10] - 14:24, 16:25, 20:15, 21:10, 21:11, 24:4, 24:16, 25:20, 29:21 processes [10] - 19:15, 19:16, 20:20, 24:7, 24:17, 25:4, 25:5, 25:19, 27:13, 27:15 produced [1] - 27:20 product [16] - 14:3, 14:4, 14:7, 15:24, 16:2, 16:11, 16:15, 16:17, 16:19, 17:5, 17:6, 17:12, 17:14, 18:25, 21:16, 25:20 products [8] - 13:8, 13:15, 14:20, 19:19, 19:22, 19:23, 25:18, 25:19 proper [1] - 20:7 properly [1] - 29:8 proposal [28] - 5:2, 6:7, 11:23, 14:17, 17:22, 18:1, 18:3, 18:6, 18:22, 19:1, 21:13, 21:15, 21:22, 21:25, 22:2, 22:4, 23:12, 23:14, 23:15, 23:17, 24:5, 24:14, 24:20, 24:25, 26:23, 30:6, 30:7 proposals [2] - 24:24, 27:18 proposed [13] - 6:7, 13:4, 13:5, 13:8, 14:10, 18:17, 19:12, 20:11, 22:10, 22:11, 23:10, 24:21 proposing [1] - 29:23 prosecuting [1] -</p>
<p>N</p> <p>name [2] - 23:4, 23:6 narrow [5] - 13:6, 13:10, 13:12, 23:19, 27:19 narrowly [1] - 24:18 NDA [6] - 13:19, 13:21, 16:7, 17:5, 17:23, 19:13 NDAs [1] - 18:2 necessarily [2] - 19:18, 20:1 necessary [3] - 11:13, 15:11, 15:25 need [9] - 8:8, 12:7, 12:11, 12:20, 12:24, 14:6, 14:22, 23:18, 30:13 needs [1] - 12:3 new [2] - 15:11, 22:17 next [2] - 12:15, 12:18 Nichols [1] - 3:6 NICHOLS [1] - 1:20 nobody [2] - 7:3,</p>	<p>O</p> <p>Obeticholic [16] - 18:19, 18:23, 18:24, 19:5, 19:6, 19:8, 19:10, 19:14, 19:22, 20:1, 20:19, 21:11, 21:15, 21:19, 24:8, 25:6 objection [2] - 4:13, 6:10 obligation [1] - 26:13 obligations [1] - 9:17 obviously [1] - 29:12 Ocaliva [32] - 13:9, 13:21, 13:24, 16:8, 17:6, 18:23, 18:24, 19:14, 19:17, 19:19, 20:1, 20:11, 20:20, 21:20, 22:3, 22:5, 22:8, 22:9, 22:15, 22:25, 23:11, 23:12, 23:22, 23:23, 23:24, 23:25, 24:1, 25:3 OF [1] - 1:2 Official [1] - 30:24 OFFIT [1] - 2:15 Offit [1] - 4:1 often [2] - 15:6, 15:11 one [21] - 5:3, 7:12, 9:4, 9:13, 9:16, 10:7, 10:13, 11:5, 11:7, 11:22, 11:25, 12:1, 21:15, 23:13, 24:15, 25:7, 25:17, 26:21, 28:5, 29:1, 30:5 ones [2] - 28:17, 28:18 ongoing [2] - 8:15, 17:15 opening [2] - 4:12, 12:19</p>	<p>P</p> <p>P.A [2] - 2:15, 2:18 p.m [2] - 1:11, 30:20 part [2] - 7:24, 9:20 participating [4] - 3:23, 13:7, 14:11, 17:17 particular [11] - 4:11, 8:23, 9:1, 13:15, 14:4, 19:5, 19:11, 20:20, 22:7, 22:17, 22:21 particularly [2] - 7:20, 13:24 parties [2] - 6:22, 26:18 party [2] - 6:3, 11:2 pass [2] - 15:10, 15:12 patent [16] - 16:24, 18:18, 18:20, 19:2, 21:17, 21:19, 22:5, 22:13, 22:14, 22:20</p>	<p>pointing [1] - 22:7 points [2] - 28:4, 29:25 portions [1] - 3:15 position [1] - 28:20 possible [2] - 26:19, 27:21 potential [1] - 6:15 potentially [4] - 10:13, 23:1, 27:16, 28:18 preference [1] - 4:11 prejudice [2] - 15:5, 18:4 present [1] - 16:16 presented [1] - 16:11 prevent [2] - 17:4, 18:18 proceeding [2] - 28:8, 30:22 process [10] - 14:24, 16:25, 20:15, 21:10, 21:11, 24:4, 24:16, 25:20, 29:21 processes [10] - 19:15, 19:16, 20:20, 24:7, 24:17, 25:4, 25:5, 25:19, 27:13, 27:15 produced [1] - 27:20 product [16] - 14:3, 14:4, 14:7, 15:24, 16:2, 16:11, 16:15, 16:17, 16:19, 17:5, 17:6, 17:12, 17:14, 18:25, 21:16, 25:20 products [8] - 13:8, 13:15, 14:20, 19:19, 19:22, 19:23, 25:18, 25:19 proper [1] - 20:7 properly [1] - 29:8 proposal [28] - 5:2, 6:7, 11:23, 14:17, 17:22, 18:1, 18:3, 18:6, 18:22, 19:1, 21:13, 21:15, 21:22, 21:25, 22:2, 22:4, 23:12, 23:14, 23:15, 23:17, 24:5, 24:14, 24:20, 24:25, 26:23, 30:6, 30:7 proposals [2] - 24:24, 27:18 proposed [13] - 6:7, 13:4, 13:5, 13:8, 14:10, 18:17, 19:12, 20:11, 22:10, 22:11, 23:10, 24:21 proposing [1] - 29:23 prosecuting [1] -</p>	

<p>22:20 prosecution [6] - 18:10, 18:11, 18:17, 20:12, 21:6, 22:14 protect [1] - 20:13 protected [2] - 14:11, 25:8 protections [1] - 11:16 protective [20] - 4:10, 4:19, 5:16, 6:12, 6:14, 8:4, 8:5, 10:25, 11:14, 11:15, 11:19, 12:3, 12:12, 12:13, 20:9, 20:23, 20:24, 20:25, 21:8, 22:23 provide [2] - 11:1, 11:16 provided [1] - 6:10 provisions [3] - 11:16, 21:7, 26:21 publicly [1] - 7:24 punitive [1] - 18:4 purposely [1] - 13:5 purposes [1] - 21:25 pursuing [1] - 13:2 put [1] - 22:8 puts [1] - 29:4 Pvt [1] - 2:17</p>	<p>28:15 regarding [2] - 14:19, 17:10 regular [1] - 12:7 regulatory [5] - 12:23, 13:20, 16:21, 17:1 reject [1] - 24:24 related [8] - 13:23, 17:2, 18:17, 18:19, 19:2, 19:14, 20:1, 24:17 relates [1] - 7:22 relative [1] - 28:22 relevant [1] - 28:18 report [1] - 3:14 Reporter [1] - 30:24 reports [1] - 28:24 represent [1] - 7:6 representation [2] - 8:17, 26:12 representatives [2] - 14:18, 15:6 represented [2] - 26:8, 29:11 representing [1] - 7:1 requested [1] - 13:18 require [3] - 28:13, 28:18, 28:25 requirements [3] - 6:17, 6:19, 7:9 requires [2] - 29:2, 29:5 research [3] - 7:11, 13:20, 17:1 resolve [1] - 23:1 respect [11] - 6:15, 10:24, 13:4, 13:6, 13:7, 13:14, 14:2, 17:24, 24:20, 28:23, 28:24 response [2] - 4:25, 28:4 responses [1] - 28:23 responsibilities [6] - 7:10, 8:9, 8:16, 8:17, 12:5, 12:8 responsibility [4] - 7:4, 7:5, 8:14, 12:9 responsible [3] - 9:11, 11:8, 16:22 responsive [1] - 19:20 rest [1] - 30:18 restriction [2] - 17:8 result [1] - 26:9 retool [1] - 15:24 review [1] - 14:19 reviewing [1] - 14:1 risk [2] - 18:4, 21:9 role [4] - 10:5, 12:5, 12:6, 13:2</p>	<p>ROSENMAN [1] - 2:21 route [1] - 26:13 run [1] - 15:9</p> <p style="text-align: center;">S</p> <p>safeguards [5] - 7:6, 8:1, 8:10, 8:13, 8:21 sanctions [1] - 6:18 saw [2] - 18:1, 21:5 scenario [2] - 16:2, 28:13 Schiff [1] - 3:22 SCHIFF [1] - 2:12 scope [4] - 18:9, 20:8, 22:2, 22:3 secrets [1] - 27:14 see [8] - 5:3, 8:6, 8:15, 11:25, 14:22, 20:9, 29:9, 29:19 seeing [2] - 21:18, 26:22 seek [2] - 16:16, 28:25 seeking [4] - 16:3, 28:17, 29:15, 30:1 seem [2] - 21:11, 21:12 send [2] - 24:23, 24:24 sense [1] - 25:10 sensitive [3] - 25:21, 27:12, 27:22 separate [1] - 25:17 setting [1] - 29:23 share [5] - 26:10, 26:13, 26:24, 27:3, 27:9 shared [2] - 26:21, 27:6 SHEA [1] - 2:3 side [2] - 21:5, 29:9 sign [2] - 8:3, 12:11 similar [1] - 16:12 simply [1] - 11:5 situation [9] - 7:15, 9:10, 9:12, 9:23, 10:24, 22:7, 22:17, 27:5, 29:15 situations [3] - 7:12, 7:14, 8:23 six [2] - 25:15, 28:9 small [1] - 27:20 Smith [1] - 3:20 SMITH [1] - 2:9 Soderstrom [2] - 4:5, 9:8 SODERSTROM [3] - 2:22, 9:7, 10:11 someone [3] - 5:4, 6:3, 15:24 sorry [1] - 10:11</p>	<p>sort [3] - 9:18, 22:24, 29:13 sought [1] - 18:24 sounds [1] - 4:16 speaking [1] - 14:16 specific [4] - 16:10, 19:8, 19:14 specifically [4] - 10:25, 13:7, 21:1 split [2] - 15:13, 15:17 spot [1] - 9:9 standard [1] - 22:23 standards [1] - 16:9 STARGATT [1] - 2:3 start [2] - 4:12, 23:5 state [1] - 19:21 STATES [1] - 1:1 States [1] - 1:16 stay [1] - 15:2 stenographic [1] - 30:22 Stern [1] - 6:11 stop [2] - 21:3, 21:4 strategically [1] - 29:24 strategies [1] - 13:24 strategy [2] - 12:23, 29:12 STRAWN [1] - 2:5 Strawn [1] - 3:14 Street [1] - 1:13 strictly [1] - 9:20 struggle [1] - 14:22 stuck [1] - 9:9 subject [1] - 6:17 subjects [1] - 6:19 submit [2] - 8:4, 12:12 sufficiently [1] - 13:12 suggest [1] - 25:25 suggested [3] - 18:5, 23:13, 24:25 suggesting [1] - 21:13 suit [1] - 27:13 support [2] - 14:1, 16:19 suspenders [1] - 21:7 system [1] - 11:4</p> <p style="text-align: center;">T</p> <p>tailored [4] - 19:1, 19:18, 20:12, 24:18 tangential [1] - 18:6 TAYLOR [1] - 2:3 team [11] - 5:15, 5:20, 9:21, 10:6, 11:4, 11:6, 11:7, 11:8, 11:11, 11:20 teams [1] - 11:1</p>	<p>technical [1] - 27:13 Teleconference [2] - 1:11, 30:20 terms [2] - 8:9, 15:23 terribly [1] - 20:18 testing [3] - 13:25, 14:4, 16:15 THE [49] - 1:1, 1:2, 1:15, 3:3, 3:9, 3:18, 3:24, 4:2, 4:7, 4:17, 4:23, 5:9, 5:21, 5:23, 6:2, 8:1, 9:3, 10:1, 10:15, 11:21, 12:18, 13:10, 14:13, 15:18, 17:3, 17:11, 17:16, 17:25, 18:15, 19:3, 19:9, 20:3, 20:14, 21:3, 22:10, 23:4, 23:17, 24:2, 24:6, 24:13, 24:22, 25:23, 26:4, 26:15, 26:23, 27:24, 28:2, 30:5, 30:16 their's [1] - 23:19 they've [1] - 16:13 thinking [4] - 4:12, 8:2, 8:11, 23:20 third [1] - 10:7 thirty [1] - 15:2 thirty-month [1] - 15:2 thoughts [1] - 24:14 three [11] - 3:12, 5:16, 5:17, 5:20, 10:6, 10:12, 11:2, 11:15, 25:24, 29:3, 29:10 throughout [1] - 7:8 tie [1] - 24:16 Tigan [1] - 3:5 TIGAN [2] - 1:20, 3:5 timing [1] - 12:24 today [4] - 3:8, 3:13, 3:14, 3:23 together [1] - 29:12 topics [1] - 28:16 Touhey [2] - 3:25, 5:24 TOUHEY [1] - 2:15 trade [1] - 27:14 transcript [1] - 30:22 trial [2] - 28:11 tried [1] - 13:5 true [2] - 15:16, 30:22 try [1] - 27:18 trying [6] - 15:19, 22:16, 27:10, 27:17, 27:19, 27:21 Tuesday [1] - 1:10 TUNNEL [1] - 1:20 two [8] - 5:22, 10:5, 11:5, 15:13, 15:17,</p>
---	--	---	---	--

16:4, 18:7, 29:2 two's [1] - 26:5 type [4] - 27:7, 27:17, 27:19, 28:16 types [1] - 28:22 typically [2] - 9:14, 16:20	Winston [2] - 3:14, 26:8 withhold [1] - 29:2 workable [4] - 28:12, 28:13, 28:25, 29:3 works [2] - 5:1, 15:8 worried [1] - 15:20 worry [1] - 20:17 written [1] - 28:14
U	Y
U.S [1] - 30:25 ultimately [1] - 16:9 unclear [1] - 23:10 under [18] - 6:14, 12:2, 12:11, 17:22, 20:9, 20:25, 21:12, 21:14, 21:22, 21:25, 22:1, 22:20, 23:9, 23:12, 23:14, 26:13, 26:23 understood [1] - 22:22 undertake [1] - 15:15 undertaking [1] - 8:3 unfortunately [1] - 9:9 unique [3] - 25:18, 25:20, 27:12 UNITED [1] - 1:1 United [1] - 1:16 unnecessary [2] - 30:7, 30:9 unrestricted [1] - 26:10 up [5] - 15:13, 15:17, 28:10, 28:22, 29:24 update [1] - 12:10 uses [1] - 19:10	YOUNG [1] - 2:3 your's [1] - 23:19
V	
validity [3] - 7:23, 28:23, 28:24 various [1] - 6:12 version [2] - 23:23, 25:4 versions [7] - 13:8, 20:11, 22:5, 22:9, 22:15, 22:25, 23:12 versus [2] - 15:8, 16:24 view [1] - 5:19	
W	
week [1] - 30:19 weighted [1] - 17:8 welcome [1] - 3:18 West [1] - 6:11 whereas [1] - 18:19 Wilmington [1] - 1:13 WINSTON [1] - 2 5	

EXHIBIT D



User Name: Labdhi Sheth

Date and Time: Friday, July 2, 2021 5:30:00 PM EDT

Job Number: 147559332

Results List (includes up to 250)

1. Results list for: defendant-litigant(MSN)

Client/Matter: 2213494-00120

Terms: [defendant-litigant\(MSN\)](#)

Search Type: Natural Language

Narrowed by:

Content Type
Dockets

Narrowed by
Case Status: Open, Unknown, Closed; Patent



Results for: defendant-litigant(MSN)

Dockets

1. [Amgen Inc. Et Al V. Msn Laboratories Private Limited Et Al](#)

... JENKINS LLP 2018-01-08T13:02:00 69209789416936 302-652-8400 Fax: 302-652-8405
 Email:Eormerod@skjlaw.Com USA 1 D **MSN** LIFE SCIENCES PRIVATE LIMITED D Defendant **MSN** LIFE SCIENCES PRIVATE LIMITED 2019-09-30T20:29:00 5 **MSN** LIFE SCIENCES PRIVATE LIMITED...
 ... TUNNELL LLP 2013-08-29T17:03:00 -1 -1 62663025568455 (302)658-9200 Email:Kjacobs@mnat.Com
 USA 2 P **MSN** LABORATORIES PRIVATE LIMITED D Defendant **MSN** LABORATORIES PRIVATE LIMITED 2015-05-18T14:49:00 3 **MSN** LABORATORIES PRIVATE LIMITED Eve H. Ormerod...
 ... JENKINS LLP 2018-01-08T13:02:00 69209789416936 302-652-8400 Fax: 302-652-8405
 Email:Eormerod@skjlaw.Com USA 1 D **MSN** Pharmaceuticals Inc. D Defendant **MSN** PHARMACEUTICALS INC 2017-01-11T08:30:00 4 **MSN** Pharmaceuticals Inc. Eve H. Ormerod...

Court: United States District Court, Delaware | **Date Filed:** May 19, 2021 | **Docket Number:** 1:21cv712 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Open

2. [Chiesi Usa, Inc. Et Al V. Msn Pharmaceuticals Inc. Et Al](#)

... 157363817 158435445 78691706517759 973-998-7477 Fax: 973-264-1159
 Email:Jason@lattimorelaw.Com USA 1 D 2013-04-29T17:00:36.120 **MSN** LIFE SCIENCES PRIVATE LIMITED D Defendant **MSN** LIFE SCIENCES PRIVATE LIMITED 2019-09-30T20:29:00 5 **MSN** LIFE SCIENCES PRIVATE LIMITED...
 ... PC 2013-10-02T15:17:00 426827 1107021 40078617129639 973-596-4500
 Email:Cchevalier@gibbonslaw.Com USA 4 P 2014-05-29T17:00:57.387 **MSN** Pharmaceuticals Inc. D Defendant **MSN** PHARMACEUTICALS INC 2017-01-11T08:30:00 3 **MSN** Pharmaceuticals Inc. JASON B. LATTIMORE...
 ... 157363817 158435445 78691706517759 973-998-7477 Fax: 973-264-1159
 Email:Jason@lattimorelaw.Com USA 1 D 2013-04-29T17:00:36.120 **MSN** Laboratories Private Ltd. D Defendant **MSN** LABORATORIES PRIVATE LTD 2017-01-17T11:46:00 4 **MSN** Laboratories Private Ltd. JASON B. LATTIMORE...

Court: United States District Court, New Jersey | **Date Filed:** Sep 30, 2019 | **Docket Number:** 2:19cv18564 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Open

3. [H. Lundbeck A/S Et Al V. Lupin Limited, Et Al](#)

... L HIRSCHHORN 2012-07-27T14:31:00 -1 -1 13126703079079 Email:Philip.Hirschhorn@bipc.Com
 2020-04-03 5 D 2013-04-26T17:44:11.313 **MSN** Pharmachem Private Limited D Defendant **MSN** PHARMACHEM PRIVATE LIMITED 2018-01-19T15:02:00 20 2021-01-19 **MSN** Pharmachem Private Limited...
 ... 2016-11-08T17:16:00 -1 -1 80106437909696 302-651-7844 Fax: 302-498-7701 Email:Pedi@rlf.Com
 USA 4 D **MSN** LABORATORIES PRIVATE LIMITED D Defendant **MSN** LABORATORIES PRIVATE LIMITED 2015-05-18T14:49:00 18 2021-01-19 **MSN** LABORATORIES PRIVATE LIMITED...
 ... L HIRSCHHORN 2012-07-27T14:31:00 -1 -1 13126703079079 Email:Philip.Hirschhorn@bipc.Com
 2020-04-03 5 D 2013-04-26T17:44:11.313 **MSN** Pharmaceuticals Inc. D Defendant **MSN**

PHARMACEUTICALS INC 2017-01-11T08:30:00 19 2021-01-19 **MSN** Pharmaceuticals Inc. Geoffrey Graham Grivner...

Court: United States District Court, Delaware | **Date Filed:** Jan 12, 2018 | **Docket Number:** 1:18cv88 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Open

4. [H. Lundbeck A/S Et Al V. Msn Laboratories Private Limited Et Al](#)

... L HIRSCHHORN 2012-07-27T14:31:00 -1 -1 13126703079079 Email:Philip.Hirschhorn@bipc.Com
2020-04-03 6 D 2013-04-26T17:44:11.313 **MSN** Pharmachem Private Limited D Defendant **MSN**
PHARMACHEM PRIVATE LIMITED 2018-01-19T15:02:00 8 **MSN** Pharmachem Private Limited Geoffrey
Graham Grivner...

... TUNNELL LLP 2014-02-27T17:13:00 -1 -1 75118614774617 302-351-9366
Email:Mdellinger@mnat.Com USA 3 P **MSN** LABORATORIES PRIVATE LIMITED D Defendant **MSN**
LABORATORIES PRIVATE LIMITED 2015-05-18T14:49:00 6 **MSN** LABORATORIES PRIVATE LIMITED
Geoffrey Graham Grivner...

... L HIRSCHHORN 2012-07-27T14:31:00 -1 -1 13126703079079 Email:Philip.Hirschhorn@bipc.Com
2020-04-03 6 D 2013-04-26T17:44:11.313 **MSN** PHARMACEUTICALS, INC. D Defendant **MSN**
PHARMACEUTICALS INC 2015-08-04T16:03:00 7 **MSN** PHARMACEUTICALS, INC. Geoffrey Graham
Grivner...

Court: United States District Court, Delaware | **Date Filed:** Jan 19, 2018 | **Docket Number:** 1:18cv114 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Closed

5. [H. Lundbeck A/S Et Al V. Msn Laboratories Private Limited Et Al](#)

... 2019-04-08T11:02:00 91193714692087 (302) 552-4207 Fax: (302) 552-4295
Email:Geoffrey.Grivner@bipc.Com USA 5 D **MSN** Pharmachem Private Limited D Defendant **MSN**
PHARMACHEM PRIVATE LIMITED 2018-01-19T15:02:00 8 **MSN** Pharmachem Private Limited Erin M.
Dunston...

... 2012-06-15T16:16:00 -1 -1 70863434373129 (302) 658-9200 Email:Menefiling@mnat.Com USA 2018-
08-10 2 P **MSN** LABORATORIES PRIVATE LIMITED D Defendant **MSN** LABORATORIES PRIVATE
LIMITED 2015-05-18T14:49:00 6 **MSN** LABORATORIES PRIVATE LIMITED Erin M. Dunston...

... 2019-04-08T11:02:00 91193714692087 (302) 552-4207 Fax: (302) 552-4295
Email:Geoffrey.Grivner@bipc.Com USA 5 D **MSN** PHARMACEUTICALS, INC. D Defendant **MSN**
PHARMACEUTICALS INC 2015-08-04T16:03:00 7 **MSN** PHARMACEUTICALS, INC. Erin M. Dunston...

Court: United States District Court, Delaware | **Date Filed:** Jun 07, 2018 | **Docket Number:** 1:18cv853 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Open

6. [Intercept Pharmaceuticals, Inc. Et Al V. Msn Laboratories Private Limited Et Al](#)

... KEVIN E WARNER 2012-06-29T16:16:00 -1 -1 9043091254096 Email:Kwarner@winston.Com 4 D
2013-04-26T17:44:11.313 **MSN** Life Sciences Private Ltd. D Defendant **MSN** LIFE SCIENCES PRIVATE
LTD 2020-09-11T08:31:00 5 2020-11-04 **MSN** Life Sciences Private Ltd....

... BE NOTICED -1 MARY K SWEARS 2020-09-15T11:04:00 7446347524607 Email:Ocaliva@cov.Com 3
P **MSN** LABORATORIES PRIVATE LIMITED D Defendant **MSN** LABORATORIES PRIVATE LIMITED
2015-05-18T14:49:00 3 **MSN** LABORATORIES PRIVATE LIMITED Anne Shea Gaza...

... KEVIN E WARNER 2012-06-29T16:16:00 -1 -1 9043091254096 Email:Kwarner@winston.Com 4 D
2013-04-26T17:44:11.313 **MSN** Pharmaceuticals Inc. D Defendant **MSN** PHARMACEUTICALS INC 2017-
01-11T08:30:00 4 **MSN** Pharmaceuticals Inc. Anne Shea Gaza...

Court: United States District Court, Delaware | **Date Filed:** Sep 10, 2020 | **Docket Number:** 1:20cv1214 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:**
Open

7. [Merck Sharp & Dohme B.V. Et Al V. Aurobindo Pharma Usa, Inc. Et Al](#)

... SAGE FISHERBROYLES LLP 2021-05-02T22:09:00 54762368482999 732-929-7298
Email:Karin.Sage@fisherbroyles.Com USA 2020-09-29 2 D **MSN** Pharmaceuticals Inc. D Defendant
Defendant in 2:20-cv-03314 | **MSN** PHARMACEUTICALS INC 2017-01-11T08:30:00 29 **MSN**
Pharmaceuticals Inc....
... BENJAMIN HALPERN SAIBER LLC 2020-10-19T22:01:00 45354772661704 973-622-3333
Email:Jbh@saiber.Com USA 3 D **MSN** LABORATORIES PRIVATE LIMITED D Defendant Defendant in
2:20-cv-03314 | **MSN** LABORATORIES PRIVATE LIMITED 2015-05-18T14:49:00 27...
... SAGE FISHERBROYLES LLP 2021-05-02T22:09:00 54762368482999 732-929-7298
Email:Karin.Sage@fisherbroyles.Com USA 2020-09-29 2 D **MSN** LIFE SCIENCES PRIVATE LIMITED D
Defendant Defendant in 2:20-cv-03314 | **MSN** LIFE SCIENCES PRIVATE LIMITED 2019-09-
30T20:29:00...

Court: United States District Court, New Jersey | **Date Filed:** Mar 10, 2020 | **Docket Number:** 2:20cv2576
| **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement |
Status: Open

8. [Merck Sharp & Dohme B.V. Et Al V. Msn Laboratories Private Limited Et Al](#)

... KRAFT SAGE FISHERBROYLES LLP 2020-03-11T22:03:00 56173650325726 732-929-7298
Email:Karin.Sage@fisherbroyles.Com USA 2 D **MSN** Pharmaceuticals Inc. D Defendant **MSN**
PHARMACEUTICALS INC 2017-01-11T08:30:00 5 **MSN** Pharmaceuticals Inc. GURPREET SINGH
WALIA...
... 2012-04-25T10:05:00 426827 1107021 40359965568670 (973) 596-4500
Email:Wdeni@gibbonslaw.Com USA 4 P 2013-06-04T17:00:56.957 **MSN** LABORATORIES PRIVATE
LIMITED D Defendant **MSN** LABORATORIES PRIVATE LIMITED 2015-05-18T14:49:00 3 **MSN**
LABORATORIES PRIVATE LIMITED GURPREET SINGH WALIA...
... KRAFT SAGE FISHERBROYLES LLP 2020-03-11T22:03:00 56173650325726 732-929-7298
Email:Karin.Sage@fisherbroyles.Com USA 2 D **MSN** LIFE SCIENCES PRIVATE LIMITED D Defendant
MSN LIFE SCIENCES PRIVATE LIMITED 2019-09-30T20:29:00 4 **MSN** LIFE SCIENCES PRIVATE
LIMITED...

Court: United States District Court, New Jersey | **Date Filed:** Mar 26, 2020 | **Docket Number:** 2:20cv3314
| **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement |
Status: Closed

9. [Novartis Pharmaceuticals Corporation V. Dr. Reddys Laboratories, Inc. Et Al](#)

... STAMOULIS WEINBLATT LLC 2019-01-25T10:26:00 62027177972605 (302) 999-1540
Email:Stamoulis@swdelaw.Com USA 3 D **MSN** LIFE SCIENCES PRIVATE LIMITED D Defendant **MSN**
LIFE SCIENCES PRIVATE LIMITED 2019-09-30T20:29:00 9 **MSN** LIFE SCIENCES PRIVATE LIMITED...
... BE NOTICED -1 KENNETH S CANFIELD 2020-04-03T10:51:00 13665925572607
Email:Kcanfield@pergamentcepeda.Com 6 D **MSN** Pharmaceuticals Inc. D Defendant **MSN**

PHARMACEUTICALS INC 2017-01-11T08:30:00 7 **MSN** Pharmaceuticals Inc. Richard Juang PRO HAC VICE; ATTORNEY TO BE NOTICED...
 ... STAMOULIS WEINBLATT LLC 2019-01-25T10:26:00 62027177972605 (302) 999-1540
 Email:Stamoulis@swdelaw.Com USA 3 D **MSN** LABORATORIES PRIVATE LIMITED D Defendant **MSN** LABORATORIES PRIVATE LIMITED 2015-05-18T14:49:00 8 **MSN** LABORATORIES PRIVATE LIMITED Richard Juang...

Court: United States District Court, Delaware | **Date Filed:** Oct 29, 2019 | **Docket Number:** 1:19cv2053 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Open

10. [Otsuka Pharmaceutical Co., Ltd. Et Al V. Msn Laboratories Private, Ltd. Et Al](#)

... BE NOTICED -1 TERESA M SUMMERS 2020-03-05T15:44:00 9413705361465
 Email:Tsummers@wiley.Law 5 D **MSN** Life Sciences Pvt. Ltd. D Defendant **MSN** LIFE SCIENCES PVT LTD 2019-10-24T09:05:00 5 2021-03-10 **MSN** Life Sciences Pvt. Ltd....
 ... BE NOTICED -1 TYLER B LATCHAM 2020-09-28T11:32:00 11765893079249
 Email:Tyler.Latcham@finnegan.Com 8 P **MSN** Laboratories Private Ltd. D Defendant **MSN** LABORATORIES PRIVATE LTD 2017-01-17T11:46:00 3 **MSN** Laboratories Private Ltd. John M. Seaman...
 ... BE NOTICED -1 TERESA M SUMMERS 2020-03-05T15:44:00 9413705361465
 Email:Tsummers@wiley.Law 5 D **MSN** Pharmaceuticals Inc. D Defendant **MSN** PHARMACEUTICALS INC 2017-01-11T08:30:00 4 **MSN** Pharmaceuticals Inc. John M. Seaman...

Court: United States District Court, Delaware | **Date Filed:** Oct 23, 2019 | **Docket Number:** 1:19cv2009 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Open

11. [Otsuka Pharmaceutical Co., Ltd. Et Al V. Msn Laboratories Private Ltd. Et Al](#)

... BE NOTICED -1 TERESA M SUMMERS 2020-03-05T15:44:00 9413705361465
 Email:Tsummers@wiley.Law 4 D **MSN** Life Sciences Pvt. Ltd. D Defendant **MSN** LIFE SCIENCES PVT LTD 2019-10-24T09:05:00 5 2021-03-10 **MSN** Life Sciences Pvt. Ltd....
 ... BE NOTICED -1 TYLER B LATCHAM 2020-09-28T11:32:00 11765893079249
 Email:Tyler.Latcham@finnegan.Com 6 P **MSN** Laboratories Private Ltd. D Defendant **MSN** LABORATORIES PRIVATE LTD 2017-01-17T11:46:00 3 **MSN** Laboratories Private Ltd. April M. Kirby...
 ... BE NOTICED -1 TERESA M SUMMERS 2020-03-05T15:44:00 9413705361465
 Email:Tsummers@wiley.Law 4 D **MSN** Pharmaceuticals Inc. D Defendant **MSN** PHARMACEUTICALS INC 2017-01-11T08:30:00 4 **MSN** Pharmaceuticals Inc. April M. Kirby...

Court: United States District Court, Delaware | **Date Filed:** Oct 23, 2020 | **Docket Number:** 1:20cv1428 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Open

12. [Otsuka Pharmaceutical Co., Ltd. Et Al V. Zenara Pharma Private Ltd. Et Al](#)

... TO BE NOTICED -1 NEAL SETH 2020-05-06T08:48:00 6434341157048 Email:Nseth@wiley.Law 3 D **MSN** Life Sciences Pvt. Ltd. D Defendant **MSN** LIFE SCIENCES PVT LTD 2019-10-24T09:05:00 32 2021-03-10 **MSN** Life Sciences Pvt. Ltd....
 ... BE NOTICED -1 RONALD M DAIGNAULT 2021-02-16T17:38:00 13463912643356
 Email:Rdaignault@daignaultiyr.Com 3 D **MSN** LABORATORIES PVT. LTD. D Defendant **MSN**

LABORATORIES PVT LTD 2015-03-03T10:02:00 30 **MSN** LABORATORIES PVT. LTD. John M. Seaman...

... TO BE NOTICED -1 NEAL SETH 2020-05-06T08:48:00 6434341157048 Email:Nseth@wiley.Law 3 D **MSN** Pharmaceuticals Inc. D Defendant **MSN** PHARMACEUTICALS INC 2017-01-11T08:30:00 31 **MSN** Pharmaceuticals Inc. John M. Seaman...

Court: United States District Court, Delaware | **Date Filed:** Oct 11, 2019 | **Docket Number:** 1:19cv1938 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Open

13. [Acadia Pharmaceuticals Inc. V. Aurobindo Pharma Limited Et Al](#)

... TODD S WERNER 2015-07-08T12:46:00 -1 -1 11420979802364 Email:Twerner@carlsoncaspers.Com 2021-05-03 4 D **MSN** LABORATORIES PRIVATE LIMITED D Defendant **MSN** LABORATORIES PRIVATE LIMITED 2015-05-18T14:49:00 10 **MSN** LABORATORIES PRIVATE LIMITED James S. Green , Jr....
... BE NOTICED -1 YIXIN H TANG 2019-06-17T16:20:00 8224130477971 Email:Yixin@ipfdalaw.Com 4 D **MSN** PHARMACEUTICALS, INC. D Defendant **MSN** PHARMACEUTICALS INC 2015-08-04T16:03:00 11 **MSN** PHARMACEUTICALS, INC. James S. Green , Jr....

Court: United States District Court, Delaware | **Date Filed:** Jul 24, 2020 | **Docket Number:** 1:20cv985 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Open

14. [Acadia Pharmaceuticals Inc. V. Msn Laboratories Private Limited Et Al](#)

... -1 SCOTT F PEACHMAN 2015-11-30T12:16:00 -1 -1 13726434801760 Email:Scottpeachman@paulhastings.Com 6 P **MSN** LABORATORIES PRIVATE LIMITED D Defendant **MSN** LABORATORIES PRIVATE LIMITED 2015-05-18T14:49:00 2 **MSN** LABORATORIES PRIVATE LIMITED James S. Green , Jr....
... BE NOTICED -1 YIXIN H TANG 2019-06-17T16:20:00 8224130477971 Email:Yixin@ipfdalaw.Com 4 D **MSN** PHARMACEUTICALS, INC. D Defendant **MSN** PHARMACEUTICALS INC 2015-08-04T16:03:00 3 **MSN** PHARMACEUTICALS, INC. James S. Green , Jr....

Court: United States District Court, Delaware | **Date Filed:** Jul 30, 2020 | **Docket Number:** 1:20cv1029 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Open

15. [Actelion Pharmaceuticals Ltd Et Al V. Msn Pharmaceuticals Inc. Et Al](#)

... (973) 690-5400 Fax: (973) 466-2760 Email:Kmillerr@rwmlegal.Com USA 1 P **MSN** Pharmaceuticals Inc. D Defendant **MSN** PHARMACEUTICALS INC 2017-01-11T08:30:00 3 **MSN** Pharmaceuticals Inc. **MSN** LABORATORIES PRIVATE LIMITED D Defendant **MSN** LABORATORIES PRIVATE LIMITED...

Court: US District Court for the District of New Jersey | **Date Filed:** Apr 09, 2020 | **Docket Number:** 3:20cv3859 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Open

16. [Actelion Pharmaceuticals Ltd Et Al V. Msn Pharmaceuticals Inc. Et Al](#)

... 2019-08-01T22:00:00 72199601940452 (973) 690-5400 Fax: (973) 466-2760 Email:Kmillerr@rwmlegal.Com USA 1 P **MSN** Pharmaceuticals Inc. D Defendant **MSN**

PHARMACEUTICALS INC 2017-01-11T08:30:00 3 2021-01-29 **MSN** Pharmaceuticals Inc. ANANDITA VYAKARNAM...
 ... MITTENDORF LLP 2019-04-18T20:18:00 66464795524320 973-966-3200 Fax: 973-966-3250
 Email:Csun@windelsmarx.Com USA 2 D **MSN** LABORATORIES PRIVATE LIMITED D Defendant **MSN**
 LABORATORIES PRIVATE LIMITED 2015-05-18T14:49:00 4 2021-01-29 **MSN** LABORATORIES
 PRIVATE LIMITED...

Court: United States District Court, New Jersey | **Date Filed:** Apr 09, 2020 | **Docket Number:** 1:20cv3859
 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement |
Status: Open

17. [Actelion Pharmaceuticals Ltd Et Al V. Msn Pharmaceuticals Inc. Et Al](#)

... (973) 690-5400 Fax: (973) 466-2760 Email:Kmillier@rwmlegal.Com USA 1 P **MSN** Pharmaceuticals Inc.
 D Defendant **MSN** PHARMACEUTICALS INC 2017-01-11T08:30:00 3 **MSN** Pharmaceuticals Inc. **MSN**
 LABORATORIES PRIVATE LIMITED D Defendant **MSN** LABORATORIES PRIVATE LIMITED...

Court: US District Court for the District of New Jersey | **Date Filed:** Apr 09, 2020 | **Docket Number:**
 2:20cv3859 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent
 Infringement | **Status:** Open

18. [Adverio Pharma Gmbh Et Al V. Msn Laboratories Private Limited Et Al](#)

... LLP 2012-08-29T11:16:00 287558 343068 62991412107411 302-351-9106 Email:Jtigan@mnat.Com
 USA 2 P 2013-04-26T17:48:45.540 **MSN** LABORATORIES PRIVATE LIMITED D Defendant **MSN**
 LABORATORIES PRIVATE LIMITED 2015-05-18T14:49:00 4 **MSN** LABORATORIES PRIVATE LIMITED
 Nathan Roger Hoeschen...
 ... HOESCHEN SHAW KELLER LLP 2017-05-02T12:22:00 58712004286689 302-298-0709
 Email:Nhoeschen@shawkeller.Com USA 1 D **MSN** Pharmaceuticals Inc. D Defendant **MSN**
 PHARMACEUTICALS INC 2017-01-11T08:30:00 5 **MSN** Pharmaceuticals Inc. Nathan Roger Hoeschen...

Court: United States District Court, Delaware | **Date Filed:** Nov 25, 2020 | **Docket Number:** 1:20cv1617 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:**
 Closed

19. [Adverio Pharma Gmbh Et Al V. Msn Laboratories Private Limited Et Al](#)

... NICHOLS ARSHT TUNNELL LLP 2021-06-09T17:36:00 70499887363491 302-351-9106
 Email:Jtigan@morrisnichols.Com USA 2 P **MSN** LABORATORIES PRIVATE LIMITED D Defendant **MSN**
 LABORATORIES PRIVATE LIMITED 2015-05-18T14:49:00 4 **MSN** LABORATORIES PRIVATE LIMITED
 Elaine H. Blais...
 ... KELLER SHAW KELLER LLP 2017-05-02T12:21:00 57753321735039 302-298-0700
 Email:Kkeller@shawkeller.Com USA 7 D **MSN** Pharmaceuticals Inc. D Defendant **MSN**
 PHARMACEUTICALS INC 2017-01-11T08:30:00 5 **MSN** Pharmaceuticals Inc. Nathan Roger Hoeschen...

Court: United States District Court, Delaware | **Date Filed:** Jan 19, 2018 | **Docket Number:** 1:18cv111 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:**
 Closed

20. [Adverio Pharma Gmbh Et Al V. Msn Laboratories Private Limited Et Al](#)

... 342993 88506379972244 Fax: (302) 571-1750 Email:Kdorsney@morrisjames.Com USA 2019-02-13 1 D 2014-06-11T17:01:18.193 **MSN** LABORATORIES PRIVATE LIMITED D Defendant **MSN** LABORATORIES PRIVATE LIMITED 2015-05-18T14:49:00 8 **MSN** LABORATORIES PRIVATE LIMITED Karen Elizabeth Keller...

... BE NOTICED -1 SRIKANTH K REDDY 2017-08-31T13:13:00 10344553544554

Email:Sreddy@goodwinlaw.Com 9 D **MSN** Pharmaceuticals Inc. D Defendant **MSN** PHARMACEUTICALS INC 2017-01-11T08:30:00 9 **MSN** Pharmaceuticals Inc. Karen Elizabeth Keller...

Court: United States District Court, Delaware | **Date Filed:** Jan 09, 2018 | **Docket Number:** 1:18cv73 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Closed

21. [Allergan Usa, Inc. Et Al V. Aurobindo Pharma Ltd. Et Al](#)

... JAMES LLP 2019-11-07T12:37:00 76671795600331 Fax: (302) 571-1750

Email:Kdorsney@morrisjames.Com USA 4 D **MSN** LABORATORIES PRIVATE LIMITED D Defendant **MSN** LABORATORIES PRIVATE LIMITED 2015-05-18T14:49:00 8 **MSN** LABORATORIES PRIVATE LIMITED Richard Juang...

... STAMOULIS WEINBLATT LLC 2019-01-25T10:26:00 62027177972605 (302) 999-1540

Email:Stamoulis@swdelaw.Com USA 3 D **MSN** PHARMACEUTICALS, INC. D Defendant **MSN** PHARMACEUTICALS INC 2015-08-04T16:03:00 9 **MSN** PHARMACEUTICALS, INC. Richard Juang PRO HAC VICE;ATTORNEY TO BE NOTICED...

Court: United States District Court, Delaware | **Date Filed:** Sep 13, 2019 | **Docket Number:** 1:19cv1727 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Open

22. [Amgen Inc. Et Al V. Msn Pharmaceuticals, Inc. Et Al](#)

... TUNNELL LLP 2016-04-04T13:46:00 -1 -1 60011672166968 302-351-9454 Email:Began@mnat.Com USA 3 P **MSN** PHARMACEUTICALS, INC. D Defendant **MSN** PHARMACEUTICALS INC 2015-08-04T16:03:00 3 **MSN** PHARMACEUTICALS, INC. Devan V. Padmanabhan...

... BE NOTICED -1 SRI K SANKARAN 2019-07-31T11:46:00 9614408276588

Email:Sri@paddalawgroup.Com 4 D **MSN** LABORATORIES PRIVATE LIMITED D Defendant **MSN** LABORATORIES PRIVATE LIMITED 2015-05-18T14:49:00 4 **MSN** LABORATORIES PRIVATE LIMITED Devan V. Padmanabhan...

Court: United States District Court, Delaware | **Date Filed:** Jan 29, 2020 | **Docket Number:** 1:20cv137 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Open

23. [Astrazeneca Ab Et Al V. Alembic Pharmaceuticals Limited Et Al](#)

... LLP 2019-11-07T12:37:00 76671795600331 Fax: (302) 571-1750 Email:Kdorsney@morrisjames.Com USA 2020-03-13 1 D **MSN** LABORATORIES PVT. LTD. D Defendant **MSN** LABORATORIES PVT LTD 2015-03-03T10:02:00 6 **MSN** LABORATORIES PVT. LTD. Eve H. Ormerod...

... MICHAEL J GAERTNER 2012-07-24T16:46:00 -1 -1 11320484045196 Email:Mgaertner@lockelord.Com 7 D 2013-04-26T17:45:06.720 **MSN** Pharmaceuticals Inc. D Defendant **MSN** PHARMACEUTICALS INC 2017-01-11T08:30:00 8 **MSN** Pharmaceuticals Inc. Eve H. Ormerod...

Court: United States District Court, Delaware | **Date Filed:** Feb 11, 2020 | **Docket Number:** 1:20cv202 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:**
Open

24. [Astrazeneca Ab Et Al V. Msn Pharmaceuticals, Inc. Et Al](#)

... BE NOTICED -1 MICHAEL E FURROW 2020-09-15T14:03:00 12404960214619
Email:Michael.Furrow@dlapiper.Com 5 P **MSN PHARMACEUTICALS, INC.** D Defendant **MSN**
PHARMACEUTICALS INC 2015-08-04T16:03:00 5 **MSN PHARMACEUTICALS, INC.** Helena C.
Rychlicki...
... NOTICED -1 STUART D SENDER 2019-04-15T17:22:00 10897885283319
Email:Ssender@windelsmarx.Com 2019-05-28 6 D **MSN LABORATORIES PVT. LTD.** D Defendant **MSN**
LABORATORIES PVT LTD 2015-03-03T10:02:00 6 **MSN LABORATORIES PVT. LTD.** Helena C.
Rychlicki...

Court: United States District Court, Delaware | **Date Filed:** Dec 26, 2018 | **Docket Number:** 1:18cv2051 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:**
Closed

25. [Bausch Health Ireland Limited Et Al V. Msn Laboratories Private Ltd. Et Al](#)

... 2012-04-25T10:05:00 426827 1107021 40359965568670 (973) 596-4500
Email:Wdeni@gibbonslaw.Com USA 3 P 2013-06-04T17:00:56.957 **MSN Laboratories Private Ltd.** D
Defendant **MSN LABORATORIES PRIVATE LTD** 2017-01-17T11:46:00 3 **MSN Laboratories Private Ltd.**
MARK S. OLINSKY...
... SILLS CUMMIS GROSS PC 2018-10-23T11:33:00 46732061310050 973-643-4775
Email:Sklein@sillscummis.Com USA 2 D **MSN Pharmaceuticals Inc.** D Defendant **MSN**
PHARMACEUTICALS INC 2017-01-11T08:30:00 4 **MSN Pharmaceuticals Inc.** MARK S. OLINSKY...

Court: United States District Court, New Jersey | **Date Filed:** Apr 22, 2021 | **Docket Number:**
2:21cv10057 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent
Infringement | **Status:** Open

26. [Biogen International Gmbh Et Al V. Amneal Pharmaceuticals Llc Et Al.](#)

... BE NOTICED -1 SAMUEL SHERRY 2017-08-15T11:17:00 10067781763032
Email:Ssherry@goodwinlaw.Com 2018-05-16 5 D **MSN Laboratories Private Ltd.** D Defendant **MSN**
LABORATORIES PRIVATE LTD 2017-01-17T11:46:00 14 W **MSN Laboratories Private Ltd.**...
... JOVIAL WONG 2012-09-09T17:03:00 -1 -1 7692281455920 Email:Jwong@winston.Com 4 D W 2013-
04-26T17:44:11.313 **MSN Pharmaceuticals Inc.** D Defendant **MSN PHARMACEUTICALS INC** 2017-01-
11T08:30:00 15 W **MSN Pharmaceuticals Inc.** John C. Phillips , Jr....

Court: United States District Court, Delaware | **Date Filed:** Jun 26, 2017 | **Docket Number:** 1:17cv823 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:**
Closed

27. [Biogen International Gmbh V. Msn Laboratories Private Ltd. Et Al](#)

... TO BE NOTICED -1 LI FENG 2017-08-03T10:01:00 7296190669579 Email:Li.Feng@finnegan.Com 7 P
MSN Laboratories Private Ltd. D Defendant **MSN LABORATORIES PRIVATE LTD** 2017-01-17T11:46:00 2
MSN Laboratories Private Ltd. David A. Bilson...

... PHILLIPS MCLAUGHLIN HALL PA 2020-05-06T11:33:00 46829556376216 302-655-4200
Email:Jcp@pgmhlaw.Com USA 4 D **MSN** Pharmaceuticals Inc. D Defendant **MSN PHARMACEUTICALS**
INC 2017-01-11T08:30:00 3 **MSN** Pharmaceuticals Inc. David A. Bilson...

Court: United States District Court, Delaware | **Date Filed:** Mar 01, 2018 | **Docket Number:** 1:18cv337 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:**
Open

28. [Biogen Ma Inc. V. Msn Laboratories Private Ltd, Et Al](#)

... BE NOTICED -1 SANYA SUKDUANG 2020-05-26T12:56:00 9494087710099
Email:Ssukduang@cooley.Com 2020-03-02 6 P **MSN** Laboratories Private Ltd. D Defendant **MSN**
LABORATORIES PRIVATE LTD 2017-01-17T11:46:00 2 **MSN** Laboratories Private Ltd. David A. Bilson...
... -1 JOVIAL WONG 2012-09-09T17:03:00 -1 -1 7692281455920 Email:Jwong@winston.Com 5 D 2013-
04-26T17:44:11.313 **MSN** Pharmaceuticals Inc. D Defendant **MSN PHARMACEUTICALS** INC 2017-01-
11T08:30:00 3 **MSN** Pharmaceuticals Inc. David A. Bilson...

Court: US District Court for the District of Delaware | **Date Filed:** Jun 28, 2017 | **Docket Number:**
1:17cv845 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent
Infringement | **Status:** Closed

29. [Boehringer Ingelheim International Gmbh Et Al V. Msn Laboratories Private Ltd. Et Al](#)

... TUNNELL LLP 2014-02-27T17:13:00 -1 -1 75118614774617 302-351-9366
Email:Mdellinger@mnat.Com USA 3 P **MSN** Laboratories Private Ltd. D Defendant **MSN** LABORATORIES
PRIVATE LTD 2017-01-17T11:46:00 4 **MSN** Laboratories Private Ltd. John C. Phillips , Jr....
... PHILLIPS MCLAUGHLIN HALL PA 2020-05-06T11:33:00 46829556376216 302-655-4200
Email:Jcp@pgmhlaw.Com USA 1 D **MSN** Pharmaceuticals Inc. D Defendant **MSN PHARMACEUTICALS**
INC 2017-01-11T08:30:00 5 **MSN** Pharmaceuticals Inc. John C. Phillips , Jr....

Court: US District Court for the District of Delaware | **Date Filed:** Oct 03, 2019 | **Docket Number:**
1:19cv1865 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent
Infringement | **Status:** Open

30. [Boehringer Ingelheim Pharmaceuticals Inc. Et Al V. Accord Healthcare, Inc. Et Al](#)

... 2012-08-13T16:16:00 8 Cadila Healthcare Ltd. **MSN** LABORATORIES PRIVATE LIMITED D Defendant
MSN LABORATORIES PRIVATE LIMITED 2015-05-18T14:49:00 9 **MSN** LABORATORIES PRIVATE
LIMITED **MSN** PHARMACEUTICALS, INC. D Defendant **MSN** PHARMACEUTICALS INC...

Court: US District Court for the District of New Jersey | **Date Filed:** Feb 17, 2016 | **Docket Number:**
3:16cv852 | **Nature of Suit:** Patent | **Cause:** Patent Infringement | **Status:** Open

31. [Boehringer Ingelheim Pharmaceuticals Inc. Et Al V. Hec Pharm Co., Ltd. Et Al](#)

... LLP 2015-12-21T18:06:00 -1 -1 59792752307971 212-261-5670 Email:Saira.B.Haider@gmail.Com USA
2015-12-14 4 D **MSN** LABORATORIES PRIVATE LIMITED D Defendant **MSN** LABORATORIES PRIVATE
LIMITED 2015-05-18T14:49:00 19 2018-05-23 **MSN** LABORATORIES PRIVATE LIMITED...

... 2016-06-30T18:03:00 -1 -1 62679117851230 973-605-8800 Fax: 973-605-8020
Email:Vpawar@pgrlawyers.Com USA 2 D **MSN PHARMACEUTICALS, INC.** D Defendant **MSN PHARMACEUTICALS INC** 2015-08-04T16:03:00 20 2018-05-23 **MSN PHARMACEUTICALS, INC.** BRIAN T. MORIARTY...

Court: United States District Court, New Jersey | **Date Filed:** Aug 04, 2015 | **Docket Number:** 3:15cv5982 | **Nature of Suit:** Patent | **Cause:** Patent Infringement | **Status:** Closed

32. [Boehringer Ingelheim Pharmaceuticals Inc. Et Al V. Mankind Pharma Ltd. Et Al](#)

... BE NOTICED -1 RICHARD JUANG 2021-02-16T17:38:00 10366405055488
Email:Rjuang@daignaultiye.Com 2021-05-25 2 D **MSN Laboratories Private Ltd.** D Defendant **MSN LABORATORIES PRIVATE LTD** 2017-01-17T11:46:00 24 **MSN Laboratories Private Ltd.** David A. Bilson...
... -1 SARAH A KRAJEWSKI 2016-11-10T17:12:00 -1 -1 10854597513484
Email:Skrajewski@winston.Com 10 D **MSN Pharmaceuticals Inc.** D Defendant **MSN PHARMACEUTICALS INC** 2017-01-11T08:30:00 25 **MSN Pharmaceuticals Inc.** David A. Bilson...

Court: United States District Court, Delaware | **Date Filed:** Oct 26, 2018 | **Docket Number:** 1:18cv1689 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Open

33. [Boehringer Ingelheim Pharmaceuticals, Inc. Et Al V. Msn Laboratories Private Limited Et Al](#)

... ARNSTEIN LEHR LLP 2017-09-05T18:01:00 53312474248801 (973) 286-6700 Email:Clizza@saul.Com
USA 1 P **MSN LABORATORIES PRIVATE LIMITED** D Defendant **MSN LABORATORIES PRIVATE LIMITED** 2015-05-18T14:49:00 4 **MSN LABORATORIES PRIVATE LIMITED** LOLY G. TOR...
... GATES LLP 2015-04-09T00:52:00 -1 -1 43380744878950 212-536-3910
Email:Peter.Giunta@klgates.Com USA 2 D **MSN PHARMACEUTICALS, INC.** D Defendant **MSN PHARMACEUTICALS INC** 2015-08-04T16:03:00 5 **MSN PHARMACEUTICALS, INC.** LOLY G. TOR...

Court: United States District Court, New Jersey | **Date Filed:** Oct 16, 2017 | **Docket Number:** 3:17cv8399 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Closed

34. [Boehringer Ingelheim Pharmaceuticals Inc. Et Al V. Msn Laboratories Private Ltd. Et Al](#)

... TUNNELL LLP 2016-04-04T13:46:00 -1 -1 60011672166968 302-351-9454 Email:Began@mnat.Com
USA 2 P **MSN Laboratories Private Ltd.** D Defendant **MSN LABORATORIES PRIVATE LTD** 2017-01-17T11:46:00 4 **MSN Laboratories Private Ltd.** John C. Phillips , Jr....
... PHILLIPS MCLAUGHLIN HALL PA 2020-05-06T11:33:00 46829556376216 302-655-4200
Email:Jcp@pgmhlaw.Com USA 1 D **MSN Pharmaceuticals Inc.** D Defendant **MSN PHARMACEUTICALS INC** 2017-01-11T08:30:00 5 **MSN Pharmaceuticals Inc.** John C. Phillips , Jr....

Court: United States District Court, Delaware | **Date Filed:** Nov 13, 2018 | **Docket Number:** 1:18cv1785 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Open

35. [Btg International Limited Et Al V. Msn Pharmaceuticals Inc. Et Al](#)

... 61568260186432 (973) 690-5400 Fax: (973) 466-2760 Email:Kmillier@rwmlegal.Com USA 1 P 2015-04-23T17:00:29.237 **MSN** Pharmaceuticals Inc. D Defendant **MSN PHARMACEUTICALS INC** 2017-01-11T08:30:00 5 **MSN** Pharmaceuticals Inc. REBEKAH R. CONROY...
... 2017-02-15T18:09:00 65508899901897 (973) 400-4181 Fax: (973) 498-0070
Email:Rconroy@stoneconroy.Com USA 1 D **MSN LABORATORIES PRIVATE LIMITED** D Defendant **MSN LABORATORIES PRIVATE LIMITED** 2015-05-18T14:49:00 6 **MSN LABORATORIES PRIVATE LIMITED** REBEKAH R. CONROY...

Court: United States District Court, New Jersey | **Date Filed:** Feb 20, 2018 | **Docket Number:** 2:18cv2372 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Closed

36. [Currax Pharmaceuticals Llc V. Msn Laboratories Private Limited Et Al.](#)

... 315857 158440101 57914678273112 302-298-3523 Fax: 302-298-3550 Email:Dao'Brien@venerable.Com USA 1 P 2015-05-08T17:00:10.600 **MSN LABORATORIES PRIVATE LIMITED** D Defendant **MSN LABORATORIES PRIVATE LIMITED** 2015-05-18T14:49:00 2 **MSN LABORATORIES PRIVATE LIMITED** Eve H. Ormerod...
... BE NOTICED -1 STUART D SENDER 2019-04-15T17:22:00 10897885283319
Email:Ssender@windelsmarx.Com 4 D **MSN Pharmaceuticals Inc.** D Defendant **MSN PHARMACEUTICALS INC** 2017-01-11T08:30:00 3 **MSN Pharmaceuticals Inc.** Eve H. Ormerod...

Court: United States District Court, Delaware | **Date Filed:** Aug 13, 2020 | **Docket Number:** 1:20cv1064 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Open

37. [Exelixis, Inc. V. Msn Laboratories Private Limited Et Al](#)

... NICHOLS ARSHT TUNNELL LLP 2021-06-21T17:35:00 76606240142913 302-351-9392
Email:Araucci@morrisnichols.Com USA 2 P **MSN LABORATORIES PRIVATE LIMITED** D Defendant **MSN LABORATORIES PRIVATE LIMITED** 2015-05-18T14:49:00 2 **MSN LABORATORIES PRIVATE LIMITED** Bryce A. Cooper...
... LLP 2017-01-03T15:16:00 77582455220382 (302)472-7311 Fax: (302) 472-7301
Email:Dgattuso@hegh.Law USA 3 D **MSN Pharmaceuticals Inc.** D Defendant **MSN PHARMACEUTICALS INC** 2017-01-11T08:30:00 3 **MSN Pharmaceuticals Inc.** Bryce A. Cooper...

Court: United States District Court, Delaware | **Date Filed:** May 11, 2020 | **Docket Number:** 1:20cv633 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Open

38. [Exelixis, Inc. V. Msn Laboratories Private Limited Et Al](#)

... BE NOTICED -1 TIMOTHY A COOK 2019-06-27T16:37:00 10496375989824
Email:Tim.Cook@wilmerhale.Com 4 P **MSN LABORATORIES PRIVATE LIMITED** D Defendant **MSN LABORATORIES PRIVATE LIMITED** 2015-05-18T14:49:00 2 **MSN LABORATORIES PRIVATE LIMITED** Dominick T. Gattuso...
... WEINBLATT LLC 2019-01-25T10:26:00 62027177972605 (302) 999-1540
Email:Stamoulis@swdelaw.Com USA 2020-04-21 8 D **MSN Pharmaceuticals Inc.** D Defendant **MSN PHARMACEUTICALS INC** 2017-01-11T08:30:00 3 **MSN Pharmaceuticals Inc.** Dominick T. Gattuso...

Court: United States District Court, Delaware | **Date Filed:** Oct 29, 2019 | **Docket Number:** 1:19cv2017 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:**
Open

39. [Forest Laboratories, Llc, Et Al V. Msn Laboratories Private Limited Et Al](#)

... FALANGA LLP 2016-06-16T09:45:00 -1 -1 73179856075629 973.757.1100
Email:Lwalsh@thewalshfirm.Com USA 2 P **MSN** LABORATORIES PRIVATE LIMITED D Defendant **MSN**
LABORATORIES PRIVATE LIMITED 2015-05-18T14:49:00 5 **MSN** LABORATORIES PRIVATE LIMITED
PHILIP L. HIRSCHHORN...
... LLP 2016-07-03T21:12:00 -1 -1 49453860587343 (609) 734-6395 Email:Csaiveriano@hillwallack.Com
USA 2 D **MSN** Pharmaceuticals Inc. D Defendant **MSN** PHARMACEUTICALS INC 2017-01-11T08:30:00 6
MSN Pharmaceuticals Inc. CHRISTINA LYNN SAVERIANO...

Court: United States District Court, New Jersey | **Date Filed:** Oct 30, 2017 | **Docket Number:**
2:17cv10140 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent
Infringement | **Status:** Closed

40. [Genentech, Inc. Et Al V. Aurobindo Pharma Limited, Et Al](#)

... BE NOTICED -1 TARA R MELILLO 2020-11-03T13:48:00 10380683279742
Email:Tmelillo@goodwinlaw.Com 5 D **MSN** LABORATORIES PRIVATE LIMITED D Defendant **MSN**
LABORATORIES PRIVATE LIMITED 2015-05-18T14:49:00 26 2020-01-02 **MSN** LABORATORIES
PRIVATE LIMITED...
... NOTICED -1 RONALD M DAIGNAULT 2021-02-16T17:38:00 13463912643356
Email:Rdaignault@daignaultiyer.Com 2020-01-02 3 D **MSN** Pharmaceuticals Inc. D Defendant **MSN**
PHARMACEUTICALS INC 2017-01-11T08:30:00 27 2020-01-02 **MSN** Pharmaceuticals Inc. Stamatis
Stamoulis...

Court: United States District Court, Delaware | **Date Filed:** Jan 14, 2019 | **Docket Number:** 1:19cv78 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:**
Open

41. [Genentech, Inc. Et Al V. Msn Laboratories Private Limited Et Al](#)

... -1 WARREN K MACRAE 2012-09-13T00:10:00 -1 -1 8078505761868 Email:Wmacrae@loeb.Com 5 P
MSN LABORATORIES PRIVATE LIMITED D Defendant **MSN** LABORATORIES PRIVATE LIMITED 2015-
05-18T14:49:00 3 **MSN** LABORATORIES PRIVATE LIMITED Richard Juang...
... STAMOULIS WEINBLATT LLC 2019-01-25T10:26:00 62027177972605 (302) 999-1540\n
Email:Stamoulis@swdelaw.Com USA 3 D **MSN** Pharmaceuticals Inc. D Defendant **MSN**
PHARMACEUTICALS INC 2017-01-11T08:30:00 4 **MSN** Pharmaceuticals Inc. Richard Juang PRO HAC
VICE;ATTORNEY TO BE NOTICED...

Court: US District Court for the District of Delaware | **Date Filed:** Jan 31, 2019 | **Docket Number:**
1:19cv205 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent
Infringement | **Status:** Closed

42. [Intercept Pharmaceuticals, Inc. Et Al V. Apotex Inc. Et Al](#)

... PA 2016-03-20T17:10:00 -1 -1 54163017435975 302- 655-4200 Email:Mch@pgmhlaw.Com USA 7 D
MSN LABORATORIES PRIVATE LIMITED D Defendant **MSN** LABORATORIES PRIVATE LIMITED 2015-
05-18T14:49:00 9 **MSN** LABORATORIES PRIVATE LIMITED Anne Shea Gaza...

... LLP 2013-06-18T14:46:00 285685 344346 67722912385593 302-571-5018 Email:Swilson@ycst.Com
USA 4 D 2014-05-05T17:01:12.593 **MSN** Pharmaceuticals Inc. D Defendant **MSN** PHARMACEUTICALS
INC 2017-01-11T08:30:00 10 **MSN** Pharmaceuticals Inc. Anne Shea Gaza...

Court: United States District Court, Delaware | **Date Filed:** Aug 21, 2020 | **Docket Number:** 1:20cv1105 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:**
Open

43. [Merck Sharp & Dohme Corp. V. Msn Laboratories Private Ltd. Et Al](#)

... ARNSTEIN LEHR LLP 2017-09-05T18:01:00 53312474248801 (973) 286-6700 Email:Clizza@saul.Com
USA 4 P **MSN** Laboratories Private Ltd. D Defendant **MSN** LABORATORIES PRIVATE LTD 2017-01-
17T11:46:00 2 **MSN** Laboratories Private Ltd. CHRISTINA LYNN SAVERIANO...
... ROONEY PC 2018-04-09T16:20:00 78921983987961 212-440-4400 Fax: 212-440-4401
Email:Philip.Hirschhorn@bipc.Com USA 3 D **MSN** PHARMACEUTICALS, INC. D Defendant **MSN**
PHARMACEUTICALS INC 2015-08-04T16:03:00 3 **MSN** PHARMACEUTICALS, INC. CHRISTINA LYNN
SAVERIANO...

Court: United States District Court, New Jersey | **Date Filed:** Jan 16, 2018 | **Docket Number:** 3:18cv675 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:**
Closed

44. [Millennium Pharmaceuticals, Inc. V. Msn Laboratories Private Ltd. Et Al](#)

... 2012-03-06T13:12:00 287558 343068 69337423008944 (302) 658-9200 Email:Jbbefiling@mnat.Com
USA 1 P 2012-11-16T17:00:17.043 **MSN** Laboratories Private Ltd. D Defendant **MSN** LABORATORIES
PRIVATE LTD 2017-01-17T11:46:00 2 **MSN** Laboratories Private Ltd. David C. Kistler...
... LLP 2015-01-21T17:13:00 286744 341993 54544443342154 302-425-6431
Email:Orlacchio@blankrome.Com USA 3 D 2015-02-05T17:00:10.367 **MSN** PHARMACEUTICALS, INC. D
Defendant **MSN** PHARMACEUTICALS INC 2015-08-04T16:03:00 3 **MSN** PHARMACEUTICALS, INC.
David C. Kistler...

Court: US District Court for the District of Delaware | **Date Filed:** Dec 19, 2016 | **Docket Number:**
1:16cv1255 | **Nature of Suit:** Patent | **Cause:** Patent Infringement | **Status:** Closed

45. [Mitsubishi Tanabe Pharma Corporation Et Al V. Msn Laboratories Private Ltd. Et Al](#)

... ARNSTEIN LEHR LLP 2017-09-05T18:01:00 53312474248801 (973) 286-6700 Email:Clizza@saul.Com
USA 4 P **MSN** Laboratories Private Ltd. D Defendant **MSN** LABORATORIES PRIVATE LTD 2017-01-
17T11:46:00 6 **MSN** Laboratories Private Ltd. JAMES S. RICHTER...
... MIDLIGE RICHTER LLC 2019-07-17T22:00:00 53040213164831 (908) 626-0622
Email:Jrichter@midlige-Richter.Com USA 1 D **MSN** PHARMACEUTICALS, INC. D Defendant **MSN**
PHARMACEUTICALS INC 2015-08-04T16:03:00 7 **MSN** PHARMACEUTICALS, INC. JAMES S.
RICHTER...

Court: US District Court for the District of New Jersey | **Date Filed:** Jul 20, 2017 | **Docket Number:**
3:17cv5302 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent
Infringement | **Status:** Open

46. [Mitsubishi Tanabe Pharma Corporation Et Al V. Msn Laboratories Private Ltd. Et Al](#)

... ARNSTEIN LEHR LLP 2017-09-05T18:01:00 53312474248801 (973) 286-6700 Email:Clizza@saul.Com
USA 4 P **MSN** Laboratories Private Ltd. D Defendant **MSN** LABORATORIES PRIVATE LTD 2017-01-17T11:46:00 6 **MSN** Laboratories Private Ltd. JAMES S. RICHTER...
... MIDLIGE RICHTER LLC 2019-07-17T22:00:00 53040213164831 (908) 626-0622
Email:Jrichter@midlige-Richter.Com USA 1 D **MSN** Pharmaceuticals Inc. D Defendant **MSN** PHARMACEUTICALS INC 2017-01-11T08:30:00 7 **MSN** Pharmaceuticals Inc. JAMES S. RICHTER...

Court: US District Court for the District of New Jersey | **Date Filed:** Oct 14, 2019 | **Docket Number:** 3:19cv18958 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Closed

47. [Mitsubishi Tanabe Pharma Corporation Et Al V. Msn Laboratories Private Ltd. Et Al](#)

... ARNSTEIN LEHR LLP 2017-09-05T18:01:00 53312474248801 (973) 286-6700 Email:Clizza@saul.Com
USA 4 P **MSN** Laboratories Private Ltd. D Defendant **MSN** LABORATORIES PRIVATE LTD 2017-01-17T11:46:00 6 **MSN** Laboratories Private Ltd. JAMES S. RICHTER...
... MIDLIGE RICHTER LLC 2019-07-17T22:00:00 53040213164831 (908) 626-0622
Email:Jrichter@midlige-Richter.Com USA 1 D **MSN** Pharmaceuticals Inc. D Defendant **MSN** PHARMACEUTICALS INC 2017-01-11T08:30:00 7 **MSN** Pharmaceuticals Inc. JAMES S. RICHTER...

Court: United States District Court, New Jersey | **Date Filed:** Jul 19, 2019 | **Docket Number:** 1:19cv15616 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Open

48. [Mitsubishi Tanabe Pharma Corporation Et Al V. Msn Laboratories Private Ltd. Et Al](#)

... ARNSTEIN LEHR LLP 2017-09-05T18:01:00 53312474248801 (973) 286-6700 Email:Clizza@saul.Com
USA 4 P **MSN** Laboratories Private Ltd. D Defendant **MSN** LABORATORIES PRIVATE LTD 2017-01-17T11:46:00 6 **MSN** Laboratories Private Ltd. JAMES S. RICHTER...
... MIDLIGE RICHTER LLC 2019-07-17T22:00:00 53040213164831 (908) 626-0622
Email:Jrichter@midlige-Richter.Com USA 1 D **MSN** Pharmaceuticals Inc. D Defendant **MSN** PHARMACEUTICALS INC 2017-01-11T08:30:00 7 **MSN** Pharmaceuticals Inc. JAMES S. RICHTER...

Court: US District Court for the District of New Jersey | **Date Filed:** Jul 19, 2019 | **Docket Number:** 3:19cv15616 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Open

49. [Mitsubishi Tanabe Pharma Corporation Et Al V. Msn Laboratories Private Ltd. Et Al](#)

... ARNSTEIN LEHR LLP 2017-09-05T18:01:00 53312474248801 (973) 286-6700 Email:Clizza@saul.Com
USA 4 P **MSN** Laboratories Private Ltd. D Defendant **MSN** LABORATORIES PRIVATE LTD 2017-01-17T11:46:00 6 **MSN** Laboratories Private Ltd. JAMES S. RICHTER...
... MIDLIGE RICHTER LLC 2019-07-17T22:00:00 53040213164831 (908) 626-0622
Email:Jrichter@midlige-Richter.Com USA 1 D **MSN** PHARMACEUTICALS, INC. D Defendant **MSN**

PHARMACEUTICALS INC 2015-08-04T16:03:00 7 **MSN** PHARMACEUTICALS, INC. JAMES S. RICHTER...

Court: United States District Court, New Jersey | **Date Filed:** Jul 20, 2017 | **Docket Number:** 1:17cv5302 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Open

50. [Novartis Pharmaceuticals Corporation Et Al V. Msn Pharmaceuticals Inc. Et Al](#)

... (302) 984-6392 Fax: (302) 450-4235 Email:Ajoyce@mccarter.Com USA 2 P **MSN** Pharmaceuticals Inc. D Defendant **MSN** PHARMACEUTICALS INC 2017-01-11T08:30:00 3 **MSN** Pharmaceuticals Inc. **MSN** LABORATORIES PVT. LTD. D Defendant **MSN** LABORATORIES PVT LTD...

Court: United States District Court, Delaware | **Date Filed:** Jul 01, 2021 | **Docket Number:** 1:21cv981 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Open

51. [Novartis Pharmaceuticals Corporation V. Accord Healthcare Inc. Et Al](#)

... (302) 573-2525 Fax: (302) 573-2524 Email:Dfinger@delawgroup.Com USA 2018-11-14 2 D 2013-04-26T17:44:11.313 **MSN** LABORATORIES PRIVATE LIMITED D Defendant **MSN** LABORATORIES PRIVATE LIMITED 2015-05-18T14:49:00 30 2018-11-14 **MSN** LABORATORIES PRIVATE LIMITED...
... (302) 573-2525 Fax: (302) 573-2524 Email:Dfinger@delawgroup.Com USA 2018-11-14 2 D 2013-04-26T17:44:11.313 **MSN** Pharmaceuticals Inc. D Defendant **MSN** PHARMACEUTICALS INC 2017-01-11T08:30:00 31 2018-11-14 **MSN** Pharmaceuticals Inc. David J. Austin...

Court: United States District Court, Delaware | **Date Filed:** Jul 16, 2018 | **Docket Number:** 1:18cv1043 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Open

52. [Onyx Therapeutics, Inc. V. Cipla Limited Et Al](#)

... TRAURIG LLP 2018-03-29T17:17:00 92587743619657 302-661-7000 Fax: 302-661-7360 Email:Moultries@gtlaw.Com USA 5 D **MSN** Pharmaceuticals Inc. D Defendant **MSN** PHARMACEUTICALS INC 2017-01-11T08:30:00 4 2019-05-08 **MSN** Pharmaceuticals Inc. R. Touhey Myer...
... SALVATORE GUERRIERO 2012-09-09T17:41:00 -1 -1 11037837807889 Email:Sguerriero@crbcp.Com 2019-05-08 6 D 2013-04-26T17:44:11.313 **MSN** LABORATORIES PRIVATE LIMITED D Defendant **MSN** LABORATORIES PRIVATE LIMITED 2015-05-18T14:49:00 5 2019-05-08 **MSN** LABORATORIES PRIVATE LIMITED...

Court: United States District Court, Delaware | **Date Filed:** Oct 24, 2016 | **Docket Number:** 1:16cv988 | **Nature of Suit:** Patent | **Cause:** Patent Infringement | **Status:** Closed

53. [Onyx Therapeutics, Inc. V. Msn Pharmaceuticals, Inc. Et Al](#)

... 2012-06-15T16:16:00 -1 -1 70863434373129 (302) 658-9200 Email:Menefiling@mnat.Com USA 2018-08-10 2 P **MSN** PHARMACEUTICALS, INC. D Defendant **MSN** PHARMACEUTICALS INC 2015-08-04T16:03:00 2 **MSN** PHARMACEUTICALS, INC. R. Touhey Myer...
... PA 2020-02-10T17:38:00 80006865897220 (302) 351-0908 Fax: 302-351-0915 Email:Touhey.Myer@offitkurman.Com USA 1 D **MSN** LABORATORIES PRIVATE LIMITED D Defendant

MSN LABORATORIES PRIVATE LIMITED 2015-05-18T14:49:00 3 **MSN LABORATORIES PRIVATE LIMITED R. Touhey Myer...**

Court: US District Court for the District of Delaware | **Date Filed:** Dec 20, 2017 | **Docket Number:** 1:17cv1833 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Closed

54. [Onyx Therapeutics, Inc. V. Msn Pharmaceuticals, Inc. Et Al](#)

... -1 WENDY A WHITEFORD 2012-09-27T17:03:00 -1 -1 8421541094204 Email:Wendy@amgen.Com 6 P **MSN PHARMACEUTICALS, INC.** D Defendant **MSN PHARMACEUTICALS INC** 2015-08-04T16:03:00 2 **MSN PHARMACEUTICALS, INC.** Lynne Terrebonne PRO HAC VICE;ATTORNEY TO BE NOTICED...
... PA 2020-02-10T17:38:00 80006865897220 (302) 351-0908 Fax: 302-351-0915
Email:Touhey.Myer@offitkurman.Com USA 5 D **MSN LABORATORIES PRIVATE LIMITED** D Defendant **MSN LABORATORIES PRIVATE LIMITED** 2015-05-18T14:49:00 3 **MSN LABORATORIES PRIVATE LIMITED R. Touhey Myer...**

Court: United States District Court, Delaware | **Date Filed:** Oct 26, 2016 | **Docket Number:** 1:16cv999 | **Nature of Suit:** Patent | **Cause:** Patent Infringement | **Status:** Closed

55. [Otsuka Pharmaceutical Co., Ltd. V. Amneal Pharmaceuticals Llc Et Al](#)

... AMNEAL PHARMACEUTICALS INDIA PVT. LTD. **MSN PHARMACHEM PVT. LTD.** D Defendant **MSN PHARMACHEM PVT LTD** 2015-03-03T10:02:00 4 **MSN PHARMACHEM PVT. LTD.** **MSN LABORATORIES PVT. LTD.** D Defendant **MSN LABORATORIES PVT LTD...**

Court: US District Court for the District of New Jersey | **Date Filed:** Oct 30, 2015 | **Docket Number:** 1:15cv7803 | **Nature of Suit:** Patent | **Cause:** Patent Infringement | **Status:** Closed

56. [Otsuka Pharmaceutical Co., Ltd. V. Amneal Pharmaceuticals Llc Et Al](#)

... 2017-02-15T18:09:00 65508899901897 (973) 400-4181 Fax: (973) 498-0070
Email:Rconroy@stoneconroy.Com USA 1 D **MSN PHARMACHEM PVT. LTD.** D Defendant **MSN PHARMACHEM PVT LTD** 2015-03-03T10:02:00 4 2016-01-14 **MSN PHARMACHEM PVT. LTD....**
... 2017-02-15T18:09:00 65508899901897 (973) 400-4181 Fax: (973) 498-0070
Email:Rconroy@stoneconroy.Com USA 1 D **MSN LABORATORIES PVT. LTD.** D Defendant **MSN LABORATORIES PVT LTD** 2015-03-03T10:02:00 5 2016-01-14 **MSN LABORATORIES PVT. LTD....**

Court: United States District Court, New Jersey | **Date Filed:** Mar 02, 2015 | **Docket Number:** 1:15cv1585 | **Nature of Suit:** Patent | **Cause:** Patent Infringement | **Status:** Closed

57. [Pfizer Inc. Et Al V. Msn Pharmaceuticals Inc. Et Al](#)

... 75118614774617 302-351-9366 Email:Mdellinger@mnat.Com USA 2 P **MSN Pharmaceuticals Inc.** D Defendant **MSN PHARMACEUTICALS INC** 2017-01-11T08:30:00 4 **MSN Pharmaceuticals Inc.** **MSN LABORATORIES PRIVATE LIMITED** D Defendant **MSN LABORATORIES PRIVATE LIMITED...**

Court: United States District Court, Delaware | **Date Filed:** Jun 15, 2021 | **Docket Number:** 1:21cv858 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Open

58. [Pfizer Inc. Et Al V. Msn Pharmaceuticals Inc. Et Al](#)

... TUNNELL LLP 2014-02-27T17:13:00 -1 -1 75118614774617 302-351-9366
 Email:Mdellinger@mnat.Com USA 3 P **MSN** Pharmaceuticals Inc. D Defendant **MSN**
 PHARMACEUTICALS INC 2017-01-11T08:30:00 4 **MSN** Pharmaceuticals Inc. Stamatios Stamoulis
 ATTORNEY TO BE NOTICED...
 ... STAMOULIS WEINBLATT LLC 2019-01-25T10:26:00 62027177972605 (302) 999-1540
 Email:Stamoulis@swdelaw.Com USA 1 D **MSN** LABORATORIES PRIVATE LIMITED D Defendant **MSN**
 LABORATORIES PRIVATE LIMITED 2015-05-18T14:49:00 5 **MSN** LABORATORIES PRIVATE LIMITED
 Stamatios Stamoulis...

Court: United States District Court, Delaware | **Date Filed:** Feb 03, 2021 | **Docket Number:** 1:21cv139 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:**
 Open

59. [Sanofi-Aventis U.S. Llc, Et Al. V. Apotex Corp., Et Al.](#)

... TODD S WERNER 2015-07-08T12:46:00 -1 -1 11420979802364 Email:Twerner@carlsoncaspers.Com
 2020-07-30 3 D **MSN** PHARMACEUTICALS, INC. D Defendant **MSN** PHARMACEUTICALS INC 2015-08-
 04T16:03:00 19 **MSN** PHARMACEUTICALS, INC. Stamatios Stamoulis LEAD ATTORNEY;ATTORNEY
 TO BE NOTICED...
 ... STAMOULIS WEINBLATT LLC 2019-01-25T10:26:00 62027177972605 (302) 999-1540
 Email:Stamoulis@swdelaw.Com USA 1 D **MSN** Laboratories Private Ltd. D Defendant **MSN**
 LABORATORIES PRIVATE LTD 2017-01-17T11:46:00 20 **MSN** Laboratories Private Ltd. Stamatios
 Stamoulis...

Court: United States District Court, Delaware | **Date Filed:** Jun 12, 2020 | **Docket Number:** 1:20cv804 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:**
 Open

60. [Sanofi-Aventis U.S. Llc Et Al V. Cadila Healthcare Limited Et Al](#)

... 287697 343235 92279918476475 (302) 984-6067 Email:Sobyne@potteranderson.Com USA 2018-01-
 02 10 D 2015-09-07T17:00:11.610 **MSN** Pharmaceuticals Inc. D Defendant **MSN** PHARMACEUTICALS
 INC 2017-01-11T08:30:00 10 2017-09-27 **MSN** Pharmaceuticals Inc. Dominick T. Gattuso...
 ... HAC VICE -1 SHARON LIN 2017-06-22T13:16:00 7079095361245 Email:Slin@winston.Com 2018-01-
 02 5 D **MSN** LABORATORIES PRIVATE LIMITED D Defendant **MSN** LABORATORIES PRIVATE LIMITED
 2015-05-18T14:49:00 19 2017-09-27 **MSN** LABORATORIES PRIVATE LIMITED...

Court: United States District Court, Delaware | **Date Filed:** Dec 22, 2016 | **Docket Number:** 1:16cv1298 |
Nature of Suit: Patent | **Cause:** Patent Infringement | **Status:** Closed

61. [Sanofi-Aventis U.S. Llc Et Al V. Msn Laboratories Private Limited Et Al](#)

... PAULA S FRITSCH 2013-09-26T10:46:00 -1 -1 8178224256384 Email:Fritsch@mbhb.Com 7 P 2014-
 05-15T17:01:18.677 **MSN** LABORATORIES PRIVATE LIMITED D Defendant **MSN** LABORATORIES
 PRIVATE LIMITED 2015-05-18T14:49:00 5 **MSN** LABORATORIES PRIVATE LIMITED Dominick T.
 Gattuso...
 ... SAMUEL S PARK 2012-08-14T15:01:00 -1 -1 8119436923718 Email:Spark@winston.Com 3 D 2013-04-
 26T17:44:11.313 **MSN** Pharmaceuticals Inc. D Defendant **MSN** PHARMACEUTICALS INC 2017-01-
 11T08:30:00 6 **MSN** Pharmaceuticals Inc. Dominick T. Gattuso...

Court: United States District Court, Delaware | **Date Filed:** Jan 10, 2017 | **Docket Number:** 1:17cv27 |
Nature of Suit: Patent | **Cause:** Patent Infringement | **Status:** Closed

62. [Sanofi-Aventis U.S. Llc Et Al V. Msn Pharmaceuticals, Inc. Et Al](#)

... BE NOTICED -1 WILLIAM E SOLANDER 2019-08-08T09:46:00 10800366617657
 Email:Wsolander@venable.Com 6 P **MSN** PHARMACEUTICALS, INC. D Defendant **MSN**
 PHARMACEUTICALS INC 2015-08-04T16:03:00 3 **MSN** PHARMACEUTICALS, INC. Stamatios Stamoulis
 LEAD ATTORNEY;ATTORNEY TO BE NOTICED...
 ... STAMOULIS WEINBLATT LLC 2019-01-25T10:26:00 62027177972605 (302) 999-1540
 Email:Stamoulis@swdelaw.Com USA 1 D **MSN** Laboratories Private Ltd. D Defendant **MSN**
 LABORATORIES PRIVATE LTD 2017-01-17T11:46:00 4 **MSN** Laboratories Private Ltd. Stamatios
 Stamoulis...

Court: United States District Court, Delaware | **Date Filed:** May 14, 2020 | **Docket Number:** 1:20cv646 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:**
 Closed

63. [Sumitomo Dainippon Pharma Co., Ltd. Et Al V. Msn Laboratories Private Ltd. Et Al](#)

... ARNSTEIN LEHR LLP 2018-04-24T12:05:00 67870781831722 (973) 286-6700
 Email:Wbaton@saul.Com USA 4 P **MSN** Laboratories Private Ltd. D Defendant **MSN** LABORATORIES
 PRIVATE LTD 2017-01-17T11:46:00 3 **MSN** Laboratories Private Ltd. CHRISTINA LYNN SAVERIANO...
 ... LLP 2016-07-12T18:06:00 -1 -1 39897796649276 (609) 734-6358 Email:Eabraham@hillwallack.Com
 USA 2 D **MSN** Pharmaceuticals Inc. D Defendant **MSN** PHARMACEUTICALS INC 2017-01-11T08:30:00 4
MSN Pharmaceuticals Inc. CHRISTINA LYNN SAVERIANO...

Court: United States District Court, New Jersey | **Date Filed:** Feb 14, 2017 | **Docket Number:** 2:17cv1010
Nature of Suit: Patent | **Cause:** Patent Infringement | **Status:** Closed

64. [Taiho Pharmaceutical Co., Ltd. Et Al V. Msn Laboratories Private Ltd. Et Al](#)

... TO BE NOTICED -1 MOLLY HAYSSSEN 2020-04-09T10:38:00 8603631688068
 Email:Mhayssen@foley.Com 6 P **MSN** Laboratories Private Ltd. D Defendant **MSN** LABORATORIES
 PRIVATE LTD 2017-01-17T11:46:00 3 **MSN** Laboratories Private Ltd. Eve H. Ormerod...
 ... TO BE NOTICED -1 CAROLINE SUN 2020-03-05T09:09:00 8877237803909
 Email:Csun@windelsmarx.Com 3 D **MSN** Pharmaceuticals Inc. D Defendant **MSN** PHARMACEUTICALS
 INC 2017-01-11T08:30:00 4 **MSN** Pharmaceuticals Inc. Eve H. Ormerod...

Court: United States District Court, Delaware | **Date Filed:** Dec 23, 2019 | **Docket Number:** 1:19cv2342 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:**
 Open

65. [Teijin Limited Et Al V. Msn Laboratories Private Ltd. Et Al](#)

... 2012-06-15T16:16:00 -1 -1 70863434373129 (302) 658-9200 Email:Menefiling@mnat.Com USA 2018-
 08-10 2 P **MSN** Laboratories Private Ltd. D Defendant **MSN** LABORATORIES PRIVATE LTD 2017-01-
 17T11:46:00 4 **MSN** Laboratories Private Ltd. Sean M. Brennecke...
 ... 341823 83014685101973 (302) 552-5518 Fax: (302)573-3501 Email:Sbrennecke@klehr.Com USA 1 D
 2013-08-12T17:01:12.507 **MSN** PHARMACEUTICALS, INC. D Defendant **MSN** PHARMACEUTICALS INC
 2015-08-04T16:03:00 5 **MSN** PHARMACEUTICALS, INC. Sean M. Brennecke...

Court: US District Court for the District of Delaware | **Date Filed:** Jun 14, 2018 | **Docket Number:** 1:18cv881 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Closed

66. [Ucb, Inc. Et Al V. Annora Pharma Private Limited Et Al](#)

... JAMES LLP 2019-11-07T12:37:00 76671795600331 Fax: (302) 571-1750
Email:Kdorsney@morrisjames.Com USA 3 D **MSN** Pharmaceuticals Inc. D Defendant **MSN**
PHARMACEUTICALS INC 2017-01-11T08:30:00 10 **MSN** Pharmaceuticals Inc. Bryce A. Cooper...
... LLP 2017-01-03T15:16:00 77582455220382 (302)472-7311 Fax: (302) 472-7301
Email:Dgattuso@hegh.Law USA 6 D **MSN** Laboratories Private Ltd. D Defendant **MSN** LABORATORIES
PRIVATE LTD 2017-01-17T11:46:00 11 **MSN** Laboratories Private Ltd. Bryce A. Cooper...

Court: United States District Court, Delaware | **Date Filed:** Jul 24, 2020 | **Docket Number:** 1:20cv987 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Open

67. [Vanda Pharmaceuticals Inc. V. Msn Pharmaceuticals Inc. Et Al](#)

... -1 NICHOLAS GROOMBRIDGE 2013-01-03T15:16:00 -1 -1 13446536102729
Email:Ngroombridge@paulweiss.Com 8 P 2013-04-26T17:45:06.720 **MSN** Pharmaceuticals Inc. D
Defendant **MSN** PHARMACEUTICALS INC 2017-01-11T08:30:00 2 **MSN** Pharmaceuticals Inc. Bryce A.
Cooper...
... PHILLIPS MCLAUGHLIN HALL PA 2020-05-06T11:33:00 46829556376216 302-655-4200
Email:Jcp@pgmhlaw.Com USA 5 D **MSN** LABORATORIES PRIVATE LIMITED D Defendant **MSN**
LABORATORIES PRIVATE LIMITED 2015-05-18T14:49:00 3 **MSN** LABORATORIES PRIVATE LIMITED
David A. Bilson...

Court: United States District Court, Delaware | **Date Filed:** May 07, 2018 | **Docket Number:** 1:18cv690 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Open

68. [Vanda Pharmaceuticals Inc. V. Msn Pharmaceuticals Inc. Et Al](#)

... -1 NICHOLAS GROOMBRIDGE 2013-01-03T15:16:00 -1 -1 13446536102729
Email:Ngroombridge@paulweiss.Com 8 P 2013-04-26T17:45:06.720 **MSN** Pharmaceuticals Inc. D
Defendant **MSN** PHARMACEUTICALS INC 2017-01-11T08:30:00 2 **MSN** Pharmaceuticals Inc. David A.
Bilson...
... PHILLIPS MCLAUGHLIN HALL PA 2020-05-06T11:33:00 46829556376216 302-655-4200
Email:Jcp@pgmhlaw.Com USA 2 D **MSN** LABORATORIES PRIVATE LIMITED D Defendant **MSN**
LABORATORIES PRIVATE LIMITED 2015-05-18T14:49:00 3 **MSN** LABORATORIES PRIVATE LIMITED
David A. Bilson...

Court: US District Court for the District of Delaware | **Date Filed:** May 17, 2019 | **Docket Number:** 1:19cv926 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:** Open

69. [Vanda Pharmaceuticals Inc. V. Msn Pharmaceuticals Inc. Et Al](#)

... LLP 2012-07-17T17:01:00 287558 343068 73414103064762 302-658-9200
Email:Dfahnestock@mnat.Com USA 2 P 2013-04-26T17:48:45.540 **MSN** Pharmaceuticals Inc. D

Defendant **MSN PHARMACEUTICALS INC** 2017-01-11T08:30:00 2 **MSN** Pharmaceuticals Inc. Bryce A. Cooper...
... PHILLIPS MCLAUGHLIN HALL PA 2020-05-06T11:33:00 46829556376216 302-655-4200
Email:Jcp@pgmhlaw.Com USA 4 D **MSN LABORATORIES PRIVATE LIMITED** D Defendant **MSN**
LABORATORIES PRIVATE LIMITED 2015-05-18T14:49:00 3 **MSN LABORATORIES PRIVATE LIMITED**
Bryce A. Cooper...

Court: US District Court for the District of Delaware | **Date Filed:** Mar 03, 2020 | **Docket Number:**
1:20cv318 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent
Infringement | **Status:** Open

70. [Vanda Pharmaceuticals Inc. V. Msn Pharmaceuticals Inc. Et Al](#)

... -1 NICHOLAS GROOMBRIDGE 2013-01-03T15:16:00 -1 -1 13446536102729
Email:Ngroombridge@paulweiss.Com 8 P 2013-04-26T17:45:06.720 **MSN** Pharmaceuticals Inc. D
Defendant **MSN PHARMACEUTICALS INC** 2017-01-11T08:30:00 2 **MSN** Pharmaceuticals Inc. Bryce A. Cooper...
... PHILLIPS MCLAUGHLIN HALL PA 2020-05-06T11:33:00 46829556376216 302-655-4200
Email:Jcp@pgmhlaw.Com USA 4 D **MSN LABORATORIES PRIVATE LIMITED** D Defendant **MSN**
LABORATORIES PRIVATE LIMITED 2015-05-18T14:49:00 3 **MSN LABORATORIES PRIVATE LIMITED**
Bryce A. Cooper...

Court: US District Court for the District of Delaware | **Date Filed:** Feb 19, 2020 | **Docket Number:**
1:20cv235 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent
Infringement | **Status:** Open

71. [Vanda Pharmaceuticals Inc. V Msn Pharmaceuticals Inc. Et Al](#)

... LLP 2012-07-17T17:01:00 287558 343068 73414103064762 302-658-9200
Email:Dfahnestock@mnat.Com USA 2 P 2013-04-26T17:48:45.540 **MSN** Pharmaceuticals Inc. D
Defendant **MSN PHARMACEUTICALS INC** 2017-01-11T08:30:00 2 **MSN** Pharmaceuticals Inc. David A. Bilson...
... PHILLIPS MCLAUGHLIN HALL PA 2020-05-06T11:33:00 46829556376216 302-655-4200
Email:Jcp@pgmhlaw.Com USA 2 D **MSN LABORATORIES PRIVATE LIMITED** D Defendant **MSN**
LABORATORIES PRIVATE LIMITED 2015-05-18T14:49:00 3 **MSN LABORATORIES PRIVATE LIMITED**
David A. Bilson...

Court: United States District Court, Delaware | **Date Filed:** Feb 24, 2021 | **Docket Number:** 1:21cv283 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:**
Open

72. [Vanda Pharmaceuticals Inc. V. Msn Pharmaceuticals Inc. Et Al.](#)

... -1 NICHOLAS GROOMBRIDGE 2013-01-03T15:16:00 -1 -1 13446536102729
Email:Ngroombridge@paulweiss.Com 7 P 2013-04-26T17:45:06.720 **MSN** Pharmaceuticals Inc. D
Defendant **MSN PHARMACEUTICALS INC** 2017-01-11T08:30:00 2 **MSN** Pharmaceuticals Inc. Bryce A. Cooper...
... PHILLIPS MCLAUGHLIN HALL PA 2020-05-06T11:33:00 46829556376216 302-655-4200
Email:Jcp@pgmhlaw.Com USA 4 D **MSN LABORATORIES PRIVATE LIMITED** D Defendant **MSN**
LABORATORIES PRIVATE LIMITED 2015-05-18T14:49:00 3 **MSN LABORATORIES PRIVATE LIMITED**
Bryce A. Cooper...

Court: United States District Court, Delaware | **Date Filed:** Oct 01, 2020 | **Docket Number:** 1:20cv1334 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:**
Open

73. [Vanda Pharmaceuticals Inc. V. Teva Pharmaceuticals Usa, Inc.](#)

... BE NOTICED -1 WILLIAM BLAKE COBLENTZ 2019-05-15T13:31:00 11052964895935
Email:Wcoblentz@cozen.Com 7 D **MSN** Pharmaceuticals Inc. D Defendant **MSN** PHARMACEUTICALS
INC 2017-01-11T08:30:00 5 **MSN** Pharmaceuticals Inc. John C. Phillips , Jr....
... -1 REID SMITH 2015-02-12T13:46:00 -1 -1 8024619690021 Email:Rfsmith@winston.Com 5 D 2015-03-
03T17:00:46.897 **MSN** LABORATORIES PRIVATE LIMITED D Defendant **MSN** LABORATORIES
PRIVATE LIMITED 2015-05-18T14:49:00 6 **MSN** LABORATORIES PRIVATE LIMITED David A. Bilson...

Court: United States District Court, Delaware | **Date Filed:** Apr 30, 2018 | **Docket Number:** 1:18cv651 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:**
Open

74. [Wyeth Llc Et Al V. Msn Laboratories Private Limited Et Al](#)

... BE NOTICED -1 VICTORIA L REINES 2018-08-17T10:31:00 15130242574653
Email:Victoria.Reines@arnoldporter.Com 9 P **MSN** LABORATORIES PRIVATE LIMITED D Defendant
MSN LABORATORIES PRIVATE LIMITED 2015-05-18T14:49:00 4 **MSN** LABORATORIES PRIVATE
LIMITED Joseph James Bellew...
... OCONNOR 2012-11-01T12:16:00 103108 342577 66356989415602 302-295-2000
Email:Jbellew@cozen.Com USA 1 D 2013-04-26T17:37:25.690 **MSN** PHARMACEUTICALS, INC. D
Defendant **MSN** PHARMACEUTICALS INC 2015-08-04T16:03:00 5 **MSN** PHARMACEUTICALS, INC.
Joseph James Bellew...

Court: United States District Court, Delaware | **Date Filed:** Mar 07, 2017 | **Docket Number:** 1:17cv233 |
Nature of Suit: Patent | **Cause:** Patent Infringement | **Status:** Closed

75. [Amgen Inc. V. Msn Laboratories Private Ltd.](#)

... GIBBONS PC 2016-10-24T11:17:00 -1 -1 37615288428177 973-596-4823
Email:Cgaddis@gibbonslaw.Com USA 2 P **MSN** Laboratories Private Ltd. D Defendant **MSN**
LABORATORIES PRIVATE LTD 2017-01-17T11:46:00 3 **MSN** Laboratories Private Ltd. LOUIS HARRY
WEINSTEIN...

Court: United States District Court, New Jersey | **Date Filed:** Jun 28, 2018 | **Docket Number:**
3:18cv11213 | **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent
Infringement | **Status:** Closed

76. [Astrazeneca Ab Et Al V. Citron Pharma Llc Et Al](#)

... 2016-08-22T18:00:00 -1 -1 88654580071199 201-287-2460 Fax: 201-489-0495
Email:Gregory.Miller@rivkin.Com USA 3 D **MSN** LABORATORIES PRIVATE LIMITED D Defendant **MSN**
LABORATORIES PRIVATE LIMITED 2015-05-18T14:49:00 6 **MSN** LABORATORIES PRIVATE LIMITED
JENNA Z. GABAY...

Court: US District Court for the District of New Jersey | **Date Filed:** May 15, 2015 | **Docket Number:**
3:15cv3383 | **Nature of Suit:** Patent | **Cause:** Patent Infringement | **Status:** Closed

77. [Astrazeneca Ab Et Al V. Torrent Pharma Inc. Et Al](#)

... 2017-02-15T18:09:00 65508899901897 (973) 400-4181 Fax: (973) 498-0070
Email:Rconroy@stoneconroy.Com USA 1 D **MSN** LABORATORIES PRIVATE LIMITED D Defendant **MSN**
LABORATORIES PRIVATE LIMITED 2015-05-18T14:49:00 9 2017-10-26 **MSN** LABORATORIES
PRIVATE LIMITED...

Court: United States District Court, New Jersey | **Date Filed:** May 15, 2015 | **Docket Number:** 3:15cv3375
| **Nature of Suit:** Patent | **Cause:** Patent Infringement | **Status:** Closed

78. [Eisai Co., Ltd. Et Al V. Msn Pharmaceuticals Inc.](#)

... TUNNELL LLP 2015-10-25T17:18:00 -1 -1 68773314886833 302-351-9392 Email:Araucci@mnat.Com
USA 2 P **MSN** Pharmaceuticals Inc. D Defendant **MSN** PHARMACEUTICALS INC 2017-01-11T08:30:00 4
MSN Pharmaceuticals Inc. R. Touhey Myer...

Court: United States District Court, Delaware | **Date Filed:** Jun 10, 2020 | **Docket Number:** 1:20cv791 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:**
Closed

79. [Newron Pharmaceuticals S.P.A Et Al V. Aurobindo Pharma Limited Et Al](#)

... Defendant AUROBINDO PHARMA USA INC 2010-06-11T15:42:00 5 Aurobindo Pharma USA Inc. **MSN**
LABORATORIES PRIVATE LIMITED D Defendant **MSN** LABORATORIES PRIVATE LIMITED 2015-05-
18T14:49:00 6 **MSN** LABORATORIES PRIVATE LIMITED Optimus Pharma Pvt Ltd...

Court: United States District Court, Delaware | **Date Filed:** Jun 10, 2021 | **Docket Number:** 1:21cv843 |
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement | **Status:**
Open

80. [Sumitomo Dainippon Pharma Co., Ltd. Et Al V. Aurobindo Pharma Ltd. Et Al](#)

... PARK WINSTON STRAWN LLP 2017-12-07T14:31:00 37758363074662 312-558-7931
Email:Spark@winston.Com USA 2 D **MSN** Laboratories Private Ltd. D Defendant **MSN** LABORATORIES
PRIVATE LTD 2017-01-17T11:46:00 7 2018-06-28 **MSN** Laboratories Private Ltd....

Court: United States District Court, New Jersey | **Date Filed:** Feb 23, 2018 | **Docket Number:** 2:18cv2620
| **Nature of Suit:** Patent - Abbreviated New Drug Application(ANDA) | **Cause:** Patent Infringement |
Status: Closed

81. [Ucb Inc. Et Al V. Accord Healthcare Inc. Et Al](#)

... LANDON 2012-06-12T16:01:00 -1 -1 53380809781553 (302) 472-8100 Email:Fmurphy@mllaw.Com
USA 1 D **MSN** LABORATORIES PVT. LTD. D Defendant **MSN** LABORATORIES PVT LTD 2015-03-
03T10:02:00 36 **MSN** LABORATORIES PVT. LTD. David A. Bilson...

Court: United States District Court, Delaware | **Date Filed:** Jul 10, 2013 | **Docket Number:** 1:13cv1206 |
Nature of Suit: Patent | **Cause:** Patent Infringement | **Status:** Closed

82. [Ucb Inc. Et Al V. Breckenridge Pharmaceutical Inc. Et Al](#)

... PA 2016-03-20T17:10:00 -1 -1 54163017435975 302- 655-4200 Email:Mch@pgmhlaw.Com USA 3 D
MSN LABORATORIES PVT. LTD. D Defendant **MSN** LABORATORIES PVT LTD 2015-03-03T10:02:00 7
MSN LABORATORIES PVT. LTD. John C. Phillips , Jr....

Court: US District Court for the District of Delaware | **Date Filed:** Jul 10, 2013 | **Docket Number:**
1:13cv1211 | **Nature of Suit:** Patent | **Cause:** Patent Infringement | **Status:** Closed